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Abstract 
 
Numerous α,α-trehalose diesters have been isolated from bacteria such as 
Mycobacteria and Corynebacteria, and more recently from Caenorhabditis elegans 
dauer larvae. Although these glycolipids are thought to confer protection to the 
bacteria and larvae against harsh environmental conditions, it is the biological 
activities of these compounds, including anti-tumour and adjuvant activities, which 
have been of major interest to scientists over recent years.  
In this thesis, three different aspects relating to the synthesis and testing of defined 
trehalose glycolipids will be presented. First, the synthesis of a variety of fatty acid 
trehalose diesters (TDEs) with varying lipid lengths was performed and the ability of 
these glycolipids to activate macrophages was studied. Two different synthetic 
strategies were employed to attain the TDEs of interest and it was observed that lipid 
lengths of more than 18 carbons were required for macrophage activation. 
Furthermore, the C22 fatty acid trehalose monoester (TME) and the C26 TME were 
also synthesised and interestingly they both showed macrophage activation abilities, 
with subsequent studies indicating that like TDEs, the TMEs were also ligands for 
mincle, a C-type lectin found on macrophages. This is the first time that TMEs have 
been tested for their ability to activate macrophages via Mincle. The cytotoxicity of 
these compounds and subsequent anti-tumour activity of a few selected compounds 
were also studied and although the TDEs and TMEs did not exhibit any significant 
cytotoxicity, in in vivo models the C10 TDE and C22 TDE both showed anti-tumour 
activity. This depicts that the mechanism for anti-tumour activity of these 
compounds is not due to cytotoxicity but due to as yet unidentified pathway.    
Methodology that can be applied to the synthesis of more complex trehalose 
glycolipids, such as trehalose dicorynomycolates (TDCMs, isolated from 
Corynebacteria) and trehalose dimycolates (TDMs, isolated from Mycobacteria) was 
also explored. One of the key steps frequently used in the synthesis of these 
glycolipids is the Fráter-Seebach alkylation. To improve the efficacy of this 
methodology allylic iodides, rather than alkyl iodides were used for the -alkylation 
of β-hydroxy esters. Our results showed that for all substrates studied, the yield of 
the α-alkylation was greatly improved when the allylic, rather that the alkyl halide 
ii 
 
was used. The use of this methodology in the synthesis of trehalose 
monocorynomycolate (TMCM) was also investigated.   
The third aspect of this thesis focuses on the use of Affinity Based Proteome 
Profiling (AfBPP) for elucidating the receptors that TDMs bind to upon interacting 
with host cell. AfBPP focuses on using small molecules which mimic the natural 
substrate for a particular protein and through the use of ‘trap’ and ‘tag’ groups on the 
molecule the identity of the protein/receptors can be determined. The synthesis of a 
TDM probe containing a benzophenone ‘trap’ group and an alkyne ‘tag’ group will 
be discussed.  
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1.1 Mycobacteria in the treatment of disease: A historical 
perspective  
The use of bacteria in the treatment of disease has been a topic of much interest to 
the scientific community for over 100 years. In the late 1800s, William Coley was 
the first to illustrate that bacteria have the potential to be used in the treatment of 
cancer. In his seminal work, Coley injected streptococcal bacteria into a cancer 
patient and noted a reduction in the tumour burden.
1
 Although this result was 
encouraging, subsequent injections with streptococcal bacteria alone sometimes 
resulted in fatalities. Accordingly, Coley switched to using a tumour vaccine 
containing Streptococcal pyogenes and Serratia marcescens. This concoction, known 
as „Coley‟s toxins‟, turned out to be more effective in treating malignant tumors.1,2  
Over the next 40 years, Coley treated more than 1000 patients, however, his work 
was often criticised due to poor documentation and follow up of patients, variability 
1 General Introduction 
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in the modes of administration, and the inconsistencies in Coley‟s Toxin preparation. 
There were 13 different toxin preparations reported, of which some were more 
effective than others.
3
 Because of this, Coley‟s experiments were largely ignored 
until the late 20
th
 century.  
Science has progressed significantly since Coley‟s original experiments and now it is 
widely acknowledged that bacteria and bacterial components can be used in disease 
treatment and in vaccination programmes. For example, inactive and dried 
Mycobacterium tuberculosis (M. tb) is a major component of Freund‟s complete 
adjuvant system which has proved to be effective in disease treatments. It has shown 
potential to prevent juvenile-onset diabetes in mouse models
4
 and its use in 
Parkinson‟s disease treatments in rat models has also been explored.5 However, the 
use of this adjuvant in humans is forbidden due to its toxicity.
6
  
Bacillus Calmette-Guérin (BCG) is the current vaccine in use for tuberculosis (TB) 
and is made up of attenuated live bovine tuberculosis bacillus, Mycobacterium bovis, 
which has lost its virulence in humans. BCG was first formulated by Calmette and 
Guérin in 1920,
7
 given to a human infant in 1921, and to date, has been administered 
to four billion people making it the most widely used vaccine in the world.
8
 Although 
the vaccine is effective against childhood tuberculosis, meningitis, and miliary 
tuberculosis, the efficacy of the vaccine is questionable in adult pulmonary 
tuberculosis where variable results have been obtained.
9
 This could be due to the 
inability of BCG to impart a memory T cell response which is vital for long-term 
immunity to TB. To address this problem, adjuvants could be incorporated into 
vaccines. Currently bacterial cell components known to induce T cell immunity are 
being tested in vaccine programmes to deduce if they boost the response of the 
vaccine over a long period of time.
10
 BCG is also used as a standard therapy in the 
treatment of bladder cancer.
11
  
Of particular interest to us is the potential use of mycobacterial cell wall components, 
from M. tb and related mycobacteria, in the treatment of disease. While there is much 
evidence to suggest that such cell wall components have important 
immunomodulatory effects,
12
 to date, the immunomodulatory properties of distinct 
(homogenous) cell wall constituents has been poorly documented. Moreover, the 
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mechanism of action of individual mycobacterial cell wall components is not fully 
understood. 
 
1.2 Overview 
The objective of this thesis is to better understand the immunomodulatory properties 
of distinct mycobacterial cell wall components with a view that this may lead to 
better therapies and vaccination protocols against tuberculosis. In particular, the 
focus of my research relates to the effects of trehalose diesters (which are the major 
cell wall components of M. tb) on the immune response. This may be achieved via 
the synthesis of distinct trehalose diesters of differing lipid lengths using novel 
Fráter-Seebach alkylation methodology, and the subsequent testing of these 
glycolipids in a number of biological assays. In addition, modified trehalose 
dimycolate (TDM) containing functionalised traps (e.g. benzophenone, azides) will 
be prepared so that the proteins that bind to TDM can be elucidated via Affinity 
Based Proteome Profiling (AfBPP).
13
 The context of this TDM work will be 
discussed following a brief discussion of M. tb and the variety of cell wall 
constituents that the bacterium contains.   
 
1.3 Mycobacterium tuberculosis and related 
mycobacteria  
M. tb is a wax-coated rod-shaped bacillus discovered by Robert Koch in 1882.
14
 It is 
a slow growing, aerobic, acid-fast, non-motile, obligate intracellular pathogen that 
can infect several animal species, as well as humans. The bacterium divides every 15 
to 20 hours which is quite slow compared to majority of other bacteria (Escherichia 
coli divides every 20 minutes).
8
 M. tb belongs to the Mycobacterium family in the 
Corynebacterinae sub-group of the Actinomycete line (Figure 1). The class 
Actinobacteria under phylum Actinobacteria comprises of Gram positive bacteria 
with high guanine and cytosine content. Although M. tb does not stain with Gram 
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staining, it is classified under this class due to lack of an outer cell membrane (as in 
Gram negative bacteria). The sub-order Corynebacteria contains most of the acid fast 
bacteria like Mycobacteriaceae, Nocadiaceae and Corynebacterineae. Bacteria 
classified under genus Mycobacterium in the Mycobacteriaceae family have a 
characteristic cell wall which is thicker than those found in other bacteria. In 
addition, the cell wall is hydrophobic, waxy and rich in mycolic acids and mycolates. 
The cell wall structure of Mycobacterium will be discussed in more detail in section 
1.4. 
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             Figure 1. Taxonomic classification of bacteria. 
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M. tb is responsible for causing TB, a pernicious disease that affects the respiratory 
system (Figure 2). One third of the world‟s population is infected by this bacteria15 
that kills about 1.7 million people every year. The occurrence of TB strongly 
correlates with reduced socio-economic status making TB more prominent in 
developing countries in Asia and Africa. M. tb is also an opportunistic pathogen 
which is quite prominent in people who are HIV positive, for whom TB is a leading 
cause of death. In order to treat TB, a cocktail of drugs is required along with very 
lengthy treatment regimes. In addition, due to the marginal efficacy of the BCG 
vaccine, the vaccination against M. tb has been discontinued in many countries, 
including NZ, except for those deemed to be in high risk groups. It is hoped that by 
understanding more about the immunomodulatory effects of the cell wall 
components of M. tb, better TB vaccines can be developed and novel drug targets 
identified.  
 
 
Figure 2. Respiratory system.  
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1.4 Mycobacterial cell wall components 
The ability of M. tb to remain in a dormant state in the host organism and evade 
destruction from drug treatment, chemical injury and the host immune system has 
been attributed to the outer cell wall structure of M. tb that has been deemed crucial 
in the survival of the bacteria.
16
 Made up of various types of lipids, the cell wall 
structure of M. tb is highly complex and contains several key features (Figure 3).
17,18
 
Closest to the plasma membrane is the peptidoglycan layer comprising of a highly 
cross-linked polymer of amino acids, like alanine and glutamic acid, and amino 
sugars. Protruding from the peptidoglycan layer are arabinogalactan saccharides 
which contain linear galactan and branched arabinose motifs. The arabinose chains 
are then linked to mycolic acids which are primarily present in two forms in the cell 
wall: covalently bonded to arabinogalactan, and as esters of trehalose giving rise to 
trehalose dimycolate (TDM), the most abundant glycolipid present in the cell wall of 
M. tb. The cell wall also contains phthiocerol dimycocerosate (PDIM) and phenolic 
glycolipids (PGL) (not shown), along with lipoarabinomannan (LAM) which 
consists of a phosphoryl-inositol-mannose (PIM) anchor and a polysaccharide 
backbone. The individual cell wall glycoconjugates are discussed in more details as 
follows.  
 
  
 
 
 
 
Figure 3. Cartoon of M. tb cell wall.  
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1.4.1 Phosphoryl-inositol-mannosides (PIMs) 
M. tb contains several phosphoryl-inositol-mannosides (PIMs) structures (1, Figure 
4) including PIM1 (where the inositol residue of PI [phosphatidyl-myo-inositol] is 
mannosylated at the C-2 position), PIM2 (where PIM1 is further mannosylated at C-6 
of inositol).
19
 Further α-1,6 mannosylation of PIM2 gives rise to PIM3 and PIM4 the 
common precursor of PIM5 and PIM6 (made by further α-1,2 mannosylation of 
PIM4). In addition, the core PI unit is found as a unique entity on its own. The 
synthesis of naturally occurring PIMs and analogues has been undertaken and many 
elegant syntheses have been reported. (For a recent review see ref.
20
)  
 
Figure 4. Structure of PIMs (1). 
 
PIMs exhibit both immunosuppressive and adjuvant activities. The ability of PIMs to 
induce cell mediated immunity, particularly, a Th1 type immune response illustrates 
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their potential to be used as adjuvants in sub-unit vaccines.
21,22
 In a study by Painter 
and co-workers, a synthetic analogue of PIM6 was shown to induce DC-mediated 
suppression of human CD8
+
 T cell proliferation, which can enhance the survival of 
M. tb when resident in the host cell.
23
 PIM6 has also been found to interact with DC-
SIGN, a receptor on dendritic cells. DC-SIGN has also been shown to be regulated 
following host infection with M. tb, thus suggesting that PIMs could potentially be 
involved in the virulence and pathogenesis of M. tb.
24
 
 
1.4.2  Lipoarabinomannan (LAMs) 
PIMs are common precursors for more complex mycobacterial cell wall components 
like lipomannan (LM, 2, Figure 5), lipoarabinomannan (LAM, 3) and mannan 
capped lipoarabinomannan (ManLAM). PIM4 is the key biosynthetic intermediate 
whereby α-1,6 linked mannose to the PIM4 backbone leads to mature branched 
lipomannan, which undergoes subsequent arabinoyslation to form 
lipoarabinomannan and further mannosylation of LAM leads to ManLAM.
25
 The use 
of LAM as a diagnostic tool for tuberculosis was investigated by Sada et al., 
whereby they noted the presence of LAM in the serum of most patients with 
pulmonary tuberculosis, indicating that the detection of LAM is an accurate 
diagnostic tool for pulmonary tuberculosis.
26
 In another study, purified LM, LAM 
and PIM1 from a cell wall fraction of M. bovis BCG Tokyo-172 strain were examined 
for their ability to induce differentiation of human peripheral blood naive CD4 T 
cells into Th1 and Th2 cells.
27
 The results showed that LAM/LM enhanced T cell 
differentiation under both Th1 and Th2 conditions, since both Th1 [e.g. interleukin 
(IL)-2, tumour necrosis factor (TNF)-α, interferon (IFN)-γ] and Th2 (e.g. IL-4, IL-5) 
cytokines were observed, indicating that LAM/LM possess a potent modulating 
activity in human systems and could thus be used in vaccine development for both 
Th1 and Th2 diseases.  
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Figure 5. LM (2) and LAM (3) structures. 
 
1.4.3 Phthiocerol dimycocerosate (PDIMs) 
Phthiocerol dimycocerosate (PDIM) (4, Figure 6) and its derivatives consist of a long 
chain β-diol (phthiocerol), which occurs naturally as diesters of polymethyl branched 
fatty acids (mycocerosic acid), and have been found in all pathogenic Mycobacteria 
except M. gastri.
28
 The methylated branched asymmetric centres can be of L or D 
configuration depending on the strain of mycobacterium. For instance, in M. 
marinum, the configuration of the asymmetric centres is L, whereas in M. leprae and 
M. tb they are of the D configuration.
29
  
11 
 
 
Figure 6: PDIM (4) from M. tb. 
 
The ester groups present at carbons 9 and 11 in PDIMs can have either an anti or syn 
relationship, again depending on the mycobacterial strain. For PDIMs isolated from 
M. tb, M. leprae, M. bovis and M. kansasii the esters are anti to each other (5), 
whereas those obtained from M. marinum (6) and M. ulcerans (7) display a syn 
relationship (Figure 7).
30
 PDIMs have also been found to be involved in the 
pathogenesis of M. tb, as illustrated by mutant strains of M. tb without PDIMs in the 
cell wall which exhibit higher cell permeability, thus making them more vulnerable 
to detergents and the host immune response.
31
  
 
Figure 7: Stereochemistry of esters in PDIM from various mycobacterial species. 
 
1.4.4 Phenolic glycolipids (PGLs) 
Structurally related to PDIMs are phenolic glycolipids (PGLs) where the lipid core is 
ω-terminated by an aromatic nucleus, which in turn is glycosylated by different 
saccharide units leading to a variety of phenolic glycolipids. The structures of PGLs 
from different mycobacterial species differ in the sugar moiety attached to the 
12 
 
aromatic nucleus.
30
 PGL (8) from M. leprae and PGL (9) from M. tb each contain 
trisaccharide sugar units (Figure 8). Similarly, PGL from M. bovis and M. marinum 
both have a single rhamnose sugar that only differs in its methylation pattern. PGLs 
from M. tb have been shown to inhibit the innate immune response in the host 
organism and thus play an important role in the virulence of TB.
32
 
Figure 8: PGL from M. leprae and M. tb. 
 
1.4.5 Trehalose dimycolates (TDMs) 
As alluded to before, trehalose dimycolates (TDMs, 10, Figure 9) are the most 
abundant glycolipids found on the cell wall of M. tb and were first discovered in the 
bacterium in the early 1950s when it was observed that virulent strains of M. tb 
expressed a material named “cord factor” which was essential for the pathogenesis of 
the bacteria.
33
 It was not until 1956, that “cord factors” were characterised as TDMs 
and since then a vast number of studies have looked at the structural requirements 
and biological activities of this class of compounds.
12,34,35
    
Amongst the different mycobacterial species, the variability of these glycolipids is 
apparent both in terms of the type and the amount of individual TDMs present.
34
 
TDMs are characterised by the presence of a mycolic acid (11, Figure 9) and a 
trehalose moiety, with the mycolic acid consisting of at least two chiral centres, α 
and β to the carboxylate, both of R configuration.36,37 The lipid chain α to the 
carboxylate is known as the α branch, while the other portion of the mycolic acid is 
termed the meromycolate. Among different TDMs, the α branch of the mycolic acid 
varies only in the number of carbons present. The meromycolate region, however, is 
13 
 
more variable with different functionalities present.
38
 Mycolic acids are generally 
divided into two groups - the α-mycolates, which have no oxygenated functional 
groups, and the oxygenated mycolates. The most common mycolic acids are the α-
mycolates in which cis-cyclopropanes are present in the meromycolate branch. The 
oxygenated mycolates include methoxy mycolates, keto mycolates and epoxy 
mycolates.
18
 The biological activity and synthesis of TDMs and related trehalose 
6,6'-diesters will be discussed in more detail later (Section 1.5.3). 
 
Figure 9. TDMs (10) and mycolic acids (11). 
 
1.4.6 Other Trehalose Glycolipids  
A second class of trehalose glycolipids found in virulent strains of mycobacteria are 
termed sulfolipids (e.g. SL-1, 12, Figure 10), to account for the presence of sulfate 
esters.
39
 Although first isolated in 1959, the structure of these sulfolipids was not 
elucidated until 1970 when Goren et al. characterised them as 2,3,6,6'-tetraesters of 
trehalose-2'-sulfate.
40
 It was not until 2004 that diacyltrehalose sulfates (13), the 
biosynthetic precursors for SL-1, were isolated from M. tb independently by 
Domenech et al.
41
 and  Gilleron et al..
42
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Figure 10. Sulfolipids. 
 
1.5 Trehalose 6,6'- diesters 
1.5.1 Overview 
In addition to TDMs, sulfolipids, and diacyl trehalose sulfates found in 
mycobacteria, a number of other trehalose diesters have been observed in other 
bacterial species, and recently in Caenorhabditis elegans. Notably, these include the 
trehalose diesters of fatty acids (TDEs) (including maradolipids) and the trehalose 
dicorynomycolates (TDCMs). Collectively, these can be defined as trehalose 6,6'-
diesters, whereby two esters are present on the 6 and 6'-positions of the trehalose 
moiety, as opposed to the 2,3-trehalose diesters (as in the case of diacyl trehalose 
sulfates) or the 2,3,6,6'-tetraesters (SL-1). The focus of this thesis concerns the 
synthesis and biological activity of trehalose 6,6'-diesters, which will be discussed in 
more detail below.   
15 
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1.5.2 Trehalose diesters of fatty acids (TDEs) 
1.5.2a Introduction 
Trehalose diesters of fatty acids (TDEs) (14, Figure 11) are the simplest glycolipids 
found in the trehalose 6,6'-diester series and can be differentiated by lipid length and 
the branching of the fatty acids. Historically, linear TDEs have been studied for their 
anti-tumor43,44,45,46,       47  and anti-bacterial activities,
48,49,50
 however, it is only in recent years 
that the presence of these compounds has been detected in the animal kingdom.
51
 
The isolation of the palmitic acid diester of trehalose (14, n = 14), from 
Mycobacterium fortuitum was also reported in the 1960s.
52
  Branched TDEs form an 
intergral part of the diacyl trehalose isolated from dauer larvae of C. elegans 
(commonly known as maradolipids, 15), while linear TDEs and cyclopropanated 
trehalose diesters are also found in maradolipid extracts, albeit in smaller 
quantities.
51
 
 
Figure 11. TDEs (14) and maradolipids (15). 
 
Of the TDEs, perhaps the most noteworthy family member is the C22 homologue,  
trehalose dibehenate (TDB), which has recently been shown to bind to and activate 
macrophages in a similar way to its more complex counterpart, TDM. TDB binds to 
Macrophage Inducible C-type Lectin (mincle, Figure 12), a calcium dependent 
receptor that posseses a carbohydrate identifying domain in its extracellular 
16 
 
region,
53,54
 and activates macrophages through a FcRgamma-Syk-Card9-dependant 
pathway. These studies have important implications as they provide insight into the 
mechanism of action of TDEs, which in turn will aid in the development of better 
therapeutics for cells of the myeloid lineage.  Toll-like receptor (TLR)-2 and dectin-1 
are examples of other surface membrane receptors found on immune cells which 
recognise certain bacteria, fungi and exogenous substances.  
 
Figure 12. Cartoon of Mincle interacting with TDM and TDB.  
 
1.5.2b Linear TDE syntheses  
Various synthetic methodologies for TDE syntheses have been developed over time 
to gain access to these intriguing diesters. One of the first synthetic methods reported 
was the potassium carbonate mediated trans-esterification of fatty acid methyl esters 
with trehalose.
55
 This reaction, however, was not selective with various other mono, 
di- and tri-esters also being formed. The synthesis of TDEs has also been reported 
17 
 
whereby 6,6'-ditosylate trehalose was subjected to esterification conditions with the 
potassium salt of palmitic acid,
56
 based on methodology developed previously.
57
 This 
synthetic strategy posed a few difficulties including the formation of 3,6-anhydro-
trehalose products and other by-products that were difficult to separate from the 
desired TDEs.
58
 Toccane
59
 and Toubiana et al.
60
 independently proposed the use of a 
6,6'-dihalo-6,6'-dideoxy trehalose derivative for the synthesis of trehalose diesters to 
eliminate these side reactions. The esterification reaction could also be improved by 
using 2,2',3,3',4,4'-hexa-O-benzyl-trehalose as an intermediate.
58
  
In 1983, Bottle and Jenkins reported on a new method for the synthesis of TDEs via 
the reaction of trehalose with fatty acids in the presence of diisopropyl 
azodicarboxylate (DIAD) and triphenyl phosphine under exceptionally mild 
conditions.
61
 In their seminal work, unprotected trehalose and palmitic acid were 
subjected to the Mitsunobo reaction
62
 to yield 6,6'-trehalose dipalmitate in 59% 
yield.
61
 Later, Jenkins and Goren extended this methodology for the synthesis of 
more complex TDMs.
63
 
In the continual search for the optimum conditions for the synthesis of TDEs, the use 
of 2,2',3,3',4,4'-hexa-O-trimethylsilyl trehalose as an intermediate for the synthesis of 
dipalmitate trehalose was reported.
64
 This intermediate was appealing due to the ease 
in which labile trimethylsilyl (TMS) protecting groups could be removed after the 
esterification reaction. In the initial studies by Toubiana et al., hexa-O-trimethylsilyl 
trehalose was synthesised in 2-steps from commercially available α,α-trehalose, 
while in the later work by Johnson, an elegant 2-step, one pot synthesis of hexa-
trimethylsilyl trehalose was developed,
65
 and later used for the synthesis of trehalose 
dipalmitate 14a (Scheme 1).
66
 Here, α,α-trehalose (16) was persilylated using N,O-
bis(trimethylsilyl)acetamide (BSA) and tetra-butylammonium fluoride (TBAF) and 
the more labile primary TMS ethers were removed via the addition of potassium 
carbonate to the same reaction vessel to give 17 in good (85%) yield.  Diol 17 was 
then converted to triflate 18 and condensed with the potassium salt of the acid to give 
the fully protected diacyl trehalose 19a, which was deprotected under acidic 
conditions to provide trehalose dipalmitate 14a in good overall yield.  
18 
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Scheme 1. Trehalose dipalmitate synthesis.
66
 
 
1.5.2c Biological Activity of linear TDEs 
The anti-tumour activity of TDEs has been studied for many years and though it is 
difficult to deduce with certainity which factors are responsible for good anti-tumour 
activity due to the different ways in which the assays were performed, several 
general conclusions can be drawn. Lipopolysaccharide (LPS) has been shown to 
enhance the anti-tumour activity of the linear TDMs in in vivo tumour assays,44,45,4     5,      47                   and 
the co-presence of an oil vehicle also appears to enhance the response.67,68,69   70   The 
importance of the acyl chain length was seen in an in vivo tumour assay, where an 
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acyl chain of more than 10 carbons was essential to induce anti-tumour activity in an 
Ehlrich ascites carcinoma model.
43
 The most common tumour model employed in 
these studies was the rat hepatoma cell line. 
The anti-bacterial activity of linear TDEs has also been studied by several groups and 
varying results obtained depending on the bacterial strain used. When tested against 
Klebsiella pneumoniae and Listeria monocytogenes in mice, the C22 diester as well 
as the C16 diester did not confer any protection.
48
 However, when tested on 
Schistosoma mansoni, the C16 diester conferred protection, whereas no protection 
was seen with the C22 diester.
49
 Similarly, the C16 diester and monoester were seen 
to confer protection against Salmonella typhi and Salmonella typhimurium.
50
 In all 
studies, the glycolipids were formulated in oil and adminstered to the mice as an 
emulsion. In the case of Schistosoma mansoni and Salmonella challenges, the mice 
were pre-treated with the TDEs before being challenged with the bacteria, whereas, 
in the K. pneumoniae and L. monocytogenes studies, the mice were first challenged 
with the infection and then the TDEs were introduced. C16 and C22 diesters of 
trehalose have also shown potential to be used in the serodiagnosis of tuberculosis.
71
  
The singularly most studied glycolipid in the TDE family is the C22 diester of 
trehalose, TDB. In addition to the aforementioned anti-tumour and anti-bacterial 
studies, TDB has been combined with dimethyldioctadecylammonium bromide 
(DDA), a cationic surfactant to produce a liposome adjuvant system which induces a 
strong cell-mediated and antibody response,
72
 and thus could be an effective adjuvant 
in M. tb subunit vaccines.
73
 Indeed, such cationic liposomes are now in Phase I 
clinical trials for their use during TB vaccination.
74
  
 
1.5.2d Maradolipid Syntheses  
Maradolipids are diacyltrehalose glycolipids containing linear, branched and 
cyclopropanated fatty acid chains, observed in the dauer larvae of C. elegans.
51
 The 
lipid composition and the relative abundances of the lipids of the dauer larvae were 
analysed using extensive NMR spectroscopy and mass spectrometric analysis and it 
20 
 
was revealed that the major TDE was maradolipid (15, Figure 13) which is an 
acylated trehalose containing a branched fatty acid moiety at position 6 and either a 
mono-unsaturated or saturated linear fatty acid at the 6' position. MS/MS analysis 
revealed that 40% of the fatty acid moieties were 15:0 and 17:0 fatty acid (FA) 
(Figure 14) and about 60% of the maradolipids were found to have a branched fatty 
acid chain. The presence of cyclopropanated lipids was also found on the 
maradolipids.
51
 As the first diacyl trehalose glycolipid found in the animal kingdom, 
the discovery of maradolipids represents a first step in understanding stress related 
lipid composition changes in cells. 
 
Figure 13. Representative maradolipid. 
 
 
Figure 14. Lipid composition of maradolipids.
51
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Two syntheses of the major maradolipids from C. elegans were reported 
simultaneously in 2011 by the groups of Sarpe and Kulkarni
75
 (Scheme 2) and 
Knölker and colleagues.
76
 In the former synthesis, α,α-trehalose (16) was 
transformed into diol 17 using similar methodology as that developed by Johnson,
65
 
and the diol was then subjected to esterification with oleic acid (1 equiv.) in the 
presence of N,N'-dicyclohexylcarbodiimide (DCC) and 4-dimethylaminopyridine 
(DMAP) to give mono-ester 20. A further esterification with 13-methylmyristic acid 
using the same coupling conditions then gave the fully protected diester 21, which 
was deprotected in the presence of acidic dowex to yield maradolipid 15 in 46% 
yield (five steps). To date, there have been no biological activities reported on the 
maradolipids aside from those saturated derivatives discussed in section 1.5.2c 
above. 
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Scheme 2. Maradolipid synthesis.
75
  
 
1.5.3. Trehalose Dicorynomycolate (TDCM) 
1.5.3a Introduction  
Trehalose dicorynomycolates (TDCMs) are found in Corynebacteria and consist of a 
trehalose carbohydrate group esterified at the 6 and 6' position with corynomycolic 
acid. The major TDCM (22, Figure 15) contains a C32 corynomycolic acid, 
however, TDCMs with shorter acid chains (C24–C30) have also been found in 
Corynebacteria. TDCMs were first isolated in 1963,
77
 and later found to be a mixture 
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of three components: dicorynomycolate, monocorynomycolate-
mono(dehydrocorynomycolate) and the bis(dehydrocorynomycolate)
78,79
 which were 
separable once converted to their trimethylsilyl derivatives.
78
 In more recent years, 
the isolation, and characterisation of TDCM (22) and mono-corynomycolate from 
Corynobacterium matruchotti using 
1
H NMR spectroscopy has been reported by 
Datta and Takayama.
80
 The stereochemistry of the two chiral centres in TDCMs lipid 
chain have been shown to be R,R.
36
  
 
Figure 15. Trehalose dicorynomycolate (22). 
 
1.5.3b TDCM Syntheses  
Most earlier syntheses of TDCMs were reported by Liav et al. whereby the synthesis 
of this glycolipid along with analogues of TDCM with different carbohydrate groups 
(e.g. dimannosides, digalactosides), and the synthesis of mono-esterified compounds 
were undertaken in order to correlate the structure to the biological activities of these 
compounds.81,82,83,84,85, 86   In these earlier reactions, the racemic corynomycolic acid was 
synthesised using Lederer and Polonsky‟s method87 which involved the self 
condensation of methyl palmitate, subsequent reduction of the keto ester using 
sodium borohydride (NaBH4), and then hydrolysis of the methyl ester in 10%  
potassium hydroxide (KOH) to give the crystalline potassium corynomycolate as the 
product.  
It was not until 1985, that the synthesis of optically pure corynomycolic acid was 
reported by Sato and co-workers. Here, corynomycolic acid was synthesised in nine 
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steps starting from n-tetradecyl iodide.
88
 Later, Ukata reported a more efficient six 
step synthesis of (+)-corynomycolic acid from 3-oxo-octadecanoic acid using an 
asymmetric reduction mediated by fermenting baker‟s yeast (Scheme 3).89 In their 
synthesis, methyl 3-oxo-octadecanoate (23) prepared from methyl acetoacetate and 
n-tetradecyl iodide in 75% yield, was hydrolysed and subsequently subjected to 
enzymatic reduction to form hydroxy acid 24. The acid was then methylated using 
diazomethane and subjected to alkylation via treatment with  lithium 
diisopropylamide (LDA) and n-tetradecyl iodide in the presence of 
hexamethylphosphoric triamide (HMPA) to form methyl corynomycolate 25. 
Finally, hydrolysis of the methyl ester led to the single enantiomer of corynomycolic 
acid (26) in 13% overall yield.  
 
Scheme 3. Corynomycolic acid synthesis.
89
 
 
The first total synthesis of naturally occurring TDCM, the 6,6'-trehalose diester of 
(2R,3R)-corynomycolic acid, was reported by Nishizawa et al. in 1994 (Scheme 4).
90
 
The required stereochemistry at the 2- and 3-positions was installed using a Katsuki-
Sharpless catalytic asymmetric epoxidation
91
 of 2-octadecenol (27) using D-(-)- 
diisopropyl tartrate (DIPT) in CH2Cl2 to give epoxide (+)-28 in quantitative yield. 
Protection of the free hydroxyl in 28 as the p-methoxybenzyl (PMB) ether, followed 
by epoxide ring opening with allylmagnesium bromide resulted in the formation of 
25 
 
alcohol 29 in combination with the undesired regioisomeric ring-opened product in a 
38:62 ratio. Benzylation of the alcohol and cleavage of the double bond by Lemieux-
Johnson oxidation
92
 provided aldehyde 30, which was then subjected to a Wittig 
reaction with the ylide derived from triphenyldodecylphosphonium bromide, 
followed by removal of the PMB protective group to give 31 as a mixture of E and Z 
isomers. Subsequent Swern
93
 and NaClO2 oxidations of 31 resulted in the protected 
cornynomycolic acid 32, ready for coupling with the selectively protected trehalose 
33. Three other stereoisomers of 32, the (2R,3S)-, (2S,3R)-, and (2S,3S)-isomers, 
were also prepared in analogous fashion. Coupling of the corynomycolates with 
hexa-benzyl trehalose derivative 33, followed by global deprotection by Pd-catalysed 
hydrogenation, with concommitant reduction of the double bond, provided the target 
TDCM 22 in excellent yield. 
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Scheme 4. Synthesis of TDCM.
90
 
 
Nishizawa et al. also reported on a more efficient route to corynomycolic acids that 
makes use of Noyori‟s 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP)-Ru-
catalysed asymmetric reduction,
94
 in the dynamic kinetic resolution of α-palmityl-
butyrolactone.
95
 This reduction was later used in the synthesis of corynomycolic acid 
analogues, whereby a tert-butyl acylacetate was stereoselectively reduced (Scheme 
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5).
96
 In order to form the natural (2R,3R)-TDCM isomer 22, the dianion of tert-butyl 
acetoacetate (34) was generated with NaH and n-BuLi, and subsequently treated with 
n-tetradecyl iodide to form the γ-alkylated product 35. Stereoselective reduction of 
the ketone in 35 using (R)-BINAP-RuCl2 and hydrogen then gave (R)-hydroxy ester 
36 in an excellent yield of 94% and more than 98% ee. Subsequent Fráter-Seebach 
alkylation
97,98,99
 of 36 with tetradecyl iodide introduced the second stereocentre, 
again with excellent selectivity (>99% de, 37). Next, reductive etherification and 
ester cleavage led to the benzyl protected corynomycolic acid 38, which was then 
coupled to the hexa-benzyl protected trehalose derivative 33. Again global 
deprotection using catalytic hydrogenation led to the target TDCM 22 in a highly 
efficient seven step synthesis. In addition, further stereoisomers and branched chain 
TDCM analogues were produced using the same strategy, but using (S)-BINAP-
RuCl2 for the stereoselective reduction, and a variety of alkylating reagents in the γ-
alkylation of the acetoacetate and Fráter-Seebach alkylation. 
           
Scheme 5. TDCM synthesis via Noyori‟s asymmetric reduction.95 
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1.5.3c TDCM  Biological Activity 
Over the years, TDCMs isolated from the cell wall of Corynebacterium have been 
shown to have a variety of biological activities, including acting as agonists for 
macrophage activation during in vivo studies.
100
 In combination with 
monophosphoryl lipid A, TDCMs form an integral part of the Ribi Adjuvant system 
which has shown to be effective in Leshmania
101
 and M. tb vaccine formulations.
102
 
The tumour regression property of synthetic racemic TDCMs has also been reported 
whereby the TDCMs were injected intralesionally as an oil emulsion in mice with 
fibrosarcoma.
100
  
The first testing on homogenous TDCMs, was carried out in 1996 when four TDCMs 
synthesised by Nishizawa et al. were tested individually for their biological 
activity.
103
 In the study, the immunoadjuvant activity of the TDCMs was analysed, 
by considering the cytolytic activity of peritoneal macrophages obtained from mice 
treated peritoneally with TDCM, to Lewis lung carcinoma cells. The results indicated 
that all four diastereomeric TDCMs had adjuvant activities, however, the natural 
(2R,3R) and its enantiomer (2S, 3S) were more potent than the 2R,3S and the 2S,3R 
isomers in terms of stimulating the cytolytic activity of the macrophages. Subsequent 
invivo studies showed that all four TDCMs were effective in prophylactically, as well 
as therapeutically, inhibiting lung metathesis produced by the highly metastatic 
tumour cells, colon 26-M3.1 carcinoma and B16-BL6 melanoma. The compounds 
were injected intravenously into mice as oil emulsions and again the 2R,3R-TDCM 
and 2S,3S-TDCM were shown to be most effective at inhibiting metathesis. The anti-
metastatic effects of TDCMs were seen to be much higher than that of TDMs. 
Furthermore, it was shown that the lethal toxicity of TDMs, apparent in mice, was 
not exhibited by the TDCMs thereby making TDCMs better candidates for future 
biological studies.
104
  
The effect of TDCMs on the production of IL-6 in in vivo murine models has also 
been explored.
96
 TDCMs induced a more potent immune response than the mono-
esters; the natural TDCM with 2R,3R stereochemistry and a C14 lipid on the fatty 
acid residue was the most active (based on IL-6 accumulation in mice serum). This is 
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an important observation and provides further evidence for the potential use of 
natural TDCM in the treatment of cancer and other diseases.  
 
1.5.4 TDM- Reported Synthesis and Biological Activity  
1.5.4a Introduction 
TDMs are the most complex form of 6,6'-diesters isolated from mycobacterial 
species. For isolation and characterisation of TDMs see section 1.4.5. The 
complexity of TDMs has presented many challenges during their synthesis, though 
much elegant work has been achieved in this field, particularly by Baird and co-
workers whose initial work focussed on the synthesis of various mycolic acids, 105106,107,108,109,110,111,112,  113 
and more recently extended to the synthesis of individual TDMs.
114
  
 
1.5.4b TDM synthesis  
One of the first mycolic acids prepared by Baird and co-workers was α-mycolate (39, 
Scheme 6)
106
 which they later transformed into α-TDM 10.114  The key steps in the 
synthesis included esterification between mycolic acid 39 and TMS trehalose 17 
(obtained from α,α-trehalose following Johnson‟s procedure),65 with mycolic acid 39 
obtained from Julia reaction
115
 between aldehyde 40 and cyclopropane building 
block 41. Aldehyde 40, in turn, was synthesised via Fráter-Seebach alkylation 
between THP-ether 42 and tetracosanoyl iodide (43). THP-ether 42 was accessed 
from epoxide 44, itself obtained from aspartic acid.
116
 The cyclopropyl building 
block 41 was prepared via Julia reaction between cyclopropyl building blocks 45 and 
46, whereby both intermediates were synthesised from the same common precursor 
47.
117
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Scheme 6. Retrosynthesis of α-TDM 10. 
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1.5.4c TDM Biological activity  
Although TDMs have been shown to play a role in the pathogenesis of M. tb  by 
conferring protection to the bacteria against harsh environmental 
conditions,
17,18,118,119
 it is the biological activity of TDMs, which have been of much 
interest over the past years. TDMs exhibit anti-tumour activity,
120,121
 adjuvant 
activity,
73
 anti-bacterial properties,
122,123
 and have the ability to induce granuloma 
formation 124,125 ,126,        127      and angiogenesis.
128
 
TDMs exhibit anti-tumour activity, through tumour prevention, tumour regression 
and immunisation. A number of studies have been conducted to illustrate the effect 
of TDM on various tumour cells. In a study by Yarkoni et.al., prior injection of 
TDMs in mice was shown to suppress the growth of Ehrlich Ascites tumour cells.
129
 
The tumour regression property of TDMs was demonstrated in a study where the 
growth of an ascetic rat hepatoma was suppressed in a mouse model following 
injection of TDM as an emulsion in peanut oil.
130
 In another study, administration of 
TDMs as liposomes led to activation of macrophages, subsequent nitric oxide (NO) 
production, and the development of anti-tumour activity against synergenic P77 
fibrohistiocytoma tumour cells.
120
 
TDMs exhibit adjuvant activity, as seen by Bekierkunst et al.,
131
 where it was found 
that pre-injection of TDMs followed by injection of antigen into the same footpad of 
mice induced a high antibody production, whereas injection of antigen alone into 
contralateral footpads resulted in a lower antibody production. A number of studies 
have also shown induction of IL-4, IL-6 and IL-10 production after exposure of mice 
cells to TDMs, indicating that TDM could potentially enhance antibody production.
36
 
In another study, it was found that TDMs caused a significant increase in IFN-γ 
production, which was accompanied by the expansion of natural killer (NK) cells and 
upregulation of MHC class II on macrophages.
132
 The increased proportion of Th1 
cells evident after 3 weeks suggest that TDMs could be potentially used as the 
adjuvant component of Th1 vaccines (e.g. cancer vaccines). 
TDMs have also been shown to produce granulomas similar to those formed during 
mycobacterial infection.
133
 The purpose of granulomas is to contain the 
mycobacterium in distinct foci preventing the spread of infection and making 
32 
 
destruction of the bacterium by cell-mediated immunity easier. However, it also 
serves to protect the bacterium from the host organism‟s natural defence system and 
allow the bacterium to multiply inside host cells.  
Inflammatory granulomas are usually associated with angiogenesis, and several 
studies have been conducted to determine the effects that TDMs have on granuloma 
formation and angiogenesis.
128,134,135
 The production of  vascular endothelial growth 
factor (VEGF) and IL-8, which are crucial for angiogenesis, were initiated in the 
presence of TDMs in macrophages indicating that TDMs play a major role in 
angiogenesis by inducing the production of cytokines required for this process.  
Cord factors have also been shown to stimulate non-specific resistance against 
bacterial infections and parasites. Mice injected with TDMs were protected against 
Salmonella typhi strain Ty2 or Salmonella typhi strain SR11.
136
 Similar studies found 
that TDMs induce non-specific response against K. pneumoniae and L. 
monocytogenes.
123
 
  
1.6 Fráter-Seebach alkylation in TDCM and TDM 
syntheses 
 1.6.1 The Fráter-Seebach alkylation 
As highlighted previously in 1.5.3b and 1.5.4b one of the key steps in TDCM and 
TDM synthesis is the Fráter-Seebach alkylation. Defined as a highly efficient means 
of diastereoselectively introducing -substituents to chiral -hydroxy-esters, this 
methodology was proposed by Fráter in 1979. He reported that by utilising LDA as a 
base, ethyl (S)-3-hydroxybutyrate (48) could be alkylated with methyl, allyl, butyl 
and benzyl bromide to give the corresponding (2S, 3S)-alkylated products 49a-c in 
good yield and excellent diastereoselectivity (Scheme 7).
98,99
 Similar methodology 
was also used for the alkylation of ethyl (R)-3-hydroxyvalerate using propyl iodide 
as the electrophile.
137 
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Scheme 7. Fráter‟s alkylation.98,99 
 
At approximately the same time as Fráter, Seebach also performed pioneering studies 
in this field, as illustrated by the alkylation of diethyl malate 50 with methyl, allyl 
and benzyl halides to yield the alkylated product 51a-c (Scheme 8).
97 
Again, 
excellent diastereoselectivities, in favour of the anti-isomer, and good yields were 
reported for the α-alkylations. To recognise the contributions by both research groups 
to this field, the α-alkylation of β-hydroxy-esters is thus referred to as the Fráter-
Seebach alkylation.   
 
Scheme 8. Seebach‟s alkylation.97 
 
Over the years, the Fráter-Seebach alkylation has formed a crucial step in the 
preparation of a variety of biologically important compounds including natural 
products
138,139,140
 and derivatives thereof,
141,142,143
 enzyme inhibitors,
144
 and other key 
chiral building blocks.
145
 The methodology has also been modified by the addition of 
HMPA to the reaction vessel so as to enhance the efficacy of the reaction. Despite 
the versatility of the Fráter-Seebach alkylation in organic synthesis, the extension of 
this methodology to longer chain alkyl halides, however, has been met with mixed 
success.
96,105,106
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1.6.2 Scope and limitations of the Fráter-Seebach alkylation in the 
synthesis of trehalose glycolipids 
During their initial syntheses of mycolic acids en route to the preparation of TDMs, 
Baird and co-workers used the Fráter-Seebach alkylation for the introduction of the 
α-chain of the mycolic acid.105,106 The synthesis of the α-alkyl-β-hydroxy fragment 
started with a Grignard type ring-opening of epoxide 44 to produce alcohol 52 as a 
single enantiomer (Scheme 9). Alcohol 52 was then transformed into diol 53 in four 
steps, after which selective protection of the primary hydroxyl in 53 as the tert-
butyldiphenylsilyl (TBDPS) ether, followed by Fráter-Seebach alkylation using 
tetracosanyl iodide 43 furnished hydroxy-ester 54, albeit in modest (31%) yield. 
Protection of the secondary alcohol in 54 as an acetate, followed by deprotection of 
the primary hydroxyl, and subsequent oxidation then yielded aldehyde 40, the core 
fragment of mycolic acid.  
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Scheme 9. Fráter-Seebach alkylation in mycolic acid synthesis.
105,106
 
 
To circumvent the low yield of α-alkylation with tetracosyl iodide, Baird and co-
workers later developed a chain-elongation strategy
112
 in order to install the required 
lipid at the α-position (Scheme 10). Here, hydroxy ester 55 was subjected to the 
Fráter-Seebach reaction with allyl iodide in the presence of HMPA to yield the α-
alkylated ester 56 in an improved 62% yield. The α-alkylated ester 56 was further 
derivatised to oxo-ester 57 via protection of the hydroxyl as the TBDMS ether 
followed by oxidation of the alkene to the corresponding aldehyde. Elongation of the 
α-position in 57 was achieved via Julia olefination with tetrazole 58, followed by 
subsequent removal of the TBDMS group and hydrogenation of the double bond to 
yield hydroxy ester 59. Although this methodology led to an increased yield for the 
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Fráter-Seebach reaction, additional steps were required to generate the desired alkyl 
length at the α-position.  
 
Scheme 10. Chain-elongation methodology in mycolic acid synthesis.
112
  
 
In their synthesis of TDCM and analogues, Nishizawa et al. noted similar difficulties 
when performing a Fráter-Seebach alkylation with long chain alkyl (eicosanyl) 
iodide.
96 
Although the synthetic strategy was successful for the synthesis of natural 
TDCM and analogues with shorter corynomycolic chains (e.g. 37a-c) (Scheme 5), 
TDCM analogues with the C20 alkyl chain (e.g. 37d) could not be synthesised via a 
Fráter-Seebach alkylation of tetracosanoyl β-hydroxy functionalised ester 36 with 
eicosanyl iodide (Scheme 11).  
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Scheme 11. Fráter-Seebach alkylation in corynomycolic acid and analogues 
syntheses.
96 
  
 
To accomplish the synthesis of the C20 TDCM analogue, 22, the authors thus 
resorted to a different strategy involving the γ-alkylation of tert-butyl acetoacetate 
(34) with bis-homoprenyl iodide 60 to form ester 61 (Scheme 12). Stereoselective 
reduction of the ketone in 61 using (R)-BINAP-RuCl2 and hydrogen gave hydroxy 
ester 62, which was subjected to a Fráter-Seebach alkylation using eicosanyl iodide 
to form product 63 in 55% yield. Here, the presence of a shorter lipid on ester 62 was 
thought to facilitate the Fráter-Seebach alkylation by increasing the solubility of the 
substrate. Reductive etherification of 63 then afforded benzyl ether 64, which was 
subjected to ozonolysis, followed by Wittig reaction and subsequent treatment with 
TMSOTf,  to liberate mycolic acid 65. Finally, acid 65 was coupled to the hexa-
benzyl protected trehalose derivative 33, followed by hydrogenation of the benzyl 
groups and reduction of the double bond to yield the desired C20 TDCM 22.  
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Scheme 12. Alternate route for C20 TDCM analogue synthesis.
96
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1.7 Trehalose diester probes to study trehalose 
immunology  
1.7.1 Introduction 
To date, aside from Mincle, there are no other known receptors for TDMs (and 
associated linear analogues such as TDB). One way to determine potential proteins 
that trehalose diesters bind to and interact with, is through the development of 
trehalose-diester probes, for use in affinity based proteome profiling (AfBPP). This, 
in turn, will aid in our understanding of the mechanism of action of this intriguing 
class of bio-molecules. 
 
1.7.2 Affinity Based Proteome Profiling (AfBPP) 
1.7.2a Overview 
Proteomic research focuses on the study of proteins, their functions, and subsequent 
interactions with other bio-molecules in complex biological systems. Instead of 
studying individual proteins separately, proteomic research allows for the study of 
distinct proteins expressed at the same time by an organism or cell type. 
Traditionally, proteins were separated using techniques such as 1D/2D gel-
electrophoresis and isotope coded affinity tagging (ICAT), followed by 
determination of the relative abundance.
146
 An alternate strategy that is now 
commonly employed is activity or affinity based proteome profiling (ABPP or 
AfBPP). ABPP and AfBPP use site-directed chemical probes to elucidate the 
functional state of enzymes in complex biological systems. They use relatively small 
organic molecules to label specific enzymes at their active site (and not their inactive 
precursor or inhibitor-bound forms).
146
 These methods are better since they can 
detect important post-translational forms of protein regulation like those mediated by 
protein-protein and/or protein-small molecule interactions.
147
 To date, probes have 
been developed for a number of enzyme classes, and these have provided a means of 
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elucidating enzyme functions, and understanding enzyme activity in specific 
physiological and pathological processes. 
 
1.7.2b Basic Technology of AfBP Probes 
To ensure selective binding of activity and affinity based proteome (ABP and AfBP) 
probes to proteins and prevent cross reactivity with other proteins in the proteome, 
most probes consist of a combination of binding and reactive groups that target 
conserved mechanistic or structural features in a protein‟s active site. The probe 
contains three major elements: the recognition group, the reactive group, and the tag. 
The recognition group directs the ABP probe and AfBP probe to the target protein 
and is designed in a way to resemble the natural substrate of the target protein. 
Closely attached to the recognition group is the reactive group („trap‟) that reacts 
with amino acids in the proteins active site and thus forms a bond between the probe 
and protein. The recognition and reactive group are linked most often via a spacer 
unit to a tag which allows for visualisation and/or purification of the bound protein 
(Figure 16).
148
  
 
 
 
 
Figure 16.  Representative cartoon of Activity/Affinity Based Proteome Probe.  
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1.7.2c AfBPP vs ABPP 
The difference between ABPP and AfBPP arises from the different reactive groups 
employed by the two profiling methods.
13
 In ABP probes, electrophilic traps are 
present which are suited for proteins that contain a nucleophilic amino acid side 
chain residue (e.g. serine, cysteine, threonine) in their active site such as: cysteine 
proteases, serine hydrolases, and proteasome subunits. ABP probes thus involve a 
directed approach in which individual probes are designed to target specific proteins 
(Figure 17A). In contrast, AfBP probes employ the use of photoreactive trap groups 
and are commonly used for proteins not relying on nucleophilic residues in their 
active site, for example, metalloproteases and histone deacetylases. Most 
photoreactive groups are used to label proximal resides in the proteins active site 
following irradiation with light (Figure 17B). The use of AfBP probes offer a non-
directed way of profiling proteins from several different classes, and in many cases 
are commonly used to profile proteins not accessible by ABP probes.  
 
Figure 17.ABPP (A) vs AfBPP (B).    
 
A 
A 
B 
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1.7.2d Tag Groups 
The tag group on a probe is used to facilitate the characterisation of the target 
protein. Some tags that are commonly used include fluorophores [(e.g. rhodamine, 
66)], biotin (67) and latent analytical handles like azides and alkynes (68) (Figure 
18).
149,150
  
 
Figure 18. Common reporter tags used in ABP and AfBP probes. 
 
The use of azides and alkynes to visualise protein targets post-labelling overcomes 
the problem of the bulkiness associated with fluorophores which can influence the 
uptake of the probe into the cells. In this approach (known as a two step labelling 
process), the ABP or AfBP probes tag is replaced by a ligation handle, which can be 
connected to the reporter group after the protein is captured. The most common 
ligation reactions used are Huisgen 2,3-dipolar cycloaddition or „click‟ reactions. 
These can be copper catalysed (I)
151
 or strain-promoted (II) (Figure 19).
152
 Recently 
a new reagent has been reported by Boons and co-workers to promote a strain-
promoted click reaction after irradiation with light.
153
 This has been termed the 
„photoclick‟ reaction (III).  
43 
 
 
Figure 19. Ligation methods for azide and alkyne coupling. 
 
1.7.2e Reactive Groups 
To be used in AfBP probes, a photoreactive group needs to meet certain criteria. 
First, they need to be activated only upon irradiation with light of a specific 
wavelength which will not damage biological systems (λact > 300 nm).
154
 Second, the 
generated reactive species should have a shorter life span than the lifetime of the 
studied protein-substrate complex in order to limit non-specific labelling. It is also 
important that the activated species reacts with any chemical entity in close 
proximity to form a stabile covalent adduct. Finally, the photoreactive group should 
be small in order to minimise its influence on the binding mode and activity of the 
AfBP probe towards the protein. 
The use of photoreactive groups was first reported by Westheimer and co-workers in 
1962 whereby they used a diazoacetyl group to deactivate chymotrypsin via 
photolysis.
155
 Over the years, many photoreactive groups have been developed but 
only few meet the requirements set out above. The common trap systems used today 
for probes are benzophenones (69, first reported in 1973),
156
 aryl azides (70)
157
 and 
diazirines (71) (Figure 20).
158
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Figure 20. Examples of common trap systems for AfBP probes. 
 
A major advantage of using benzophenones and diazirines, as opposed to aryl azides, 
is that they can be excited at wavelengths of 350-360 nm, and therefore no 
significant damage to the biological system occurs. Aryl azides have their maximum 
absorption wavelength below 300 nm; however this could be improved by using an 
electron withdrawing substituent (e.g. nitro, hydroxyl, and acyl groups) on the phenyl 
group. The major advantage of using aryl azides, is their small size which allows for 
easy incorporation into natural biological compounds without too much alteration of 
the original structure. 
Unlike diazirines and aryl azides, most benzophenone building blocks are 
commercially available and in recent years, many examples of AfBP probes 
containing benzophenone have been reported.
159,160,161
 Although, the benzophenone 
group might seem like an ideal photo-crosslinking reagent, it has drawbacks such as 
being relatively bulky, which may influence the interaction between the enzyme and 
substrate and lead to non-specific labelling. Benzophenones also need prolonged 
time for irradiation (>30 minutes) to result in reasonable cross-linking. The 
mechanism of cross-linking of the benzophenones to proteins can be explained as 
depicted in Scheme 13.
162
 After irradiation of benzophenone, the triplet diradical 72 
is formed which abstracts a hydrogen atom from the α-centre of a nearby amino acid 
73 to form a ketyl radical (74) and an amino acid alkyl radical (75). These radical 
species then rapidly combine to form the desired cross-linked species, benzhydrol 76. 
In the presence of a glycine amino acid residue (R' = H), there is the possibility of 
water eliminating from bezhydrol (76) resulting in olefin 77, detection of which can 
be used to elucidate the presence of glycine in the active site of the protein. If 
diradical 72 reacts with water, the corresponding hydrate 78 forms, which rapidly 
loses water to form the starting benzophenone. One possible side reaction that can 
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take place is homodimerisation of the ketyl 74 to form benzopinacol 79, however due 
to the relative large difference between hydrogen abstraction and recombination to 
form the benzhydrol 76, only a small amount of this by-product is formed. 
  
Scheme 13. Chemistry of benzophenone after photolysis. 
 
1.7.2f Applications and Synthesis of AfBP probes 
Over the years, many aryl azide based AfBP probes have been developed which can 
target various classes of enzymes and enhance our understanding of the mechanistic 
and functional states of these enzymes. In one such study, Dive and co-workers 
synthesised AfBP biotinylated probe 80 and ABP biotinylated probe 81 to study     
matrix metalloproteinases (MMPs) from tumour extracts (Figure 21).
163
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Figure 21. Aryl azide and diazirines based AfBPs. 
 
There are also a number of interesting AfBP probes containing diazirines as „traps‟, 
and these include photo-leucine (82) and photo-methionine (83), synthesised in 2005 
by Thiele and co-workers, which were used as photoactivatable amino acids to study 
protein-protein interactions in living cells.
164
 Here, it was shown that both 
photoactivatable amino acids could be readily incorporated into proteins, and 
protein-protein interactions not identified previously were detected using these traps. 
Qui et al. reported on the synthesis of L288–probes 84 and 85, and analysed them for 
their ability to label methionine aminopeptidases (MetAPs).
165
 L288 (86) is a potent 
inhibitor of type I MetAP, an enzyme that is a potential target for new anti-bacterial 
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and anti-fungal therapeutics. Both ABPs 84 and 85, were able to bind MetAP, with 
probe 85 being more selective for MetAP protein labelling.  
There are many examples of AfBP probes containing benzophenone groups reported 
in literature. To study histone deactylases (HDACs), a key regulator of gene 
expression that assembles into larger protein complexes, Salisbury and Cravatt 
reported the synthesis of SAHA-Bryne 87 (Figure 22).
159
 This probe contains the 
important structural elements of HDAC inhibitor suberoylanilide hydroxamic acid 
[SAHA, (88)] as well as benzophenone and alkyne moieties for targeting the 
HDACs. SAHA-Bryne 87 demonstrated good HDAC binding specificity and could 
also be used to measure HDAC content in different forms of cancer. Results 
indicated that SAHA was quite selective for HDACs and thus could be a valuable 
tool for profiling both the activity of HDAC proteins, and the binding proteins that 
regulate their function, particularly in cancer.
159
 Benzophenone based ABPs have 
also been used for targeting metalloproteases. For example, GM600 (89) a matrix 
metalloprotease inhibitor, was converted to photoaffinity probe 90 by incorporating a 
benzophenone building block and a fluorophore.
160
 This probe could then be used to 
covalently label and visualise several active MMPs in complex proteomes.  
 
Figure 22. Benzophenone based AfBP probes. 
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1.7.2g Click chemistry based AfBP probes 
In recent years, the use of click chemistry (CC) in proteomic research has 
significantly increased. Earlier designs of AfBP probes used CC as a mode of 
introducing the linker unit. Due to the high specificity of this reaction, functional 
group protection and deprotection was not required and the trizole ring, formed after 
ligation, was thought to facilitate some protein-binding interactions. CC probes are 
commonly used since the „reporter‟ group in this case is either the alkyne or azide 
moiety, which is much smaller than other reporter groups (e.g. biotin, fluorophores) 
and thus does not hamper the interaction between the probe and protein. Fuwa et al. 
used CC to synthesise a diazirine based benzodiazepine probe 91 (Figure 23), in 
order to study the enzyme γ-secretase.166 CC was also used by Yao and co-workers, 
to synthesise probe 92 for the detection of all four plasmesins in the malarial parasite 
Plasmodium falciparum.
167
  
 
Figure 23. CC-based AfBP probes. 
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1.7.3 Elucidation of bound enzymes 
Once the proteins have been „trapped‟ by the probe, the complex is isolated, digested 
using trypsin and the peptide fragments are characterised using analytical platforms 
like gel electrophoresis (e.g. SDS-PAGE) and liquid chromatography-mass 
spectrometry (LC-MS).
146
 Trypsin is commonly used for peptide digestion as it is 
known to cleave peptide chains at the carboxyl side of lysine and arginine residues 
specifically, except when they are attached to a proline residue. In gel 
electrophoresis, the probe-treated proteome is first resolved using one- (1D) or two-
dimensional (2D) polyacrylamide gel electrophoresis (PAGE), which differentiates 
peptide fragments based on their molecular weights, and the labelled proteins are 
visualised by in-gel fluorescence scanning (for fluorescent probes) or avidin blotting 
(for biotinylated probes). In LC-MS analysis, after digestion with trypsin, the 
streptavidin enriched peptides are analysed using LC-MS/MS.  
 
1.8 Thesis Outline 
The work described in this thesis focuses on trehalose glycolipids, particularly the 
synthesis and biological testing of these compounds. In Chapter 2, investigations 
into the synthesis of trehalose diesters of fatty acids (TDEs, 14, Figure 24) with 
varying lipid lengths and a discussion on the different synthetic strategies employed 
in order to obtain all required compounds will be presented. This will be followed by 
the biological evaluation of TDEs by way of macrophage activation studies and 
subsequent investigation of structural requirements of trehalose glycolipids for the 
activation of macrophages in Chapter 3. The effect of TDEs on cytotoxicity would 
also be analysed and correlations made to the previously observed anti-tumour 
activity of these compounds. 
50 
 
 
Figure 24. TDEs 
 
In Chapter 4, the development of an improved method for the α-alkylation of β-
hydroxy-esters will be presented (Scheme 14). Here, it will be illustrated that diethyl 
malate (50) is more effectively alkylated using allylic iodides, 93, to yield α-
alkylated-β-hydroxy esters, 94, when compared to alkyl iodides, in the Fráter-
Seebach alkylation methodology. This method is commonly used in the synthesis of 
TDMs and TDCMs and thus our methodology could lead to more effective synthesis 
of these glycolipids.  This will be followed by the use of this improved methodology 
for the synthesis of a trehalose monocorynomycolate (TMCM) analogue (95, Figure 
25) in Chapter 5 in order to set the conditions required for the synthesis of other 
TMCMs and related TDCM glycolipids. 
 
 
Scheme 14.  Improved methodology for Fráter-Seebach alkylation  
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Figure 25. TMCM analogue  
 
Chapter 6 would focus on the synthesis of an AfBPP probe (96, Figure 26), which 
can be used to elucidate the proteins that TDMs bind to upon interaction with host 
cells. The probe will consists of a benzophenone trap and an alkyne tag group and 
together with the reactive trehalose moiety has all the components needed in an AfBP 
probe.    
 
Figure 26. AfBPP probe  
 
Chapter 7 would comprise of a summary of this thesis and some of the future work 
which will be carried out. Unless otherwise stated, all work was performed by the 
candidate. 
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2.1 Introduction 
Trehalose diesters of fatty acids (TDEs, 1, Figure 1) are the simplest form of 
trehalose glycolipids that have been studied for many decades for their biological 
activities such as anti-tumour, anti-bacterial and macrophage activation 
properties.
2,3,4
 Perhaps the most well known member of the TDE family is the C22 
diester, trehalose dibehenate (TDB) that has shown comparable macrophage 
activation properties to the more complex trehalose dimycolates (TDMs).
5
 This 
observation has renewed interest in these glycolipids and one area of interest for us 
was to investigate the effect that lipid length has on the ability of TDEs to activate 
macrophages and lead to subsequent activation of the immune system.  
To correlate the lipid length to the biological activity of these glycolipids (see 
Chapter 3 for biological analysis), we planned to synthesise TDEs containing short 
2 TDE Synthesis1 
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(C4), medium (C7, C10), long (C18, C20 and C22) and very long (C26) aliphatic 
lipid chains (Figure 1).  
 
Figure 1. Target TDEs 1 
 
2.2 TDE Synthesis  
2.2.1 Initial Strategy 
In order to synthesise a range of TDEs, we envisaged a single synthetic strategy that 
could be used for the synthesis of all these related compounds. To this end, 
commercially available α,α'-D-trehalose (2) was selectively tritylated at the 6 and 6' 
positions using trityl chloride and pyridine,
6
 perbenzylated
7
 using benzyl bromide 
and sodium hydride to form the fully protected compound 3 in 85% over two steps 
(Scheme 1). The trityl groups were subsequently removed using trifluoroacetic acid 
(TFA) and triethylsilane resulting in diol 4 in good (80%) yield. Diol 4 was then 
subjected to esterification with various fatty acids using 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDCI) and 4-dimethylamino-pyridine (DMAP) 
to form the fully protected diacyl trehaloses 5a-g. Most of the carboxylic acids were 
sourced commercially, except for docosanoic acid which was obtained after Jones 
oxidation of docosanol.
8
 The optimum conditions for the esterification reaction were 
found to be 1 equiv. of diol 4, 4.4 equiv. of the acid, 6.6 equiv. of EDCI, and 0.15 
equiv of DMAP with the reaction being stirred overnight. However, it was noted that 
longer reaction times were required for the longer lipids (Table 1). With the 
protected diacyl trehaloses 5 in hand, attempts were then made to remove the benzyl 
protecting groups so as to generate the target TDEs 1. Initially, Pd/C in 
CHCl3:MeOH (3:2) was used for the reaction; however, no product formation was 
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seen with only starting material retrieved from the reaction mixture. Next, catalytic 
Pd(OH)2 was used and the debenzylation proceeded uneventfully for the C4–C18 
derivatives (5a-d, Table 1, Entries 1-4). Unfortunately, the extension of this 
methodology to the C20–C26 homologues (5e-g, Entries 5-7) was unsuccessful and 
only product degradation was observed.   
 
 
 
Scheme 1. Initial synthetic strategy 
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Table 1. Formation of TDEs 
Entry Cn  Coupling 
Conditions  
EDCI = 6.6 equiv., 
DMAP = 0.15 equiv 
CH2Cl2  
Yield-
Coupling 
(%)  
Debenzylation  
Conditions  
Yield-
Debenzylation 
(%)  
 
1 
 
2  
 
C4 acid = 4.4 equiv., 
overnight, r.t. 
 
   88  
 
Pd(OH)2, 
CHCl3:MeOH 3:2,     
1 atm  
 
     62  
2 5  C7 acid = 4.4 equiv., 
overnight, r.t. 
   85  Pd(OH)2, 
CHCl3:MeOH 3:2,     
1 atm  
     67  
3 8  C10 acid = 4.4 equiv., 
overnight, r.t. 
   83  Pd(OH)2, 
CHCl3:MeOH 3:2,     
1 atm  
     63  
4 16  C18 acid = 4.4 equiv., 
overnight, r.t. 
   85  Pd(OH)2, 
CHCl3:MeOH 3:2,     
1 atm  
     88  
5 18  C20 acid = 4.4 equiv., 
overnight, r.t. 
   80  Pd(OH)2, 
CHCl3:MeOH 3:2,     
1 atm  
     0 
6 20  C22 acid = 4.4 equiv., 2 
days, r.t. 
   78  Various (see Table 2)      0 
7 24  C26 acid = 4.4 equiv., 7 
days, r.t. 
   71  Various (see Table 2)      0 
 
The key reason for the low reactivity of the longer chain TDEs was attributed to the 
low solubility of these compounds leading to reduced reactivity. Hence different 
catalysts, solvent systems, reaction temperatures and pressures were used, but at best, 
only minor amounts of partially debenzylated products were observed (Table 2). This 
result was disappointing, however, the sluggish hydrogenation of benzyl protected 
long-chain glycolipids has been reported previously.
9
 The lack of reactivity of the 
long chain diacyl trehaloses 5e-g towards hydrogenation led us to adopt an 
alternative approach for the preparation of the C20–C26 TDEs focusing on using 
another protecting group for the trehalose unit. 
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Table 2. Attempted debenzylation conditions  
Entry Cn  Debenzylation  Conditions Results  
 
1 
 
20 
 
Pd(OH)2, CHCl3:MeOH 3:2, 1 atm at 
r.t. over 3 days  
 
Degradation (loss of lipid chain) and 
starting material  
2 20 Pd(OH)2, CHCl3:MeOH 3:2, 15 psi at 
r.t. overnight 
Degradation  
3 20 Pd/C, EtOH:EtOAc:CHCl3 1:1:1,     
15 psi at r.t. overnight  
partially-debenzylated products  
4 20 Pd/C, THF:EtOH:EtOAc 1:1:1, 1 atm 
at 50 °C, over 2 days  
Degradation  
5 24  Pd(OH)2, CHCl3:MeOH 3:2, 1 atm at 
r.t. over 3 days  
Degradation  
6 24 Pd/C, THF:EtOH:EtOAc 1:1:1, 1 atm 
at 50 °C over 4 days  
Degradation  
 
2.2.2 Alternate Synthetic Strategy  
With a view to using protecting groups that could be more readily removed at the 
final stage in the synthesis, we employed the strategy of Toubiana and co-workers to 
prepare 2,2',3,3',4,4'-hexa-O-trimethylsilyl-,-trehalose.10 This elegant two-step 
one-pot synthesis of hexa-silylated trehalose was proposed by Johnson
11
 and the 
reaction proceeds through per-silylation of the trehalose moiety followed by the 
removal of the more labile primary trimethylsilyl (TMS) ethers using potassium 
carbonate. The reaction is initiated with the attack on the silyl atom in N,O-bis-
trimethylsilylacetamide (BSA) (I) by the fluoride anion of tetra-butylammonium 
fluoride (TBAF), generating intermediate II (Scheme 2).  The preference for attack 
on this silyl group is due to the stability of the resulting intermediate II, attributed to 
resonance stabilization of the negative charge on the oxygen in II by the nitrogen as 
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shown in intermediate III. The negatively charged nitrogen in intermediate III 
abstracts a proton from one of the trehalose hydroxyls. The resulting negatively 
charged oxygen in IV then attacks the silyl group in another molecule of BSA (I) 
leading to the formation of a TMS ether (V) and regeneration of the BSA 
intermediate (II). 
 
Scheme 2. Reaction mechanism for BSA mediated silylation of trehalose  
 
Accordingly, ,-D-trehalose (2) was treated with BSA and catalytic TBAF, 
followed by K2CO3 to generate diol 6 in a good (85%) yield over two steps (Scheme 
3). Diol 6 was then coupled to the longer chain carboxylic acids using the protocols 
outlined in Table 3. Formation of the C20 trehalose diester (n = 18) proceeded 
uneventfully mediated by EDCI and DMAP in CH2Cl2 to give trehalose diester 7e in 
93% yield (Table 3, Entry 1). Surprisingly, extension of this methodology to the C22 
homologue proved unsuccessful with none of the desired trehalose diester 7f 
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observed even after the use of excess acid, the addition of further equivalents of 
EDCI and DMAP, or refluxing of the reaction mixture (Entries 2-5). In all instances, 
only minor (<40%) amounts of the corresponding mono-ester were observed. 
Although, a change of solvent to dimethylformamide (DMF) did not lead to any 
improvement (Entries 4 and 5), the use of toluene and heating the reaction at 70 °C 
for 2 days saw complete conversion of starting material and the desired trehalose 
diester 7f was isolated in 86% yield (Entry 6). These conditions were then used for 
the synthesis of the C26 trehalose diester 7g, which was formed in a respectable 
(60%) yield although a longer reaction time (6 days) was required to see complete 
consumption of starting material (entry 7). The TMS-groups were then readily 
removed following subjection of the diesters to Dowex-H
+
 resin to yield the target 
TDEs (1e-g) in 80%, 80% and 70% yield, respectively. 
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Scheme 3. Alternate synthetic strategy used 
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Table 3. Esterification reaction using diol 6 
Entry Cn Conditions 
 
EDCI (6.6 equiv.), DMAP (0.15 equiv.), 
Product Yield
[a]
 
1 18 CH3(CH2)18CO2H (4.4 equiv.), CH2Cl2, rt, 18 h 7e 93% 
2 20 CH3(CH2)20CO2H (4.4 equiv.), CH2Cl2, rt, 18 h 7f 0%
[b]
 
3 20 CH3(CH2)20CO2H (4.4 equiv.), CH2Cl2, reflux, 48 h 7f 0%
[b]
 
4 20 CH3(CH2)20CO2H (4.4 equiv.), DMF, rt, 48 h 7f 0%
[b]
 
5 20 CH3(CH2)20CO2H (4.4 equiv.), DMF, 50 °C, 48 h 7f 0%
[b]
 
6 20 CH3(CH2)20CO2H (4.4 equiv.), toluene, 70 °C, 48 h 7f 86% 
7 24 CH3(CH2)24CO2H (4.4 equiv.), toluene, 70 °C, 6 days 7g 60% 
[a] Isolated yield 
 [b] Only monoester (12–40%) was observed. 
 
In addition to the protected TDEs, the esterification reaction also yielded about 12-
20% of the protected trehalose monoesters of fatty acids (TMEs, 8f and 8g). Both the 
protected TMEs were more polar than the corresponding trehalose diesters 7f and 7g, 
making it possible to separate the monoesters from the diesters through silica gel 
flash chromatography. The protected TMEs were then deprotected using Dowex-H
+
 
resin to yield the target TMEs 9f and 9g in good yields.  
 
2.2.3 Isolation of final compounds and characterisation  
For C4–C22 TDEs, the compounds were readily purified using silica gel flash 
chromatography, with the compounds eluting in 1–3% MeOH in EtOAc. For the 
purification of C26 TME (9g) and TDE (1g) silica gel chromatography was not ideal 
for the separation of compounds from impurities. Reversed phase chromatography 
gave better results with the C26 TME eluting in MeOH, however, the C26 TDE 
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could only be eluted using pyridine in reversed phase chromatography. The final 
compounds were obtained as white solids and NMR analyses of the glycolipids 
comprising of 18 carbon lipid chains or lower were carried out in a mixture of 
deuterated chloroform and methanol. For the longer TDEs and TMEs, pyridine was 
used as the NMR solvent.   
The TDEs and TMEs were characterised based on NMR and mass spectral analysis. 
For the C26 TME (9g, Figure 2 and 3), the chemical shifts for the anomeric protons 
were different in the 
1
H NMR spectrum, with two doublet resonances observed at 
5.84 (J = 3.9 Hz) and 5.82 ppm (J = 3.9 Hz), indicating that the trehalose molecule 
was no longer symmetrical. In addition, the protons at 6 and 6' positions had very 
different chemical shifts indicative of different groups attached to the carbons at 
these positions. Integral comparison of the α-protons of the lipid chain and the 
anomeric protons indicated a 1:1 ratio. An HMBC correlation was found between the 
carbonyl carbon at 173.8 ppm and the protons at the 6 position but not at the 6' 
position and this together with the mass spectral analysis [HRMS(ESI) m/z calcd. for 
[C38H72O12+Na]
+
: 743.4916, obsd.: 743.4907] unequivocally established that only 
one of the primary positions in the trehalose moiety was esterified. On the other 
hand, for the C26 TDE (1g, Figure 4 and 5), the 
1
H NMR spectrum showed only one 
doublet resonance at 5.78 ppm (J = 3.7 Hz) for the anomeric protons and using 
COSY correlations the resonances for the protons at 6a/6a' and 6b/6b' positions were 
found to being 4.87 ppm (m) and 4.82 ppm (dd, J = 11.7 Hz, J = 5.4 Hz,) with both 
showing HMBC correlations to the carbonyl carbon at 173.8 ppm. Here, integral 
comparison of the α-protons of the lipid chain and the anomeric protons clearly 
indicated a 2:1 ratio indicating that lipid chains were attached at both the 6 and 6' 
position of the trehalose. Mass spectral analysis of the product was in agreement with 
the expected mass [HRMS(ESI) m/z calcd. for [C64H122O12 +Na]
+
: 1121.8783, 
obsd.:1121.8764]. Full assignments for all the compounds were made on the basis of 
2D NMR (COSY, HSQC and HMBC) (see experimental for full assignment).   
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Figure 2. 
1
H NMR spectrum of C26 TME (9g) 
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Figure 3. 
13
C NMR spectrum of C26 TME (9g) 
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Figure 4. 
1
H NMR spectrum of C26 TDE (1g) 
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Figure 5. 
13
C NMR spectrum of C26 TDE (1g) 
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2.3 Conclusion 
In this work, 7 TDEs ranging from C4-C26 were prepared, along with the C22 and 
C26 TMEs. Two different synthetic strategies were used to obtain these final 
compounds with the use of TMS protecting groups deemed more favourable in the 
synthesis of these trehalose glycolipids.  
 
2.4 Experimental Section 
Unless otherwise stated, all reactions were performed under N2. Prior to use, pyridine 
was dried and stored over 4 Å molecular sieves (4 Å MS), CH2Cl2 was distilled from 
P2O5 and toluene was dried and stored under Na wire. D-(+)-Trehalose dihydrate 
(Sigma), trityl chloride (Acros), anhydrous DMF (Acros), TBAI (Riedel-de Haen), 
NaH (Avocado Research Chemicals, 60% dispersion in mineral oil), Et3SiH (Sigma), 
TFA (Aldrich), EDCI (Aldrich), DMAP (Merck), n-butyric acid (BDH), heptanoic 
acid (BDH), decanoic acid (Merck), stearic acid (ICN Pharmaceuticals), arachidic 
acid (Sigma), 1-docosanol (Fluka), hexacosanoic acid (Acros), Pd (OH)2/C (Aldrich, 
20 wt%), TBAF (Aldrich), N,O-bis(trimethylsilyl)acetamide (Fluka), Dowex-H
+
 
(Supelco),  anhydrous Et2O (Biolab), EtOAc (Panreac), petroleum ether (Pure 
Science), anhydrous MeOH (Panreac), isopropanol (Pure Science), CHCl3 (Panreac), 
NaHCO3 (Pure Science), K2CO3 (Pure Science),  MgSO4  (Pure Science) and NaCl 
(Panreac) were used as received. All solvents were removed through evaporation 
under reduced pressure. Reactions were monitored by TLC analysis on Macherey-
Nagel silica gel coated plastic sheets (0.20 mm with fluorescent indicator UV254) via 
detection by UV-absorption (254 nm) and by dipping in 10% H2SO4 in EtOH 
followed by charring at 150 °C. Column chromatography was performed using Pure 
Science silica gel (40-63 μm). AccuBOND II ODS-C18 (Agilent) was used for 
reversed phase chromatography. High resolution mass spectra were recorded on a 
Waters Q-TOF Premier
TM 
Tandem Mass Spectrometer using positive electro-spray 
ionisation. Optical rotations were recorded on a Perkin-Elmer 241 polarimeter or 
Autopol II (Rudolph Research Analytical) at 589 nm (sodium D-line). Infrared 
spectra were recorded as thin films using a Bruker Tensor 27 FTIR spectrometer 
equipped with an Attenuated Total Reflectance (ATR) sampling accessory and are 
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reported in wave numbers (cm
-1
). Nuclear magnetic resonance spectra were at 20
 
°C 
in C5D5N, CD3OD or CDCl3 using a Varian INOVA operating at 500 MHz. 
Chemical shifts are given in ppm (δ) relative to solvent residual peak. NMR peak 
assignments were made using COSY, HSQC and HMBC 2D experiments. Melting 
points were obtained using a Gallenkamp Melting Point Apparatus. 
 
 
                                   2,2',3,3',4,4'-Hexa-O-benzyl-6,6'-di-O-
trityl-α,α'-D-trehalose (3). α,α'-Trehalose 2 (5.26 g, 14.6 
mmol) was co-evaporated with pyridine (3 x 20 mL) and then 
dissolved in 30 mL of pyridine. Trityl chloride (28.5 g, 102.2 
mmol) was added and the resulting mixture stirred at 40 °C under nitrogen for 16 h 
after which dry methanol (40 mL) was added and the reaction stirred for a further 0.5 
h. The solvent was removed under reduced pressure to give a pale yellow solid. 
Diethyl ether (100 mL) was added to the crude product and the resulting suspension 
filtered through a Büchner filter. The solid product was repeatedly washed with 
diethyl ether until free from triphenylmethyl chloride, as gauged by TLC. The solid 
was then washed with 3% NaHCO3 and dried under vacuum and stored in a 
dessicator.  
6,6'-Di-O-trityl-trehalose (2.57 g, 3.12 mmol) was co-evaporated with anhydrous 
DMF (3 x 5 mL) and dissolved in 15 mL of DMF. Catalytic TBAI (103 mg, 0.28 
mmol) was added and the resulting solution cooled down to 0 °C. Benzyl bromide 
(3.14 mL, 28.1 mmol) was added slowly to the reaction mixture followed by portion-
wise addition of sodium hydride (60% dispersion in mineral oil) (1.86 g, 46.7 mmol), 
and the reaction was allowed to warm up to room temperature. After stirring for 2 h, 
the reaction was quenched with MeOH (30 mL), stirred vigorously for 10 min and 
concentrated in vacuo. The resulting crude mixture was dissolved in Et2O (200 mL), 
washed with water (3 x 50 mL) and brine (50 mL), dried (MgSO4), filtered and 
concentrated in vacuo. The title compound was obtained after silica gel flash 
chromatography eluting in 15:1 (v/v) Pet. Ether/EtOAc, as a white crystals (3.62 g, 
2.65 mmol, 85% over 2 steps). Mp 91.0–94.0 °C; Rf = 0.5 (4/1, PE/EA, v/v); [α]
23
D = 
+60.5 (c = 1.0 CHCl3); IR (film): 3019, 2878, 2212, 1265, 1214, 744, 668 cm
-1
; 
1
H 
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NMR (500 MHz, CDCl3)  6.76–7.42 (m, 60H, Harom), 5.47 ( d, J1,2 = 3.7 Hz, 2H, H-
1), 4.92 (d, Ja,b = 10.7 Hz, 2H, CH-a, 3-O-Bn), 4.80 (d, Ja,b = 10.7 Hz, 2H, CH-b, 3-
O-Bn), 4.72 (d, Ja,b = 10.3 Hz, 2H, CH-a, 4-O-Bn), 4.67 (d, Ja,b = 11.9 Hz, CH-b, 2-
O-Bn), 4.66 (d, Ja,b = 11.9 Hz, 2H, CH-a, 2-O-Bn), 4.23 (d, Ja,b = 10.3 Hz, 2H, CH-a, 
4-O-Bn), 4.17 (bd, J4,5 = 9.6 Hz, 2H, H-5), 3.97 (t, J2,3 = J3,4 = 9.6 Hz, 2H, H-3), 3.87 
(t, J3,4 = J4,5 = 9.6 Hz, 2H, H-4), 3.72 (dd, J2,3  = 9.6 Hz, J1,2 = 3.7 Hz, 2H, H-2), 3.33 
(dd, J6a,6b = 10.3 Hz, J5,6a = 2.7 Hz, 2H, H-6a), 3.06 (dd, J6a,6b = 10.3 Hz, J5,6b = 1.7 
Hz, 2H, H-6b); 
13
C NMR (125 MHz, CDCl3)  143.8, 138.7, 138.2, 138.0 (Ci-Tr and 
Bn), 128.9, 128.4, 128.2, 128.1, 128.1, 127.8, 127.6, 127.5, 127.1, 126.9, 126.8 
(CHarom), 94.9 (C-1), 81.8 (C-3), 80.3 (C-2), 77.8 (C-4), 75.9 (CH2, 3-O-Bn), 75.1 
(CH2, 4-O-Bn), 72.5 (CH2, 2-O-Bn), 70.7 (C-5) and 62.2 (C-6); HRMS(ESI) m/z 
calcd. for [C92H86O11+Na]
+
: 1389.6068, obsd.: 1389.6072. 
 
                                  2,2',3,3',4,4'-Hexa-O-benzyl-α,α'-D-
trehalose (4). Et3SiH (0.75 mL, 4.74 mmol) was added to the 
hexa-O-benzyl-di-O-trityl-trehalose (3.24 g, 2.37 mmol) (co-
evaporated 3 x with toluene) in dry CH2Cl2 (30 mL). 10% 
TFA solution was then added drop-wise to the reaction mixture until the yellow 
colour no longer appeared. The reaction was completed in 30 min, (as determined via 
TLC monitoring) after which MeOH (6 mL), saturated NaHCO3 (20 mL) and brine 
(20 mL) was added. The aqueous layer was extracted with CH2Cl2 (2 x 50 mL) and 
the combined organic layer was dried (MgSO4), filtered and concentrated in vacuo. 
The residue was subjected to silica gel flash chromatography and eluted with 1:1 
(v/v) Pet. Ether/EtOAc to afford the title compound 4 as a colourless viscous oil 
(1.675 g, 1.90 mmol, 80%). Rf = 0.38 (PE/EA, 1/1, v/v); [α]
23
D = +68.0 (c = 1.0, 
CHCl3); IR (film): 3465, 3067, 3016, 2928, 2875, 1360, 1215, 1155, 1095, 1068, 
1027 cm
-1
; 
1
H NMR (500 MHz, CDCl3)  7.27–7.53 (m, 30H, Harom), 5.13 (d, J1,2 = 
3.6 Hz, 2H, H-1), 5.01 (d, Ja,b = 11.0 Hz, 2H, CH-a, 3-O-Bn), 4.89 (d, Ja,b = 11.0 Hz, 
2H, CH-b, 3-O-Bn), 4.88 (d, Ja,b = 11.0 Hz, 2H, CH-a, 4-O-Bn), 4.72 (d, Ja,b = 11.7 
Hz, 2H, CH-a, 2-O-Bn), 4.67 (d, Ja,b = 11.7 Hz, 2H, CH-b, 2-O-Bn), 4.65 (d, Ja,b = 
11.0 Hz, 2H, CH-b, 4-O-Bn), 4.08 (m, 4H, H-3 and H-5), 3.55–3.60 (m, 6H, H-4 and 
H-6a,b), 3.54 (dd, J2,3 = 10.0 Hz, J1,2 = 3.6 Hz, 2H, H-2); 
13
C NMR (125 MHz, 
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CDCl3)  138.8 (C-i, 3-O-Bn), 138.2 (C-i, 4-O-Bn), 138.0 (C-i, 2-O-Bn), 128.9, 
128.5, 128.4, 128.1, 127.9, 127.7, 127.6, 127.5 (CHarom), 94.1 (C-1), 81.6 (C-3), 79.5 
(C-2), 77.3 (C-4), 75.6 (CH2, 3-O-Bn), 75.1 (CH2, 4-O-Bn), 73.0 (CH2, 2-O-Bn), 
71.3 (C-5) and 61.5 (C-6); HRMS(ESI) m/z calcd. for [C54H58O11+Na]
+
: 905.3877, 
obsd.: 905.3881. 
 
General Procedure for Esterification. To a solution of diol 4 (1 mmol, 1 equiv.) in 
DCM (10 mL) the carboxylic acid (4.4 mmol, 4.4 equiv.), EDCI (6.6 mmol, 6.6 
equiv.) and DMAP (0.15 mmol, 0.15 equiv.) were added. The reaction was stirred at 
room temperature overnight, after which the resulting precipitate was removed from 
the mixture by filtration and washed with cold DCM. The combined organic layers 
were washed with water (30 mL), dried (MgSO4), filtered and concentrated in vacuo. 
The residue was purified using silica gel flash chromatography and the eluent given. 
 
                                        2,2',3,3',4,4'-Hexa-O-benzyl-
6,6'-di-O-butanoyl-α,α'-D-trehalose (5a). By subjecting 
diol 4 (100 mg, 0.11 mmol), butyric acid (44 mg, 0.50 
mmol), EDCI (143 mg, 0.73 mmol) and DMAP (2.06 mg, 
0.002 mmol) to the general procedure for esterification, 
the title compound was obtained (eluting with 5:1 (v/v) Pet. Ether/EtOAc) as a 
colourless oil (101.8 mg, 0.097 mmol, 88%). Rf = 0.76 (PE/EA, 1/1, v/v) ); [α]
18
D = 
+90.25 (c = 1.0, CHCl3); IR (film): 3028, 2934, 1733, 1497, 1454, 1359, 1215, 1158, 
1070, 1028, 995, 747, 697, 667 cm
-1
; 
1
H NMR (500 MHz, CDCl3)  7.25–7.38 (m, 
30H, Harom), 5.17 (d, J1,2 = 3.5 Hz, 2H, H-1), 5.01 (d, Ja,b = 10.5 Hz, 2H, CH-a, 3-O-
Bn), 4.87 (d, Ja,b = 10.5 Hz, 2H, CH-b, 3-O-Bn), 4.87 (d, Ja,b = 10.6 Hz, 2H, CH-a, 4-
O-Bn), 4.72 (d, Ja,b = 11.9 Hz, 2H, CH-a, 2-O-Bn), 4.69 (d, Ja,b = 11.9 Hz, 2H, CH-b, 
2-O-Bn), 4.52 (d, Ja,b = 10.6 Hz, 2H, CH-b, 4-O-Bn), 4.23 (bd, J4,5 = 9.5 Hz, 2H, H-
5), 4.15 (dd, J6a,6b = 12.2 Hz, J5,6a = 3.4 Hz, 2H, H-6a), 4.06 (dd, J6a,6b = 12.2 Hz, J5,6b 
= 2.4 Hz, 2H, H-6b), 4.05 (t, J2,3 = J3,4 = 9.3 Hz, H-3), 3.55 (dd, J2,3 = 9.3 Hz, J1,2 = 
3.5 Hz, H-2), 3.53 (t, J3,4 = J4,5 = 9.5 Hz, 2H, H-4), 2.24 (t, J8,9 = 6.9 Hz, 4H, H-8), 
1.63–1.60 (m, 4H, H-9), 0.91 (t, J9,10 = 7.3 Hz, 6H, H-10); 
13
C NMR (125 MHz, 
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CDCl3)  173.3 (C-7), 138.6 (C-i, 3-O-Bn), 137.8 (C-i, 4-O-Bn), 137.8 (C-i, 2-O-
Bn), 128.53, 128.5, 128.1, 128.0, 127.8, 127.7, 127.5 (CHarom), 94.0 (C-1), 81.6 (C-
3), 79.3 (C-2), 77.5 (C-4), 75.7 (CH2, 3-O-Bn), 75.2 (CH2, 4-O-Bn), 72.9 (CH2, 2-O-
Bn), 69.1 (C-5), 62.5 (C-6), 36.0 (C-8), 18.4 (C-9), 13.6 (C-10); HRMS(ESI) m/z 
calcd for [C62H70O13 +Na]
+
: 1045.4714, obsd.: 1045.4720. 
 
 
                                            2,2',3,3',4,4'-Hexa-O-
benzyl-6,6'-di-O-heptanoyl-α,α'-D-trehalose (5b). By 
subjecting diol 4 (0.41 g, 0.46 mmol), heptanoic acid 
(0.29 mL, 2.02 mmol), EDCI (0.58 g, 3.03mmol) and 
DMAP (0.008 g, 0.07 mmol) to the  general procedure 
for esterification, the title compound was obtained (eluting in 10:1 (v/v) Pet. 
Ether/EtOAc) as a colourless oil (0.43 g, 0.39 mmol, 85%). Rf = 0.8 (PE/EA, 1/1, 
v/v); [α]18D = +69.8 (c = 1.0, CHCl3); IR (film): 3018, 2981, 1732, 1454, 1215, 1159, 
1069, 996, 747, 697, 667 cm
-1
; 
1
H NMR (500 MHz, CDCl3)  7.25–7.38 (m, 30H, 
Harom), 5.17 (d, J1,2 = 3.6 Hz, 2H, H-1), 5.01 (d, Ja,b = 10.7 Hz, 2H, CH-a, 3-O-Bn), 
4.87 (d, Ja,b = 10.7 Hz, 2H, CH-b, 3-O-Bn), 4.87 (d, Ja,b = 10.5 Hz, 2H,  CH-a, 4-O-
Bn), 4.72 (d, Ja,b = 11.9 Hz, 2H,  CH-a, 2-O-Bn), 4.69 (d, Ja,b = 11.9 Hz, 2H, CH-b, 
2-O-Bn), 4.52 (d, Ja,b = 10.5 Hz, 2H, CH-b, 4-O-Bn), 4.23 (bd, J4,5 = 9.6 Hz, 2H, H-
5), 4.15 (dd, J6a,6b = 12.5 Hz, J5,6a = 3.5 Hz, 2H, H-6a), 4.06 (dd, J6a,6b = 12.5 Hz, J5,6b 
= 2.4 Hz, 2H, H-6b), 4.05 (t, J2,3 = J3,4 = 9.6 Hz, H-3), 3.58 (dd, J2,3 = 9.6 Hz, J1,2 = 
3.6 Hz, H-2), 3.54 (t, J3,4 = J4,5 = 9.6 Hz, 2H, H-4), 2.25 (t, J8,9 = 7.1 Hz, 4H, H-8), 
1.60–1.56 (m, 4H, H-9), 1.29–1.22 (m, 12H, H-10–H-12), 0.86 (t, J12,13 = 6.6 Hz, 6H, 
H-13); 
13
C NMR (125 MHz, CDCl3)  173.5 (C-7), 138.6 (C-i, 3-O-Bn), 137.9 (C-i, 
4-O-Bn), 137.8 (C-i, 2-O-Bn), 128.53, 128.5, 128.1, 128.0, 127.8, 127.7, 127.5 
(CHarom), 94.0 (C-1), 81.6 (C-3), 79.3 (C-2), 77.5 (C-4), 75.7 (CH2, 3-O-Bn), 75.2 
(CH2, 4-O-Bn), 72.9 (CH2, 2-O-Bn), 69.1 (C-5), 62.5 (C-6), 34.1 (C-8), 28.8, 24.8 
22.5, 18.4 (C-9–C-12), 14.0 (C-13); HRMS(ESI) m/z calcd. for [C68H82O13+Na]
+
: 
1129.5653, obsd.:1129.5646. 
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                                           2,2',3,3',4,4'-Hexa-O-
benzyl-6,6'-di-O-decanoyl-α,α'-D-trehalose (5c). By 
subjecting diol 4 (0.47 g, 0.53 mmol), decanoic acid 
(0.40 g, 2.35 mmol), EDCI (0.68 g, 3.52 mmol) and 
DMAP (0.01 g, 0.08 mmol) to the general procedure for esterification, the title 
compound was obtained (eluting in 10:1 (v/v) Pet. Ether/EtOAc) as a yellow oil 
(0.53 g, 0.45 mmol, 83%). Rf = 0.74 (PE/EA, 1/1, v/v); [α]
18
D = +70.0 (c = 1.0, 
CHCl3); IR (film):
 
2927, 1732, 1454, 1215, 1157, 1070, 996, 747, 697, 667 cm
-1
; 
1
H 
NMR (500 MHz, CDCl3) 7.38–7.26 (m, 30H, Harom), 5.17 (d, J1,2 = 3.4 Hz, 2H, H-
1), 5.01 (d, Ja,b = 10.7 Hz, 2H, CH-a, 3-O-Bn and), 4.88 (d, Ja,b = 10.7 Hz, 2H, CH-b, 
3-O-Bn), 4.86 (d, Ja,b = 10.8 Hz, 2H, CH-a, 4-O-Bn), 4.72 (d, Ja,b = 11.8 Hz, 2H, CH-
a, 2-O-Bn), 4.68 (d, Ja,b = 11.8 Hz, 2H, CH-b, 2-O-Bn), 4.52 (d, Ja,b = 10.8 Hz, 2H, 
CH-b, 4-O-Bn), 4.24– 4.21 (m, 2H, H-5), 4.15 (dd, J6a,6b = 12.2 Hz, J5,6a = 3.7 Hz, 
2H, H-6a), 4.05 (dd, J6a,6b = 12.2 Hz, J5,6b = 3.1 Hz, 2H, H-6b), 4.04 (t, J2,3 = J3,4 = 9.3 
Hz, H-3), 3.57 (dd, J2,3 = 9.3 Hz, J1,2 = 3.4 Hz, H-2), 3.54 (t, J3,4 = J4,5 = 9.3 Hz, 2H, 
H-4), 2.25 (t, J8,9 = 7.3 Hz, 4H, H-8), 1.58–1.55 (m, 4H, H-9), 1.29–1.22 (m, 24H, H-
10–H-15), 0.87 (t, J15,16 = 7.0 Hz, 6H, H-16); 
13
C NMR (125 MHz, CDCl3)  173.5 
(C-7), 138.6 (C-i, 3-O-Bn), 137.9 (C-i, 4-O-Bn), 137.8 (C-i, 2-O-Bn), 128.53, 128.5, 
128.1, 128.0, 127.8, 127.7, 127.5 (CHarom), 94.0 (C-1), 81.6 (C-3), 79.3 (C-2), 77.5 
(C-4), 75.7 (CH2, 3-O-Bn), 75.2 (CH2, 4-O-Bn), 72.9 (CH2, 2-O-Bn), 69.1 (C-5), 
62.5 (C-6), 34.1 (C-8), 31.8, 29.4, 29.2, 29.1, 24.9, 22.7(C-9–C-15) and 14.1 (C-16); 
HRMS(ESI) m/z calcd. for [C74H94O13+Na]
+
:1213.6592, obsd.:1213.6591. 
 
                                         2,2',3,3',4,4'-Hexa-O-benzyl-
6,6'-di-O-stearoyl-α,α'-D-trehalose (5d). By subjecting 
diol 4 (0.21 g, 0.24 mmol), stearic acid (0.31 g, 1.07 
mmol), EDCI (0.31 g, 1.61 mmol) and DMAP (0.005 g, 
0.04 mmol) to the general procedure for esterification, 
the title compound was obtained (eluting in 10:1 (v/v) 
Pet. Ether/EtOAc) as a colourless oil (0.30 g, 0.21 mmol, 85%). Rf = 0.79 (PE/EA, 
2/1, v/v); [α]18D = +61.8 (c = 1.0,  CHCl3); IR (film):
  
3055, 2926, 2855, 1732, 1455, 
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1265, 1157, 1071, 998, 896, 733, 701, 669 cm
-1
; 
1
H NMR (500 MHz, CDCl3) 7.38–
7.26 (m, 30H, Harom), 5.17 (d, J1,2 = 3.4 Hz, 2H, H-1), 5.01 (d, Ja,b = 10.9 Hz, 2H, 
CH-a, 3-O-Bn), 4.87 (d, Ja,b = 10.9 Hz, 2H, CH-b, 3-O-Bn), 4.87 (d, Ja,b = 10.5 Hz, 
2H, CH-a, 4-O-Bn), 4.72 (d, Ja,b = 11.8 Hz, 2H, CH-a, 2-O-Bn), 4.69 (d, Ja,b = 11.8 
Hz, 2H, CH-b, 2-O-Bn), 4.52 (d, Ja,b = 10.5 Hz, 2H, CH-b, 4-O-Bn), 4.23 (bd, J4,5 = 
9.2 Hz, 2H, H-5), 4.16 (dd, J6a,6b = 12.4 Hz, J5,6a = 3.7 Hz, 2H, H-6a) 4.05 (dd, J6a,6b = 
12.4 Hz, J5,6b = 2.1 Hz, 2H, H-6b), 4.06 (t, J2,3 = J3,4 = 9.2 Hz, H-3), 3.57 (dd, J2,3 = 
9.2 Hz, J1,2 = 3.4 Hz, H-2), 3.54 (t, J3,4 = J4,5 = 9.2 Hz, 2H, H-4), 2.24 (t, J8,9 = 7.3 Hz, 
4H, H-8), 1.59–1.56 (m, 4H, H-9), 1.31–1.23 (m, 56H, H-10–H-23), 0.88 (t, J23,24 = 
7.0 Hz, 6H, H-24); 
13
C NMR (125 MHz, CDCl3)  173.5 (C-7), 138.6 (C-i, 3-O-Bn), 
137.9 (C-i, 4-O-Bn), 137.9 (C-i, 2-O-Bn), 128.5, 128.4, 128.1, 128.0, 127.8, 127.5 
(CHarom), 94.1 (C-1), 81.6 (C-3), 79.3 (C-2), 77.5 (C-4), 75.7 (CH2, 3-O-Bn), 75.2 
(CH2, 4-O-Bn), 72.9 (CH2, 2-O-Bn), 69.1 (C-5), 62.5 (C-6), 34.1 (C-8), 31.9, 30.9, 
29.7, 29.6, 29.5,  29.4, 29.3, 29.2, 29.1, 24.8, 22.7(C-9–C-23) and 14.1 (C-24); 
HRMS(ESI) m/z calcd. for [C90H126O12+Na]
+
: 1437.9096, obsd.: 1437.9098. 
 
General procedure for debenzylation. Pd(OH)2 (2.5 mol%) was added to a solution 
of the benzylated trehalose diesters (1 mmoL) in a mixture of CHCl3/MeOH (10 mL, 
3/2, v/v) and stirred at room temperature under a steam of H2 (gas) at 1 atm for 7 h. 
The reaction mixture was then filtered through Celite, the Celite washed thoroughly 
with CHCl3/MeOH (20 mL, 3/2, v/v) and the filtrate concentrated in vacuo. The 
product was purified using silica gel flash chromatography and the eluent given.  
 
                                         6,6'-Di-O-butanoyl-α,α'-D-
trehalose (1a). By subjecting dibutyl trehalose 5a (180 
mg, 0.17 mmol) to the procedure for debenzylation, 
trehalose diester 1a was obtained (eluting in 95:5 (v/v) 
EtOAc/MeOH) as a white powder (52.9 mg, 0.10 mmol, 
62%). Rf = 0.2 (EtOAc); [α]
24
D = +132.75 (c = 1.0, 
MeOH); IR (film): 3318, 2943, 2832, 1732, 1449, 1114, 1022 cm
-1
; 
1
H NMR (500 
MHz, CD3OD)  5.04 (d, J1,2 = 3.6 Hz, 2H, H-1), 4.36 (dd, J6a,6b = 11.9 Hz, J5,6a = 2.0 
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Hz, 2H, H-6a), 4.20 (dd, J6a,6b = 11.9 Hz, J5,6b = 5.1 Hz, 2H, H-6b), 4.04–4.00 (m, 
2H, H-5), 3.78 (t, J2,3 = J3,4 = 9.2 Hz, H-3), 3.46 (dd, J2,3 = 9.2 Hz, J1,2 = 3.6 Hz, 2H, 
H-2), 3.35 (t, J3,4 = J4,5 = 9.2 Hz, 2H, H-4), 2.33 (t, J8,9 = 7.3 Hz, 4H, H-8), 1.65 
(pentet, Jα,β = Jβ,γ =  7.3 Hz, 4H, H-9), 0.96 (t, J9,10 = 7.3 Hz, 6H, H-10); 
13
C NMR 
(125 MHz, CD3OD)  173.9 (C-7), 93.9 (C-1), 73.1 (C-3), 71.7 (C-2), 70.4 (C-4), 
70.1 (C-5), 62.9 (C-6), 36.8 (C-8), 18.0 (C-9), 12.5 (C-10); HRMS(ESI) m/z calcd. 
for [C20H34O13+Na]
+
: 505.1897, obsd.: 505.1891. 
 
6,6'-Di-O-heptanoyl-α,α'-D-trehalose (1b). By 
subjecting diheptyl trehalose 5b (105.6 mg, 0.096 mmol) 
to the general procedure for debenzylation, trehalose 
diester 1b was obtained (eluting in 95:5 (v/v) 
EtOAc/MeOH) as a white solid (35.9 mg, 0.064 mmol, 
67%). Rf = 0.75 (EtOAc/MeOH, 9/1, v/v); [α]
24
D = +70.8 (c = 1.0, EtOH); IR (film): 
3319, 2943, 2831, 1735, 1448, 1113, 1022 cm
-1
; 
1
H NMR (500 MHz, CD3OD)  
5.04 (d, J1,2 = 3.1 Hz, 2H, H-1), 4.36 (dd, J6a,6b = 11.7 Hz, J5,6a = 2.0 Hz, 2H, H-6a), 
4.20 (dd, J6a,6b = 11.7 Hz, J5,6b = 4.9 Hz, 2H, H-6b), 4.03–4.00 (m, 2H, H-5), 3.88 (t, 
J2,3 = J3,4 = 9.3 Hz, H-3), 3.47 (dd, J2,3 = 9.3 Hz, J1,2 = 3.1 Hz, 2H, H-2), 3.34 (t, J3,4 = 
J4,5 = 9.3 Hz, 2H, H-4), 2.35 (t, J8,9 = 7.4 Hz, 4H, H-8), 1.62 (pentet, Jα,β = Jβ,γ = 7.3 
Hz, 4H, H-9), 1.36–1.32 (m, 12H, H-10–H-12), 0.96 (t, J12,13 = 7.3 Hz, 6H, H-13); 
13
C NMR (125 MHz, CD3OD)  174.1 (C-7), 93.8 (C-1), 73.1 (C-3), 71.7 (C-2), 70.5 
(C-4), 70.1 (C-5), 63.0 (C-6), 33.6 (C-8), 31.3, 28.5, 24.6, 22.2 (C-9–C-12), 13.0 (C-
13); HRMS(ESI) m/z calcd. for [C26H46O13+Na]
+
: 589.2836, obsd.: 589.2837. 
 
6,6'-Di-O-decanoyl-α,α'-D-trehalose (1c). By subjecting 
didecanoyl trehalose 5c (119 mg, 0.10 mmol) to the 
general procedure for debenzylation, trehalose diester 1c 
was obtained (eluting in 95:5 (v/v) EtOAc/MeOH) as a 
white solid (40.9 mg, 0.063 mmol, 63%). Rf =  0.5 
(EA/MeOH, 9/1, v/v); [α]24D = +111.3 (c = 1.0, EtOH); IR (film): 3320, 2973, 2882, 
1736, 1379, 1275, 1088, 1046, 880 cm
-1
; 
1
H NMR (500 MHz, CD3OD)  5.05 (d, J1,2 
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= 3.9 Hz, 2H, H-1), 4.35 (dd, J6a,6b = 11.9 Hz, J5,6a = 2.0 Hz, 2H, H-6a), 4.20 (dd, 
J6a,6b = 11.9 Hz, J5,6b = 5.1 Hz, 2H, H-6b), 4.05–4.01 (m, 2H, H-5), 3.78 (t, J2,3 = J3,4 
= 9.1 Hz, H-3), 3.47 (dd, J2,3 = 9.1 Hz, J1,2 = 3.9 Hz, 2H, H-2), 3.34 (t, J3,4 = J4,5 = 9.1 
Hz, 2H, H-4), 2.35 (t, J8,9 = 7.5 Hz, 4H, H-8), 1.62 (pentet, Jα,β = Jβ,γ =  7.1 Hz, 4H, 
H-9), 1.33–1.30 (m, 24H, H-10–H-15), 0.90 (t, J15,16 = 7.3 Hz, 6H, H-16); 
13
C NMR 
(125 MHz, CD3OD)  174.1 (C-7), 93.8 (C-1), 73.1 (C-3), 71.2 (C-2), 70.5 (C-4), 
70.1 (C-5), 63.0 (C-6), 33.7 (C-8), 31.7, 29.2, 29.0, 28.8, 24.7, 22.3 (C-9–C-15), 13.1 
(C-16); HRMS(ESI) m/z calcd. for [C32H58O13+Na]
+
: 673.3775, obsd.: 673.3773. 
 
6,6'-Di-O-stearoyl-α,α'-D-trehalose (1d). By subjecting 
distearoyl trehalose 5d (112.1 mg, 0.079 mmol) to the 
general procedure for debenzylation, trehalose diester 1d 
was obtained after silica gel chromatography eluting in 
95:5 (v/v) EtOAc/MeOH as a white solid (60.9 mg, 
0.070 mmol, 88%). Rf = 0.64 (EA/MeOH, 9/1, v/v); [α]
22
D = +16.0 (c = 1.0, EtOH); 
IR (film):
 
3330, 2919, 2850, 2835, 1660, 1453, 1109, 697 cm
-1
; 
1
H NMR (500 MHz, 
CD3OD)  5.06 (d, J1,2 = 3.7 Hz, 2H, H-1), 4.35 (dd, J6a,6b = 11.4 Hz, J5,6a = 2.0 Hz, 
2H, H-6a), 4.21 (dd, J6a,6b = 11.4 Hz, J5,6b = 5.1 Hz, 2H, H-6b), 4.02–3.98 (m, 2H, H-
5), 3.77 (t, J2,3 = J3,4 = 9.3 Hz, H-3), 3.48 (dd, J2,3 = 9.3 Hz, J1,2 = 3.7 Hz, 2H, H-2), 
3.34 (t, J3,4 =  J4,5 = 9.3 Hz, 2H, H-4), 2.34 (t, J8,9 = 7.4 Hz, 4H, H-8), 1.62 (pentet, 
Jα,β = Jβ,γ = 7.1 Hz, 4H, H-9), 1.32–1.27 (m, 56H, H-10–H-23), 0.89 (t, J23,24 = 7.3 
Hz, 6H, H-24); 
13
C NMR (125 MHz, CD3OD)  174.2 (C-7), 93.7 (C-1), 73.2 (C-3), 
71.7 (C-2), 70.4 (C-4), 70.0 (C-5), 63.1 (C-6), 33.8 (C-8), 31.7, 29.5, 29.4, 29.3, 
29.1, 29.1, 28.9, 24.7, 22.4 (C-9–C-23), 13.1 (C-24); HRMS(ESI) m/z calcd. for 
[C48H90O13+Na]
+
: 897.6279, obsd.: 897.6279. 
 
2,2',3,3',4,4'-Hexa-O-trimethylsilyl-α,α'-D-trehalose (6). 
α,α-D-Trehalose dihydrate 2 (0.25 g, 0.66 mmol) was co-
evaporated with anhydrous DMF (3 x 5 mL) and then 
dissolved in DMF (1 mL). To this solution, N,O-
bis(trimethylsilyl)acetamide (1.4 mL, 5.70 mmol) and TBAF (0.04 mL, 0.04 mmol) 
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were added and the reaction stirred at room temperature for 1.5 h. The reaction was 
quenched with 0.25 mL iso-propanol and the resulting solution was diluted with 15 
mL MeOH and cooled down to 0 °C. K2CO3 solution (0.091 g in 20 mL MeOH) was 
added to the reaction mixture and stirring at 0 °C was continued for 2 h. The reaction 
mixture was concentrated in vacuo and the resulting residue partitioned between 
ether and brine. The aqueous layer was extracted twice more with diethyl ether (30 
mL x 2) and the combined organic layer dried (MgSO4) and concentrated in vacuo. 
Flash chromatography of the crude product gave diol 6, eluting in 4:1 (v/v) Pet. 
Ether/EtOAc, as a white solid (0.43 g, 0.56 mmol, 85%). Rf = 0.29 (PE/EA, 3/1, v/v); 
[α]18D = +109 (c = 1.0, CHCl3), Lit
11 [α]25D = +103; IR (film): 3628, 3019, 2958, 
1558, 1541, 1387, 1250, 1215, 1166, 1109, 1075, 1005 cm
-1
; 
1
H NMR (500 MHz, 
CDCl3)  4.91 (d, J1,2 = 3.1 Hz, 2H, H-1), 3.90 (t, J2,3 = J3,4 = 9.0 Hz, 2H, H-3), 3.88–
3.84 (m, 2H, H-5), 3.72 (dd, J6a,6b = 11.8 Hz, J5,6a = 2.7 Hz, 2H, H-6a), 3.70, (dd, 
J6a,6b = 11.8 Hz, J5,6b = 3.9 Hz 2H, H-6b), 3.49 (t, J3,4 = J4,5 = 9.1 Hz, 2H, H-4), 3.42 
(dd, J2,3 = 9.0 Hz, J1,2 = 3.1 Hz, 2H, H-2), 0.17, 0.15, 0.13 (3 s, 54H, CH3, TMS); 
13
C 
NMR (125 MHz, CDCl3)  94.6 (C-1), 73.3 (C-3), 73.0 (C-2), 72.8 (C-5), 71.4 (C-4), 
61.7 (C-6), 1.0, 0.8, 0.07 (TMS); HRMS(ESI) m/z calcd. for [C30H70O11Si6+Na]
+
: 
797.3431, obsd.:797.3424. 
 
2,2',3,3',4,4'-Hexa-O-trimethylsilyl-6,6'-di-O-
eicosanoyl-α,α'-D-trehalose (7e). To a solution of diol 6 
(37.6 mg, 0.049 mmol) and arachidic acid (84.6 mg, 0.22 
mmol) in anhydrous CH2Cl2 (3 mL) was added EDCI 
(61.4 mg, 0.32 mmol) and DMAP (8.8 mg, 0.001 mmol) 
and the reaction stirred at room temperature for 2 nights. The resulting precipitate 
was removed by filtration and washed thoroughly with EtOAc (2 x 10 mL). The 
combined organic layers were washed with water (20 mL), brine (20 mL), dried 
(MgSO4), filtered and concentrated in vacuo. Purification of the crude product by 
silica gel flash chromatography gave the title compound 7e, eluting in 50:1 (v/v) Pet. 
Ether/EtOAc, as pale yellow oil (61.5 mg, 0.045 mmol, 93%). Rf = 0.83 (PE/EtOAc, 
5/1, v/v); [α]18D = +45.0 (c = 0.1 CHCl3); IR (film): 3016, 2970, 2924, 2853, 1739, 
1010, 966, 843 cm
-1
; 
1
H NMR (500 MHz, CDCl3)  4.92 (d, J1,2 = 3.2 Hz, 2H, H-1), 
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4.28 (dd, J6a,6b = 12.0 Hz, J5,6a = 2.2 Hz, 2H, H-6a), 4.06 (dd, J6a,6b = 12.0 Hz, J5,6b = 
4.4 Hz, 2H, H-6b), 4.06–3.99 (m, 2H, H-5), 3.90 (t, J2,3 = J3,4 = 9.0 Hz, 2H, H-3), 
3.49 (t, J3,4 = J4,5 = 9.0 Hz, 2H, H-4), 3.45 (dd, J2,3 = 9.0 Hz, J1,2 = 3.2 Hz, 2H, H-2), 
2.37 (dt, J8a,8b  = 13.7 Hz, J8a,9 = 7.6Hz, 2H, H-8a), 2.36 (dt, J8a,8b = 13.7 Hz, J8b,9 = 
7.5 Hz, 2H, H-8b), 1.66–1.60 (m, 4H, H-9), 1.30–1.26 (m, 64H, H-10–H-25), 0.89 (t, 
J25,26 = 7.1 Hz, H-26), 0.16, 0.141, 0.137 (3 s, 54H, CH3, TMS); 
13
C NMR (125 
MHz, CDCl3) 173.4 (C-7), 94.4 (C-1), 73.5 (C-3), 72.6 (C-2), 71.9 (C-4), 70.7 (C-
5), 63.3 (C-6), 34.2 (C-8), 31.9, 29.71, 29.67, 29.5, 29.4, 29.3, 29.2, 29.1, 24.8, 22.7 
(C-9–C-25), 14.1 (C-26), 1.1, 0.9, 0.2 (TMS)  HRMS(ESI) m/z calcd. for 
[C70H146O13Si6+Na]
+
: 1385.9277, obsd.:1385.9282. 
 
General Procedure for Esterification in Toluene. To a solution of diol 6 (1 mmol, 
1 equiv.) and the carboxylic acid (4.4 mmol, 4.4 equiv.) in dry toluene (5 mL), EDCI 
(6.6 mmol, 6.6 equiv.) and DMAP (0.15 mmol, 0.15 equiv.) were added. The 
reaction was stirred at 70 °C until analysis by TLC showed no further formation of 
product. The resulting precipitate was removed by filtration and the precipitate 
washed thoroughly with EtOAc (2 x 50 mL). The combined organic layers were 
washed with water (50 mL) and brine (40 mL), dried (MgSO4), filtered and 
concentrated in vacuo. The product was purified by silica gel flash chromatography 
using the eluent given.    
 
2,2',3,3',4,4'-Hexa-O-trimethylsilyl-6,6'-di-O-
docosanoyl-α,α'-D-trehalose (7f). By subjecting diol 6 
(106.1 mg, 0.14 mmol), docosanoic acid (205 mg, 0.60 
mmol), EDCI (177 mg, 0.92 mmol) and DMAP (2.5 mg, 
0.02 mmol) to the general procedure for esterification (2 
days), the title compound 7f was obtained (eluting in 50:1 (v/v) Pet. Ether/ EtOAc) 
as a white solid (170 mg, 0.12 mmol, 86%). Rf = 0.84 (PE/EA, 5/1, v/v); [α]
18
D = 
+46.1 (c = 0.1 CHCl3); IR (film): 2970, 2926, 2854, 1737, 1046, 1032, 993, 755, 704 
cm
-1
; 
1
H NMR (500 MHz, CDCl3)  4.93 (d, J1,2 = 2.9 Hz, 2H, H-1), 4.29 (dd, J6a,6b = 
11.9 Hz, J5,6a = 2.2 Hz, 2H, H-6a), 4.07 (dd, J6a,6b = 12.0 Hz, J5,6b = 4.7 Hz, 2H, H-
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6b), 4.02–3.98 (m, 2H, H-5), 3.91 (t, J2,3 = J3,4 = 9.0 Hz, 2H, H-3), 3.49 (t, J3,4 = J4,5 = 
9.0 Hz, 2H, H-4), 3.45 (dd, J2,3 = 9.0 Hz, J1,2 = 2.9 Hz, 2H, H-2), 2.37 (dt, J8a,8b = 
13.1 Hz, J8a,9 = 7.3 Hz, 2H, H-8a), 2.36 (dt, J8a,8b = 13.1 Hz J8b,9 = 7.4 Hz, 2H, H-8b), 
1.64–1.58 (m, 4H, H-9), 1.34–1.22 (m, 72H, H-10–H-27), 0.89 (t, J27,28 = 6.8 Hz, H-
28), 0.16, 0.141, 0.137 (3 s, 54H, CH3, TMS); 
13
C NMR (125 MHz, CDCl3) 173.8 
(C-7), 94.4 (C-1), 73.5 (C-3), 72.6 (C-2), 71.9 (C-4), 70.7 (C-5), 63.8 (C-6), 34.2 (C-
8), 31.9, 29.71, 29.67, 29.6, 29.5, 29.4, 29.3, 29.2, 24.8, 22.7 (C-9–C-27), 14.1 (C-
28), 1.1, 0.9, 0.2 (TMS); HRMS (ESI) m/z calcd. for [C74H154O13Si6+Na]
+
: 
1441.9903, obsd.: 1441.9901. 
 
 2,2',3,3',4,4'-Hexa-O-trimethylsilyl-6-docosanoyl-6’-
hydroxy-α,α'-D-trehalose (8f). The title compound 8f 
was obtained (eluting in Hex: EtOAc 20:1) as a white 
solid (20 mg, 0.018 mmol, 12%). Rf = 0.55 (PE/EA, 5/1, 
v/v); [α]D
18
 = +20.2 (c =1.0, CHCl3); IR (film): 3017, 
2923, 2852, 1737, 1372, 1250, 1076, 1007, 965, cm
-1
; 
1
H NMR (500 MHz, CDCl3)  
4.94 (d, J1/1',2/2'  = 3.5 Hz, 1H, H-1/1'), 4.92 (d, J1/1',2/2'  = 3.7 Hz, 1H, H-1/1'), 4.30 (dd,  
J6a,6b = 12.0 Hz, J5,6a = 2.2 Hz, 1H, H-6a), 4.07 (dd, J6a,6b = 12.0 Hz, J5,6b = 4.6 Hz, 
1H, H-6b), 4.03–4.00 (m, 1H, H-5), 3.92 (t,  J2/2',3/3' = J3/3',4/4' = 8.8 Hz, 1H, H-3/3'), 
3.91 (t, J2/2',3/3' = J3/3',4/4' = 9.0 Hz, 1H, H-3/3'), 3.85 (dt, J4',5' = 9.5 Hz, J5',6a' = J5',6b' = 
3.5 Hz, 1H, H-5'), 3.86–3.83 (m, 2H, H-6a' and H-6b'), 3.49 (t, J3,4 = J4,5 = 9.0 Hz, 
1H, H-4), 3.47 (t, J3',4' = J4',5' = 9.0 Hz, 1H, H-4'), 3.44 (dd, J2,3/2',3' = 9.0 Hz, J1,2/1',2' = 
3.5 Hz, 1H, H-2/2'), 3.43 (dd, J2,3/2',3' = 9.0 Hz, J1,2/1',2' = 3.5 Hz, 1H, H-2/2'), 2.35 (dt, 
J8a,8b = 13.2 Hz, J8a,9 = 7.3 Hz, 1H, H-8a), 2.34 (dd, J8a,8b = 13.2 Hz, J8b,9 = 7.4 Hz, 
1H, H-8b), 1.66–1.57 (m, 2H, H-9), 1.34–1.26 (m, 36H, H-10–H-27), 0.89 (t, J27,28 = 
7.1 Hz, 3H, H-28), 0.17, 0.16, 0.15, 0.14, 0.13 (6 s, 54H, CH3, TMS); 
13
C NMR (125 
MHz, CDCl3) 173.8 (C-7), 94.5 (C-1/1'), 94.4 (C-1/1'), 73.5 (C-3/3'), 73.3 (C-3/3'), 
72.9 (C-2/2'), 72.8 (C-5'), 72.6 (C-2/2'), 71.9 (C-4), 71.4 (C-4'), 70.8 (C-5), 63.3 (C-
6), 61.7 (C-6'), 34.2 (C-8), 31.9, 29.70, 29.66, 29.60, 29.5, 29.4, 29.3, 29.2, 24.8, 
22.7 (C-9–C-27), 14.1 (C-28), 1.04, 1.00, 0.89, 0.85, 0.14, 0.10 (TMS) HRMS (ESI) 
m/z calcd. for [C52H112O12Si6+Na]
+
: 1119.6662, obsd.: 1119.6667.  
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2,2',3,3',4,4'-Hexa-O-trimethylsilyl-6,6'-di-O-
hexacosanoyl-α,α'-D-trehalose (7g). By subjecting diol 6 
(17 mg, 0.022 mmol), hexacosanoic acid (37.9 mg, 0.096 
mmol), EDCI (27.7 mg, 0.14 mmol) and DMAP (0.39 
mg, 0.003 mmol) to the general procedure for 
esterification (6 days), the title compound 7g was obtained (eluting in 50:1  (v/v) Pet. 
Ether/ EtOAc) as a white solid (20 mg, 0.013 mmol, 60%). Rf = 0.83 (PE/EA, 5/1, 
v/v); [α]18D = +43.2 (c = 1.0, CHCl3); IR (film): 3016, 2970, 2919, 2851, 1739, 966, 
899, 760 cm
-1
; 
1
H NMR (500 MHz, CDCl3)  4.92 (d, J1,2 = 2.9 Hz, 2H, H-1), 4.28 
(dd, J6a,6b = 11.7 Hz, J5,6a = 2.2 Hz, 2H, H-6a), 4.06 (dd, J6a,6b = 11.7 Hz, J5,6b = 4.7 
Hz, 2H, H-6b), 4.02–3.98 (m, 2H, H-5), 3.91 (t, J2,3 = J3,4 = 9.0 Hz, 2H, H-3), 3.48 (t, 
J3,4 = J4,5 = 9.0 Hz, 2H, H-4), 3.45 (dd, J2,3 = 9.0 Hz, J1,2 = 2.9 Hz, 2H, H-2), 2.36 (dt, 
J8a,8b = 13.6 Hz, J8a,9 = 7.3 Hz, 2H, H-8a), 2.34 (dt, J8a,8b = 13.6 Hz, J8b,9 = 7.0 Hz, 2H, 
H-8b), 1.64–1.60 (m, 4H, H-9), 1.34–1.18 (m, 88H, H-10–H-31), 0.89 (t, J31,32 = 6.7 
Hz, H-32), 0.16, 0.14, 0.137 (3 s, 54H, CH3, TMS); 
13
C NMR (125 MHz, CDCl3) 
174.0 (C-7), 94.4 (C-1), 73.5 (C-3), 72.6 (C-2), 71.9 (C-4), 70.7 (C-5), 63.3 (C-6), 
34.2 (C-8), 31.9, 29.71, 29.67, 29.6, 29.5, 29.4, 29.31, 29.28 29.2, 24.8, 22.7 (C-9–C-
31), 14.1 (C-32), 1.1, 0.9, 0.2 (TMS); HRMS (ESI) m/z calcd. for 
[C82H170O13Si6+Na]
+
: 1554.1155, obsd.: 1554.1166. 
 
 
2,2',3,3',4,4'-Hexa-O-trimethylsilyl-6-hexacosanoyl-6'-
hydroxy-α,α'-D-trehalose (8g). The title compound was 
obtained after (eluting in Hex: EtOAc 20:1) a colourless 
oil (5 mg, 0.005 mmol, 20%). Rf = 0.61 (PE/EA, 5/1, v/v); 
[α]D
18
 = 23.2 (c = 1.0 CHCl3); IR (film): 3400, 2920, 2851, 1739, 1457, 1166, 1077, 
1008, 843, 760 cm
-1
; 
1
H NMR (500 MHz, CDCl3)  4.93 (d, J1/1',2/2' = 3.5 Hz, 1H, H-
1/1'), 4.92 (d, J1/1',2/2' = 3.5 Hz, 1H, H-1/1'), 4.30 (dd,  J6a,6b = 11.7 Hz, J5,6a = 2.2 Hz, 
1H, H-6a), 4.07 (dd, J6a,6b = 11.7 Hz, J5,6b = 4.7 Hz, 1H, H-6b), 4.03–3.99 (m, 1H, H-
5), 3.91 (t, J2/2',3/3' = J3/3',4/4' = 9.0 Hz, 1H, H-3/3'), 3.90 (t, J2/2',3/3' = J3/3',4/4' = 9.0 Hz, 
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1H, H-3/3'), 3.85 (dt, J4',5' = 9.6 Hz, J5',6a' = J5',6b' = 3.4 Hz, 1H, H-5'), 3.71 (dd, J6a',6b' = 
11.7 Hz, J5',6a' = 3.0 Hz, 1H, H-6a'), 3.69 (dd, J6a',6b' = 11.7 Hz J5',6b' = 3.9 Hz, 1H, H-
6b'), 3.49 (t, J3,4 = J4,5 = 9.0 Hz, 1H, H-4), 3.48 (t, J3',4' = J4',5' = 9.0 Hz, 1H, H-4'), 3.44 
(dd, J2,3/2',3' = 9.0 Hz, J1,2/1',2' = 3.5 Hz, 1H, H-2/2'), 3.43 (dd, J2,3/2',3' = 9.0 Hz, J1,2/1',2' = 
3.5 Hz, 1H, H-2/2'), 2.36 (dt, J8a,8b = 12.5 Hz, J8a,9 = 7.1 Hz, 1H, H-8a), 2.34 (dt, J8a,8b 
= 12.5, J8b,9 = 7.0 Hz, 1H, H-8b), 1.63 (pentet, Jα,β  = Jβ,γ = 6.8 Hz, 2H, H-9), 1.38–
1.20 (m, 44H, H-10–H-31), 0.89 (t, J31,32 = 6.8 Hz, 3H, H-32), 0.17, 0.16, 0.15, 0.14, 
0.13 (5 s, 54H, CH3, TMS); 
13
C NMR (125 MHz, CDCl3) 173.8 (C-7), 94.5 (C-
1/1'), 94.4 (C-1/1'), 73.5 (C-3/3'), 73.3 (C-3/3'), 72.9 (C-2/2'), 72.8 (C-5'), 72.6 (C-
2/2'), 71.9 (C-4), 71.4 (C-4'), 70.8 (C-5), 63.3 (C-6), 61.7 (C-6'), 34.2 (C-8), 31.9,  
31.4, 30.3, 30.2 29.70, 29.68, 29.67, 29.60, 29.5, 29.4, 29.3, 29.2, 24.8, 22.7 (C-9–C-
31), 14.1 (C-32), 1.05, 1.00, 0.89, 0.85, 0.14, 0.10 (C-TMS); HRMS(ESI) m/z calcd. 
for [C56H120O12Si6+Na]
+
: 1175.7288, obsd.: 1175.7285. 
  
General Procedure for Desilylation. To a solution of the trehalose diester 7e-7g or 
trehalose monoester 8f-8g (1 mmol) in 5 mL CH2Cl2:MeOH mixture (3/1, v/v) 
Dowex-H
+
 (10% by weight) was added and the reaction stirred at room temperature. 
After 30 min, the reaction mixture was filtered and concentrated in vacuo, and the 
resulting residue subjected to column chromatography (straight phase or reverse 
phase) using the eluent given in order to obtain the fully deprotected compounds.  
 
6,6'-Di-O-eicosanoyl-α,α'-D-trehalose (1e). By 
subjecting trehalose diester 7e (13 mg, 0.010 mmol) to 
the general procedure for desilylation, the title compound 
1e was obtained after silica gel flash chromatography 
eluting in 98:2 (v/v) EtOAc/MeOH as a white solid (7.5 
mg, 0.008 mmol, 80%). Rf = 0.47 (EA/MeOH, 95/5, v/v); [α]
18
D = +29.8 (c = 0.1, 
C5H5N); IR (film); 3567, 3459, 2967, 2926, 1737, 1016, 846, 750 cm
-1
; 
1
H NMR 
(500 MHz, C5H5N)  5.79 (d, J1,2 = 3.6 Hz, 2H, H-1), 5.00–4.97 (m, 2H, H-5), 4.90 
(m, 2H, H-6a), 4.72 (dd, J6a,6b = 11.7 Hz, J5,6b = 5.4 Hz, 2H, H-6b), 4.64 (t, J2,3 = J3,4 
= 9.0 Hz, 2H, H-3), 4.20 (bd, J2,3 = 9.0 Hz, 2H, H-2), 4.07 (t, J3,4 = J4,5 = 9.0 Hz, 2H, 
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H-4), 2.22 (dt, J8a,8b = 12.2 Hz,  J8a,9 = 7.9 Hz, 2H, H-8a), 2.20 (dt, J8a,8b = 12.2 Hz,  
J8b,9 = 7.3 Hz , 2H, H-8b), 1.51 (pentet, Jα,β = Jβ,γ = 7.3 Hz, 4H, H-9), 1.19–1.09 (m, 
64H, H-10–H-25), 0.75 (t, J25,26 = 6.8 Hz, 6H, H-26); 
13
C NMR (125 MHz, C5H5N) 
173.7 (C-7), 95.9 (C-1), 75.0 (C-3), 73.5 (C-2), 72.2 (C-4), 71.7 (C-5), 64.5 (C-6), 
34.5 (C-8), 32.2, 30.09, 30.05, 30.0, 29.9, 29.7, 29.5, 25.4, 23.0 (C-9–C-25), 14.3 (C-
26); HRMS(ESI) m/z calcd. for [C52H98O13+Na]
+
:953.6905, obsd.:953.6904. 
 
6,6'-Di-O-docosanoyl-α,α'-D-trehalose (1f). By 
subjecting trehalose diester 7f (42 mg, 0.030 mmol) to 
the general procedure for desilylation, the title 
compound 1f was obtained  after silica gel flash 
chromatography eluting in 98:2 (v/v) EtOAc/MeOH as a 
white solid (23.3 mg, 0.024 mmol, 80%) Rf = 0.52 (EA/MeOH, 95/5, v/v); [α]
25
D = 
+1.3 (c = 0.1 C5H5N); IR (film): 3324, 2944, 2832, 1737, 1449, 1216, 1114, 1022, 
737 cm
-1
; 
1
H NMR (500 MHz, C5H5N) 5.78 (d, J1,2 = 3.4 Hz, 2H, H-1), 5.00–4.97 
(m, 2H, H-5), 4.89 (m, 2H, H-6a), 4.73 (dd, J6a,6b = 11.7 Hz, J5,6b = 5.3 Hz, 2H, H-
6b), 4.64 (t, J2,3 = J3,4 = 9.6 Hz, 2H, H-3), 4.20 (bd, J2,3 = 9.6 Hz, 2H, H-2), 4.07 (t, 
J3,4 = J4,5 = 9.6 Hz, 2H, H-4), 2.22 (dt, J8a,8b = 11.7 Hz, J8a,9 = 7.5 Hz, 2H, H-8a), 2.18 
(dt, J8a,8b = 11.7 Hz,  J8b,9 = 7.2 Hz , 2H, H-8b), 1.51 (pentet, Jα,β = Jβ,γ =  7.1 Hz, 4H, 
H-9), 1.20–1.14 (m, 72H, H-10–H-27), 0.76 (t, J27,28 = 6.8 Hz, 6H, H-28); 
13
C NMR 
(125 MHz, C5H5N) 173.8 (C-7), 95.9 (C-1), 75.0 (C-3), 73.5 (C-2), 72.1 (C-4), 71.7 
(C-5), 64.5 (C-6), 34.5 (C-8), 32.3, 30.14, 30.09, 30.0, 29.9, 29.72, 29.69, 29.5, 25.4, 
23.0 (C-9–C-27), 14.4 (C-28); HRMS(ESI) m/z calcd. for [C56H106O13+Na]
+
: 
1009.7531, obsd.: 1009.7532. 
 
6,6'-Di-O-hexacosanoyl-α,α'-D-trehalose (1g). By 
subjecting trehalose diester 7g (3 mg, 0.002 mmol) to 
the general procedure for desilylation, the title 
compound 1g was obtained after reverse phase  
chromatography eluting in pyridine as a white solid 
(1.53 mg, 0.0014 mmol, 70%). Rf = 0.52 (EA/MeOH, 95/5, v/v); [α]
25
D = +0.7 (c = 
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0.1, C5H5N); IR (film) cm
-1
 3361, 2923, 2851, 2215, 1733, 1181, 1107, 1022; 
1
H 
NMR (500 MHz,C5H5N)  5.78 (d, J1,2 = 3.7 Hz, 2H, H-1), 4.98–4.96 (m, 2H, H-5), 
4.87 (m, 2H, H-6a), 4.72 (dd, J6a,6b = 11.7 Hz, J5,6a = 5.4 Hz, 2H, H-6b), 4.64 (t, J2,3 = 
J3,4 = 9.0 Hz, 2H, H-3), 4.21 (dd, J2,3 = 9.0 Hz, J1,2 = 3.7 Hz, 2H, H-2), 4.01 (t, J3,4 = 
J4,5 = 9.0 Hz, 2H, H-4), 2.23 (dt, J8a,8b = 12.2 Hz, J8a,9 = 7.5 Hz, 2H, H-8a), 2.17 (dt, 
J8a,8b = 12.2 Hz, J8a,9 = 7.5 Hz, 2H, H-8b), 1.50 (pentet, Jα,β = Jβ,γ = 7.4 Hz, 4H, H-9), 
1.26–1.04 (m, 88H, H-10–H-31), 0.73 (t, J31,32 = 6.8 Hz, 6H, H-32); 
13
C NMR (125 
MHz, C5H5N) 173.8 (C-7), 95.9 (C-1), 75.0 (C-3), 73.5 (C-2), 72.1 (C-4), 71.7 (C-
5), 64.5 (C-6), 34.5 (C-8), 32.2, 30.17, 30.16, 30.12, 30.07, 30.04, 29.9, 29.74, 29.72, 
29.5, 25.4, 23.0 (C-9–C-31), 14.4 (C-32); HRMS(ESI) m/z calcd. for [C64H122O12 
+Na]
+
: 1121.8783, obsd.:1121.8764. 
 
 
  6-O-Docosanoyl-α,α'-D-trehalose (9f). By subjecting 
trehalose monoester 8f (5.6 mg, 0.005 mmol) to the 
procedure described above, the title compound 9f was 
obtained after flash chromatography (eluting in 2% MeOH) 
as a white solid (3.2 mg, 0.0048 mmol, 96%). Rf = 0.37 (5% 
MeOH in EtOAc); [α]D
23
 = 0.6 (c = 0.1, C5H5N); IR (film) IR (film); 3350, 2917, 
2926, 1642, 1443, 1021, 942 cm
-1
; 
1
H NMR (500 MHz, C5H5N)   5.84 (d, J1/1',2/2'  = 
3.7 Hz, 1H, H-1/1'), 5.83 (d, J1/1',2/2'  = 3.7 Hz, 1H, H-1/1'), 5.04–5.00 (m, 1H, H-5), 
4.91 (dd,  J6a,6b = 11.7 Hz, J5,6a = 1.7 Hz, 1H, H-6a), 4.87–4.84 (m, 1H, H-5'), 4.73 
(dd, J6a,6b = 11.7 Hz, J5,6b = 5.1 Hz, 1H, H-6b), 4.71 (t, J2/2',3/3' = J3/3',4/4' = 9.5 Hz, 1H, 
H-3/3'), 4.69 (t, J2/2',3/3' = J3/3',4/4' = 9.0 Hz, 1H, H-3/3'), 4.39 (dd, J6a',6b' = 12.0 Hz, J5',6a' 
= 2.7 Hz, 1H, H-6a'), 4.31 (dd,  J6a',6b' = 12.0 Hz, J5',6a' = 4.9 Hz, 1H, H-6b'), 4.20 (dd, 
J2,3/2',3' = 9.5 Hz, J1,2/1',2' = 3.7 Hz, 1H, H-2/2'), 4.19 (dd, J3',4' = J4',5' = 9.5 Hz, 1H, H-
4') 4.18 (dd, J2,3/2',3' = 9.5 Hz, J1,2/1',2' = 3.2 Hz, 1H, H-2/2'), 4.08 (t, J3',4' = J4',5' = 9.5 
Hz, 1H, H-4), 2.24 (dt, J8a,8b = 11.4 Hz, J8a,9 = 7.5 Hz, 1H, H-8a), 2.23 (dt, J8a,8b = 
11.4 Hz, J8b,9 = 7.4 Hz, 1H, H-8b), 1.52 (pentet, Jα,β =  Jβγ = 7.6 Hz, 2H, H-9), 1.20–
1.08 (m, 36H, H-10–H-27), 0.73 (t, J27,28 = 7.1 Hz, 3H, H-28); 
13
C NMR (125 MHz, 
C5H5N) 173.9 (C-7), 95.9 (C-1/1'), 95.7 (C-1/1'), 75.1 (C-3/3'), 74.9 (C-3/3'), 74.6 
(C-5'), 73.6 (C-2/2'), 73.5 (C-2/2'), 72.4 (C-4'), 72.1 (C-4), 71.5 (C-5), 64.5 (C-6), 
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62.8 (C-6'), 34.4 (C-8), 32.3, 30.7, 28.62, 28.57, 28.52, 28.36, 28.20, 28.19, 27.98, 
23.88, (C-9–C-27), 14.4 (C-28); HRMS(ESI) m/z calcd. for [C34H64O12+Na]
+
: 
687.4290, obsd.: 687.4287. 
 
6-O-Hexacosanoyl-α,α'-D-trehalose (9g). By subjecting 
trehalose monoester 8g (5 mg, 0.004 mmol) to the procedure 
described above, the title compound 9g was obtained after 
reverse phase chromatography (eluting in MeOH) as a white 
solid (3 mg, 0.004 mmol, 97%) Rf = 0.38 (5% MeOH in 
EtOAc); [α]D
25
 = 2.0 (c = 0.1, CHCl3); IR (film) 3322, 2917, 2932, 1659, 1449, 1022, 
736 cm
-1
; 
1
H NMR (500 MHz, C5H5N)   5.84 (d, J1/1',2/2'  = 3.9 Hz, 1H, H-1/1'), 5.82 
(d, J1/1',2/2'  = 3.9 Hz, 1H, H-1/1'), 5.01–5.91 (m, 1H, H-5), 4.89 (dd,  J6a,6b = 11.5 Hz, 
J5,6a = 1.9 Hz, 1H, H-6a), 4.89–4.86 (m, 1H, H-5'), 4.73 (dd, J6a,6b = 11.5 Hz, J5,6b = 
5.2 Hz, 1H, H-6b), 4.70 (t, J2/2',3/3' = J3/3',4/4' = 8.9 Hz, 1H, H-3/3'), 4.68 (t, J2/2',3/3' = 
J3/3',4/4' = 8.9 Hz, 1H, H-3/3'), 4.37 (dd,  J6a',6b' = 11.7 Hz, J5',6a' = 2.5 Hz, 1H, H-6a'), 
4.31 (dd,  J6a',6b' = 11.7 Hz, J5',6a' = 4.9 Hz, 1H, H-6b'), 4.22 (dd, J2,3/2',3' = 9.4 Hz, 
J1,2/1',2' = 3.9 Hz, 1H, H-2/2'), 4.19 (dd, J3',4' = J4',5' = 9.4 Hz, 1H, H-4'), 4.18 (dd, 
J2,3/2',3' = 9.4 Hz, J1,2/1',2' = 3.9 Hz, 1H, H-2/2'), 4.08 (t, J3',4' = J4',5' = 9.4 Hz, 1H, H-4), 
2.22 (dt, J8a,8b = 11.5 Hz, J8a,9 = 7.4 Hz, 1H, H-8a), 2.21 (dd, J8a,8b = 11.5 Hz, J8b,9 = 
7.4 Hz, 1H, H-8b), 1.51 (pentet, Jα,β =  Jβγ = 7.3 Hz, 2H, H-9), 1.27–1.06 (m, 36H, H-
10–H-31), 0.74 (t, J31,32 = 7.1 Hz, 3H, H-32); 
13
C NMR (125 MHz, C5H5N) 173.8 
(C-7), 95.8 (C-1/1'), 95.7 (C-1/1'), 75.1 (C-3/3'), 74.9 (C-3/3'), 74.6 (C-5'), 73.7 (C-
2/2'), 73.5 (C-2/2'), 72.4 (C-4'), 72.1 (C-4), 71.6 (C-5), 64.5 (C-6), 62.9 (C-6'), 34.5 
(C-8), 32.2, 30.1, 30.1, 30.04, 30.01, 29.9, 29.71, 29.69, 29.48, 25.4, 23.0 30.7, 
28.62, 28.57, 28.52, 28.36, 28.20, 28.19, 27.98, 23.88 (C-9–C-31), 14.4 (C-32); 
HRMS(ESI) m/z calcd. for [C38H72O12+Na]
+
: 743.4916, obsd.: 743.4907. 
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3.1 Introduction 
Although the biological properties of trehalose dimycolates (TDMs, 1, Figure 1) and 
trehalose diesters of fatty acids (TDEs, 2) have been studied for many years, it was 
only in 2009 that TDM and its simpler analogue, trehalose dibehenate (TDB, 2f), 
were found to activate macrophages via the Macrophage Inducible C-type Lectin 
‘Mincle’.1,2,3 It has been suggested that Mincle binds to the ester and carbohydrate 
groups in trehalose derivatives,
1,4
 however, to date, no comprehensive structure-
activity studies have been performed. In view of this, we were interested in 
determining the structural requirements of trehalose glycolipids for the activation of 
macrophages by way of the Mincle receptor. We were also interested in investigating 
how TDE structure influences cytotoxicity and whether this correlates to the 
previously observed anti-tumour activity of these compounds.5 
,6,7
 
,8,9  
 3 TDE Biological Testing 
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Figure 1. TDM (1), TDEs (2) and TMEs (3) 
 
To meet the aforementioned objectives, TDEs of different lipid length (2a-g, Figure 
1) were tested for their ability to activate macrophages, as evidenced by nitric oxide 
(NO) and cytokine production [interleukin (IL)-6 and IL-1].10,11 The mechanism of 
activation was then explored by determining whether Mincle
-/-
 or  specific Toll-like-
receptor (TLR)
-/- 
macrophages are activated in the presence of TDEs 2a-g. In 
addition to these studies, the requirements for Mincle binding were further probed by 
testing trehalose monoesters of fatty acids (TMEs), such as 3f-g, in similar 
macrophage activation assays. Finally, the cytotoxicity of each TDE was determined 
and two representative TDEs were subsequently tested in an in vivo tumour model. 
The results of these studies and their implications are discussed in this chapter. 
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3.2 Results and Discussion 
3.2.1 Bone Marrow Macrophage (BMM) Assay Optimisation 
Macrophages are the first line of defense for the host organism against bacterial 
infection.
12,13
 Since TDB (2f) has been shown to bind to Mincle on macrophages and 
lead to macrophage activation we wanted to investigate if other TDEs can also lead 
to macrophage activation as evidenced by the production of NO and cytokines such 
as IL-6 and IL-1β. NO is commonly produced by activated macrophages and is the 
radical responsible for cytotoxic effects.
14,15
 Macrophages release IL-6 in response to 
specific microbial molecules known as pattern associated molecular patterns 
(PAMPs) for example, trehalose glycolipids, which are recognised by pattern 
recognition receptors. IL-6 can act both as a pro-inflammatory and anti-inflammatory 
cytokine. IL-1β is produced by activated macrophages as a pro-protein which is 
processed to its active form by caspase 1. It is an important mediator of the 
inflammatory response and has been shown to be involved in cell proliferation and 
differentiation. Thus using NO and cytokine IL-6 and IL-1β readouts, the activation 
state of macrophages can be deduced. Initial experiments were done using TDB as a 
model compound to set up the parameters for analysis of these glycolipids in a bone 
marrow macrophage (BMM) assay. 
NO production is commonly analysed using Griess assay, which is a chemical test 
that detects the amount of nitrite present by spontaneous oxidation of NO under 
physiological conditions.
16,17
 Griess reagent consists of  N-(1-
naphthyl)ethylenediamine (4) and sulfanilic acid (5) (Scheme 1). The sulfanilic acid 
in the presence of nitrite anion forms the diazonium salt, 6 which further reacts with 
N-(1-naphthyl)ethylenediamine (4) to form the azo dye 7, detectable at 548 nm.   
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Scheme 1. Griess reaction 
  
The first parameter to establish was the number of bone marrow (BM) cells required 
to be derivatised into macrophages in order to get a response from these compounds. 
To this end, BM cells were isolated from C57BL/6 mice, plated out in 24-well plates 
at 2.5 x 10
5
 cell/mL, 5 x 10
5
 cells/mL, 1 x 10
6 
cells/mL and 2 x 10
6 
cells/mL to a total 
of 1 mL in each well, and differentiated into macrophages over 10 days (see 
experimental section for more details). On day 10, the BMM were primed with IFN-γ 
(10 ng/mL) for 3 hours after which time they were incubated with TDB at four 
concentrations (50, 10, 2 and 0.4 μg/mL), and lipopolysaccharide (LPS, 100 ng/mL) 
which was used as positive control. IFN-γ priming is commonly used to skew naïve 
macrophages more towards a Th1 phenotype (classically activated macrophages).
18,19
 
As the TDEs and TMEs are similar to the bacterial cell wall component TDMs, a 
Th1 response is more akin to that which would be observed when considering the 
immune response to the whole bacteria.
20
 The supernatants were analysed for NO 
production using Griess assay at 96 hours (Figure 2). In all cases, good dose response 
curves were observed when starting with the four different concentrations of cells. 
We opted for the lower number of cells (250 000) because this enabled more assays 
to be performed per animal. 
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Figure 2. NO production by TDB-treated BMM. Bone marrow cells were plated out 
at four different concentrations, differentiated into macrophages over 10 days, 
primed with 10 ng/mL IFN-γ and stimulated with TDB (50, 10, 2 and 0.4 μg/mL) or 
LPS (100 ng/mL) for 96 h, after which levels of NO production in the supernatants 
were analysed.  
 
 
The next parameters analysed were the amounts of IFN-γ and TDB required to 
activate macrophages. Thus BMM were cultured, incubated with IFN-γ at 10 ng/mL 
and 20 ng/mL for 3 hours, after which time they were incubated with TDB at six 
concentrations (80, 40, 20, 10, 5 and 2.5 μg/mL) and LPS (100 ng/mL). The 
supernatants were analysed after 96 hours and as illustrated in Figure 3, more 
consistent NO readings were obtained when the macrophages were primed with 10 
ng/mL IFN-γ followed by stimulation with TDB at either 20 or 40 μg/mL. Thus 
future experiments were performed using 10 ng/mL IFN-γ for priming and samples 
at 20 and 40 μg/mL.  
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Figure 3. NO production by TDB-treated BMM following IFN-γ priming at different 
concentrations. BMM were primed with IFN-γ (10 or 20 ng/mL), followed by 
stimulation with TDB (80, 40, 20, 10, 5 and 2.5 μg/mL) or LPS (100 ng/mL) and the 
supernatants analysed for NO production after 96 h.  
  
In order to determine the optimum time-point for cytokine read-outs, a time-course 
experiment for cytokine analysis was undertaken. To this end, BMM were stimulated 
with TDB (20 μg/mL) and the supernatants analysed for IL-1β and IL-6 production 
at 24, 48, 72 and 96 hours by enzyme-linked immunosorbent assay (ELISA) 
[Cytokine analysis was performed by Rene McLaughlin, a PhD student in Dr Jacquie 
Harper’s group at MIMR]. The induction of IL-6 and IL-1 by TDB (2f) reached a 
plateau at 72 h (Figure 4A and 4B). As with NO production, TDB (2f) induced 
production of IL-6 and IL-1β, exhibited delayed kinetics and was weaker than LPS 
induced production.   
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Figure 4. Cytokine production by TDB-treated BMM. BMM were treated with TDB 
(20 μg/mL) or LPS (100 ng/mL). At 24, 48, 72 and 96 h the supernatants were 
analysed for A) IL-6 and B) IL-1β levels by ELISA.  
 
3.2.2 Understanding how trehalose lipid length affects 
macrophage activation  
With the BMM assay set-up, all the synthesised TDEs were tested for their ability to 
activate macrophages. Here, IFN- primed BMM were treated with 20 μg/mL of 
TDEs, and at different time points supernatants were collected for NO analysis 
(Figure 5A). Trehalose and the uncoupled C22 (behenic) acid were used as controls 
in the experiment. The longer chain TDEs 2e-g all induced NO production, with NO 
levels reaching a plateau at 96 h (C22 > C20 > C26). The shorter TDEs (C4-C10) 
were inactive. The C18 analogue led to a small but significant (p<0.05) increase in 
NO production. Trehalose and the uncoupled C22 (behenic) acid showed no activity. 
To determine the influence of TDE concentration on NO production, BMM were 
then incubated with 20 g/mL and 40 g/mL of each compound and NO production 
measured at 96 h (Figure 5B). For those TDEs that stimulated BMM (2e-g), there 
was a modest increase in NO production with increased glycolipid concentration. 
A B 
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Figure 5. NO production by TDE-treated BMM. A) BMM were stimulated with 
TDEs (20 μg/mL) or with LPS (100 ng/mL). At 24, 48, 72 and 96 h the supernatants 
were analysed for NO production using Griess assay. B) BMM were treated with 
TDEs, trehalose or behenic acid (40 μg/mL and 20 μg/mL) or with LPS (100 ng/mL) 
and NO production was determined at 96 h. The mean and SD of triplicate samples 
from a represenative experiment of two are shown.   
  
 
The levels of IL-6 and IL-1β production were also measured at 96 hours for all the 
TDEs. In both cases, only the longer TDEs (C22~C26>C20) induced significant 
cytokine production (Figure 6A and 6B). TDEs induced lower levels of IL-6 
production by the BMMs when compared to LPS. The shorter lipid chain analogues 
(C4-C10) showed no activity. 
 
B A 
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Figure 6. Cytokine production by TDE-treated BMM. BMM were stimulated with 
TDEs (20 μg/mL) or with LPS (100 ng/mL) for 96 h, and the supernatants were 
analysed for the accumulation of A) IL-6 and B) IL-1β by ELISA. The mean and SD 
of triplicate samples from a representative experiment of two are shown.   
 
 
In this work, the importance of the lipid chain length on trehalose in inducing 
macrophage activation is clearly emphasised. Taken as a whole, these results indicate 
that longer lipids (C18) are required for the activation of macrophages by 
diacyltrehalose glycolipids whereas TDEs with short chain lipids (<C18) are 
inactive. In addition to the lipid length, the ester linkage was also found to be an 
important moiety required for the recognition of trehalose glycolipids by 
macrophages since both trehalose and behenic acid on their own were unable to 
induce macrophage activation. These observations are interesting as they provide 
insight into why M. tb, which expresses long lipid chain TDMs, triggers an innate 
immune response in the host upon invasion.  
 
 
 
A B 
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3.2.3 On One Leg: Trehalose Mono-Esters (TMEs) Activate 
Macrophages in a Mincle-Dependant Manner 
As highlighted previously, diacyltrehalose glycolipids, in the form of trehalose 6,6'-
dimycolates [TDMs (1), Figure 1], are the most abundant cell surface glycolipid 
from M. tb and related mycobacteria, and have important immunomodulatory 
functions in M. tb pathogenicity.
21,22,23,24
 In particular, the pivotal role of TDMs in 
granuloma formation and in the prevention of phagosome–lysosome fusion, thus 
facilitating bacterial survival within the host macrophages
25,26
 has led to much 
interest in the mechanism by which TDMs interact with macrophages. Initially it was 
proposed that TDMs regulate the immune response by binding to the cluster of 
differentiation (CD) 1 isoform CD1d on macrophages, thus allowing for subsequent 
glycolipid presentation to Natural Killer (NK) T cells,
27,28
 however, further studies 
using CD1d
-/-
 mice revealed that the activity of TDMs was independent of CD1d 
interaction.
29
 It was not until 2009 that Ishikawa and co-workers
1
 and Lang and co-
workers
2
 independently identified Mincle as a receptor for TDMs. Lang then 
followed on from these studies to illustrate that TDM-Mincle interaction induces a 
SyK-Card9-Bcl1-Malt1 signalling pathway,
3
 and furthermore, that the simple 
straight-chain TDM analogue TDB (2f) also activates macrophages in a manner 
similar to the parent esters. This work proved revolutionary, not only because the 
binding of TDMs/TDB to Mincle provides insight into the mechanisms by which M. 
tb interacts with its host cell, but also because the Th-1 type cytokine response 
generated by macrophages upon stimulation with trehalose glycolipids may be better 
harnessed in the development of M. tb vaccine adjuvants
30,31
 if more knowledge 
about the requirements of TDM-Mincle binding are known. To date, however, the 
limited availability of the appropriate Mincle
-/-
 murine models has meant that much 
in this field remains unanswered. 
Mincle, (also known as Clec4e and Clecf9)
32,33
 is a trans-membrane protein found on 
cells of the myeloid lineage (predominantly macrophages) and was discovered just 
over ten years ago by Akira and co-workers.
34
 Mincle has an extracellular Ca
2+–
dependent carbohydrate recognition domain and is highly conserved between mice 
and humans with 85% protein similarity,
34
 however, to date, no tertiary structure is 
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known. In addition to the trehalose diesters, Mincle is also a receptor for Candida 
albicans
35
 and the pathogenic fungus Malassezia.
36
 It has been proposed that Mincle 
binds to -linked mannose containing glycolipids in these organisms, although no 
specific agonists were identified. Moreover, Mincle does not recognise -1,2 
mannose containing glycolipids from mycobacterium cell wall extracts.
3,4
 
To better understand the influence that trehalose diesters have on the immune 
response, and in particular, the manner in which they bind to macrophages the 
structural requirements for TDE/Mincle binding was explored. In the earlier studies 
reported here, it has been shown how lipid length affects the innate immune response 
of macrophages to trehalose diesters and observed that long lipids (C18) are 
required for the activation of macrophages.
37
 The mechanism of activation, however, 
was not investigated, although others have suggested that trehalose diesters bind to 
Mincle via their carbohydrate and ester groups.
3,4
 Herein, the structural requirements 
for the binding of TDEs with Mincle, including unprecedented insight into the 
number of esters required for macrophage activation and the mechanisms of 
activation is reported. 
 
3.2.3a Trehalose mono-esters of carbon length ≥ C20 activate macrophages 
To understand more about the structural requirements for the binding of trehalose 
esters to Mincle, the ability of trehalose mono-esters of fatty acids (TMEs, 3, Figure 
1) to activate macrophages was investigated. Given that long lipids (C18) are 
required for macrophage activation,
37
 C22 TMEs (3f) and C26 TME (3g), and along 
with C22 TDE (TDB, 2f, as positive control) were prepared and the ability of each of 
these glycolipids to activate BMMs derived from C57BL/6 mice, as determined by 
NO and cytokine production (Figure 8) was explored. As illustrated, NO production 
by the BMMs in response to C22 TME (3f) and C26 TME (3g) (20 μg/mL) increased 
over the 96 h time period, although at a much slower rate when compared to the toll-
like receptor (TLR) 4 ligand, LPS (Figure 7A). At 24 h, C22 TMEs (3f) and C26 
TME (3g) and TDB (2f) all induced similar levels of NO, however by 96 h, levels of 
this intracellular mediator were lower for C22 TME (3f) and C26 TME (3g) (with 
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3g<3f). The influence of glycolipid concentration on NO production was then 
investigated and BMMs were incubated with 20 and 40 μg/mL of the TMEs/TDB 
and NO levels recorded at 96 h. As illustrated (Figure 7B), a modest increase in NO 
production with increased glycolipid concentration was observed for both the mono- 
and di-esters. 
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Figure 7. NO and cytokines IL-6 and IL-1β production by TDB/TME-treated BMM. 
A) BMM were stimulated with TMEs, TDB (20 μg/mL) or with LPS (100 ng/mL). 
At 24, 48, 72 and 96 h the supernatants were analysed for NO accumulation. B) 
BMM were treated with TMEs, TDB (40 μg/mL or 20 μg/mL) or with LPS (100 
ng/mL) and NO production was determined at 96 h. BMM were stimulated with 
TMEs, TDB (20 μg/mL) or LPS (100 ng/mL) for 96 h, and the supernatants were 
analysed for the accumulation of C) IL-6 and D) IL-1β by ELISA. For all graphs, the 
mean and SD of triplicate samples from a representative experiment of two are 
shown. 
A 
 
D 
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Having established that C22 and C26 TMEs (3f and 3g), stimulate the production of 
NO by BMMs, the effect of these mono-esters on the production of the intracellular 
cytokines, IL-6 and IL-1 was then investigated. To this end, BMMs were stimulated 
with the trehalose esters and the levels of each cytokine measured at 96 h, which was 
previously determined as being the optimum time-point.
37
 Surprisingly, levels of IL-
6 were similar for C22 TME (3f) and the corresponding C22 TDE (2f), while 
treatment of the BMMs with C26 TME (3g) also led to IL-6 production, albeit at 
lower levels (Figure 7C). Production of IL-1 was slightly lower for C22 and C26 
TME (3f and 3g), when compared to both TDB (2f) and LPS (Figure 7D). Taken as a 
whole, these observations are interesting and suggest that trehalose structure can 
influence the relative ratios of cytokines produced. Moreover, the first evidence to 
suggest that trehalose mono-esters also activate macrophages is provided, which is 
surprising and contrary to current ideas about the requirements for trehalose 
glycolipid/Mincle interactions.
1,4
  
 
3.2.3b Mincle is a key cellular mediator in the activation of macrophages by 
trehalose mono- and di-esters 
In the earlier studies the effect of lipid length on the activation of BMMs by TDEs 
was demonstrated; however, no insight was provided for the mechanism of this 
phenomenon.
37
 Although one could assume that all linear trehalose diesters that 
activate BMMs do so via Mincle [as established by Lang and co-workers for TDB 
(2f)],
2
 this hypothesis needs to be explored. Similarly, the manner by which trehalose 
C22 and C26 TME, (3f and 3g), activate BMMs also needs to be determined. To this 
end, the ability of C20 and C22 TDEs (2e and 2f) and C22 and C26 TMEs (3f and 
3g) to activate Mincle
-/-
 BMMs was investigated. Given that other C-type lectins, 
such as Dectin-1, act synergistically with other receptors (e.g., TLR2 and TLR4),
38
 
we also explored the ability of the trehalose esters to activate TLR2/4
-/-
 BMMs. This 
work was carried out by Dr. Faustin Kamena at Max Plank Institute, Berlin, 
Germany.  
Using the NO BMM assay developed above, C22 and C26 TMEs (3f and 3g), and 
C20 TDE (2e), C22 TDE (2f) and C4 TDE, (2a, as a negative control),
37
 were tested 
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for their ability to activate BMMs (Figure 8). In this experiment, the C20 TDE (2e) 
did not lead to the generation of NO by wild-type BMMs, however, TDB (2f) did. 
What is more important, however, is that both C22 (3f) and C26 (3g) TMEs were 
able to activate wild-type BMMs but not Mincle
-/-
 BMMs, thus highlighting the 
importance of this receptor for the activation of macrophages by trehalose 
monoesters. The ability of C22 and C26 TMEs, (3f and 3g), and TDB (2f) to activate 
TLR2/4
-/-
 macrophages, also suggests that neither of these TLRs binds to the 
trehalose glycolipids. This finding is supported by Lang’s earlier studies where it was 
illustrated that both TDM and TDB were able to activate BMMs from MyD88
-/-
 
mice, as measured by NO and cytokine production.
2
 Here, it should be noted 
however, that care needs to be taken in the interpretation of our TLR2 data because 
the control (PamCys – a TLR2 ligand) led to the activation of TLR2/4-/- BMMs. This 
unusual result could either be due to too high levels of PamCys being used in the 
assay or the PamCys being contaminated. These assays will be repeated in due 
course to better explain this phenomenon. 
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Figure 8. NO production from TDE/TME-treated BMM derived from Mincle
-/-
, 
TLR2/4
-/-
 and wild type mice. BMM were primed with IFN-γ (10 ng/mL) and 
stimulated with C4 TDE (2a), C20 TDE (2e), C22 TDE (2f) C22 TME (3f), and C26 
TME (3g) at 40 μg/mL, LPS (10 ng/mL) or PamCys (10 ng/mL) and NO measured 
after 72 h.  
 
Although there are still a number of experiments to be performed using the trehalose 
mono- and di-esters (including the testing of further analogues in the BMM assays), 
results obtained to date, point to a number of interesting facts. First, the ability of 
trehalose diesters to activate BMMs appears to be a general phenomenon of all 
diesters which have a lipid length C20, with the mechanism of macrophage 
activation being Mincle, but not TLR, dependent. While earlier studies by Giesel et 
al.
39
 and Bowdish et al.
40
 had implicated TLRs (including TLR2) in TDM-binding 
and recognition, the studies by Ishikawa,
1
 Lang,
2
 and now the results obtained during 
this research, point to a mechanism of macrophage activation by TDEs that is 
independent of TLRs. To add to this argument, the ability of the TDEs and TMEs to 
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activate BMMs in the absence of other TLRs (e.g. by using TLR9
-/-
, Myd88
-/- 
BMMs 
etc.) will be further explored. 
In addition to providing insight into the mechanism of action for a range of TDE’s, 
we have also illustrated that C22 and C26 TMEs (3f and 3g) activate macrophages 
via Mincle. Although, it is generally thought that the induction of intracellular 
signalling by macrophages in response to trehalose esters requires two esters to bind 
to and activate Mincle,
3,4
 through this work, however, it has been demonstrated that 
only one ester group is necessary, and by doing so, a new sub-class of Mincle ligands 
have been uncovered, which will provide potential for the future development of 
agonists for this receptor. 
 
3.2.3c Trehalose diesters (TDEs) can prime macrophages 
To engage a full immune response, macrophages are typically primed prior to the 
addition of any subsequent immunomodulatory compound. Priming of macrophages 
is often performed using IFN-γ, which causes an increase in antigen presentation and 
lysosome activity of macrophages and skews naïve macrophages towards a Th1 
phenotype (classically activated macrophages).
18,19
 The TLR4 ligand LPS has also 
shown potential to be used as a priming agent for macrophages, making macrophages 
sensitive to induction of pro-inflammatory cytokines in the presence of secondary 
stimuli.
41
 The identification of a new class of compounds that can prime 
macrophages in a TLR-independent manner, however, provides a new way to 
enhance the immune response and may lead to the identification of new 
combinations of therapies to generate the desired immunological response. 
To this end, the ability of TDE’s to activate macrophages with different levels of 
IFN-γ priming was explored. Preliminary work in this area was performed by Lang 
and co-workers,
2
 whereby BMMs were incubated with TDM and TDB (20 µg/mL) 
and found to produce NO, albeit at a lower level than the IFN-γ primed (20 ng/mL) 
BMMs. In the current study, however, the ability of unprimed BMMs to generate NO 
and cytokines (e.g. IL-6) upon exposure to a variety of TDE’s was investigated. 
Accordingly, BMMs were stimulated with different concentrations of IFN-γ (0, 10 
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and 20 ng/mL) 3 h prior to the addition of TDB (2f) and the supernatant analysed for 
NO and IL-6. As illustrated (Figure 9A), in the absence of IFN-γ priming, there was 
no NO production by the BMMs in response to TDB (2f), however, IL-6 production 
for the unprimed BMMs was similar to that for BMMs primed with 10 ng/mL of 
IFN-γ (Figure 9B). 
 
 
Figure 9. The effect of priming with IFN-γ on BMM stimulated with TDB. BMM 
were primed with IFN-γ (0, 10 or 20 ng/mL) for 3 h followed by stimulation with 
TDB (80, 40, 20, 10, 5, 2.5 μg/mL) or LPS (100 ng/mL); A) The supernatants were 
analysed for NO production after 96 h. B) The supernatants from BMM stimulated 
with TDB (20 μg/mL), LPS (100 ng/mL) were analysed for IL-6 production at 96 h.     
 
From the above preliminary results, it is apparent that TDB (2f) is able to activate 
macrophages independent of IFN-γ priming. There are, however, some differences 
between the results reported here and those obtained by Weringhaus et al. who 
showed that in the absence of IFN-γ priming, macrophages were able to induce 
modest NO production in response to 20 µg/mL of TDB (2f).
2
 That said, no 
investigations into the levels of cytokines produced by unprimed macrophages in 
response to TDB (2f) were reported.
2
 
 
 A 
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,43–47 
To further explore the potential of trehalose diesters as priming agents, there are a 
number of experiments that should follow. First, a variety of TMEs and TDEs should 
be tested for their ability to activate BMMs (without priming) to determine whether 
this is a response unique to TDB (2f) or more widely applicable. Moreover, it should 
be determined whether BMMs treated with LPS show greater activity following 
priming with TDB (2f). By performing this assay, the potential of trehalose 
glycolipids to act as priming agents can be more readily assessed. Indeed, if 
increased BMM activation is observed following TDB priming, a variety of other 
immunostimulatory molecules could then be tested following TDB (or similar 
trehalose glycolipid) priming, thus opening-up a whole new avenue of research and 
means by which to generate an enhanced immune response. 
 
3.2.4 Application of TMEs and TDEs in cancer therapy 
It has been known for some time that trehalose glycolipids have potential in the 
treatment of solid tumours,   however, the mechanism of action and the means by 
which to develop an optimum anti-tumour response are poorly understood. This is in 
part due to the variety of assays that have been performed, which involve either 
intravenous (i.v.), intra-tumoural, subcutaneous or oral administration of different 
trehalose diesters (C2-C22) in different vehicles (e.g. as saline solutions or as oil 
emulsions with or without the addition of LPS), and in different tumour  models.
5,7,9
,42,43,44,45 
From an analysis of the literature, it would appear as though use of an oil vehicle 
leads to a better anti-tumour effect,
42,44
 as does the addition of LPS,
7,9,45
 however, 
these conclusions can only be reached by considering experiments that were 
performed using similar assays and where only one variable was altered at a time. 
Given this, it is difficult to determine whether there is a particular trehalose lipid 
length that leads to an optimum anti-tumour response. For example, trehalose 
diesters with lipids of lengths C8, C10, C18, C22 have all shown anti-tumour 
potential, depending on the assay used. Moreover, it is not known whether the anti-
tumour effect of the trehalose esters is due to their cytotoxic or immunomodulatory 
effects (or both). Given that previously it has been observed that only trehalose esters 
with lipid length C18 were able to activate BMMs,37 the mechanism by which 
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trehalose esters exert their anti-tumour activity was explored next, particularly since 
solid tumours contain large numbers of the immunosuppressive tumour associated 
macrophages (TAMs).
46
  
To determine whether the anti-cancer activities of trehalose esters are due to general 
cytotoxicity, the compounds were tested in an in vitro MTT viability assay using a 
human hepatocellular carcinoma (HepG2) cell line. HepG2 is a liver cancer cell line 
commonly used to study liver metabolism and toxicity. The MTT assay assesses cell 
viability by determining whether the yellow tetrazolium salt MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (8) is reduced to the purple 
formazan product 9 by NADPH in the presence of dehydrogenase, which occurs 
during normal cellular respiration (Scheme 2). In the presence of a cytotoxic agent 
however, cellular growth is suppressed and no or limited colour change of the dye 
occurs. Cell viability is than expressed in a percentage of MTT reduction with 
respect to an untreated control. 
 
Scheme 2. MTT reduction  
 
The results of the MTT assay are depicted in Figure 10 [Assays performed by Dr 
James Baty, MIMR]. None of the tested trehalose glycolipids showed appreciable 
cytotoxicity at concentration under 50 μM (data not shown). At the two highest 
concentrations (50 and 150 μM), however, the more lipophilic compounds, the C26 
monoester and the C20, C22 and C26 diesters of trehalose, appeared to be slightly 
cytotoxic, in a concentration dependant manner. Interestingly, the C22 TME did not 
follow this trend, as it did not show any cytotoxicity at the concentrations tested.  
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Figure 10. Cytotoxicities of TMEs and TDEs against HepG cell line. HepG cells 
were stimulated with TDEs, TMEs, Doxorubicin (positive control) at 50 and 150 μM 
for 2 days after which time 20 μL MTT was added, followed by addition of SDS 
lysing buffer after 2 hours. The cells were incubated a further overnight and 
absorbance were measured in a FLUOstar OPTIMA plate reader at 570 nm.   
 
Future Directions 
Though investigations into understanding the mechanism by which trehalose diesters 
exert their anti-cancer activity is very much in its infancy, from the analysis it is 
apparent that when the trehalose esters are administered in PBS they exhibit poor 
cytotoxicities therefore direct killing of cancer cells by the TDMs is unlikely. It has, 
however, been shown that the same TDEs are able to activate BMMs, leading to the 
generation of NO and cytokines (such as IL-1 and IL-6), which suggests an ability 
to induce a Th1 immune response in macrophages. Given this, one could suggest that 
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the anti-tumour activity of the trehalose diesters is due to the ability of the 
compounds to invoke the systemic activation of macrophages, which could lead to 
tumour regression, or potentially switch the phenotype of the immunosuppressive 
TAMs to that of the tumour suppressive M1 phenotype (a phenotypic ‘switch’ 
known to occur via the agency of Th-1 cytokines such as tumour necrosis factor 
(TNF)-α and IL-12.46,47 Indeed, if this is true, then improved anti-tumour 
immunomodulators may be generated through the development of trehalose esters 
that lead to an optimum ‘Th-1’ response. 
To further substantiate this hypothesis, however, numerous other experiments need 
to be performed. First, the cytotoxicity of the trehalose esters should be determined 
when administered in an oil vehicle. Perhaps the cytotoxicity of the compounds 
depends on the mode of administration, as has been suggested in earlier studies 
whereby the co-presence of an oil vehicle was necessary for anti-tumour activity.
42,44  
It has also been suggested that oil primarily functions as a carrier of the glycolipids 
to the tumour site,
44
 and that the lack of activity of trehalose diesters when 
administered in aqueous media is due to micelle formation, thus rendering the 
trehalose esters biologically inert.
43
 During the course of this thesis, however, some 
provisional in vivo results were obtained which suggest that the trehalose diesters 
(when administered as a solution in 2% DMSO and PBS) do exhibit an ability to 
reduce tumour growth [Assay performed by Sabine Kuhn, MIMR]. As this 
experiment was only performed once, it is too premature to present the work here, 
however, as some tumour regression was observed, it would therefore be instructive 
to determine the critical micelle concentration of our diesters. This can readily be 
achieved by fluorescent measurements of the trehalose glycolipids at 25°C, using 
pyrene or pyrene-3-carboxaldehyde as the probe.
48
 Following on from this, the in 
vivo assays can then be repeated using a selection of trehalose glycolipids. Here, a 
number of variables can be considered including glycolipid concentration, tumour 
type,
5
 and the co-administration of LPS.
7,9,45,49
 If significant tumour regression is 
observed using any one combination of reagents, this experiment could then be 
repeated using Mincle
-/-
 mice to understand more about the mechanism of action. 
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Finally, whether trehalose esters have the ability to switch the phenotype of 
macrophages, for example from TAM to M1 (thus leading to better tumour 
regression),
46,47,50,51
 could be investigated by following the protocols of Duluc et al.
52
  
and Eriksson et al..
47
 Here, TAMs would be generated from naïve macrophages 
(obtained from BM cells) by culturing them form 48 hours in complete medium 
containing 30% medium from tumour cultures. Subsequent treatment with the TDEs 
followed by analysis of immunosuppressive and pro-tumoural mediators [e.g. IL-10, 
Vascular endothelial growth factor (VEGF) and Chemokine ligand (CCL) 18] would 
then be used to determine if phenotype switching occurs. Should macrophage 
phenotype switching be observed, these studies can then be repeated using Mincle
-/-
 
mice to understand more about the mechanism of action. 
 
3.3 Conclusion 
From the first part of this work, it is clearly evident that long chain trehalose diesters 
(≥C18) are required to activate macrophages. The activation of macrophages was 
measured using NO and cytokine IL-6 and IL-1β read-outs. In addition the C22 and 
C26 TMEs were also shown to activate macrophages, thus unveiling a new sub-class 
of compounds which have macrophage activation abilities. The work with Mincle
-/-
 
and TLR2/4
-/-
 BMM clearly showed that Mincle is the key receptor on macrophages 
for TDEs and TMEs binding. The recognition of TDEs and TMEs is independent of 
TLR2 and 4 receptors and further testing using other TLR
-/- 
and MyD88
-/- 
BMM 
needs to be performed to rule out involvement of other TLR receptors. TDB has also 
shown potential to be used as a priming agent, leading to the discovery of a new class 
of compounds, independent of TLR binding, that can be used to generate an 
enhanced immune response. 
The anti-tumour activity of the TDEs and TMEs was also probed and results from 
the cytotoxicity assay using HepG2 cell line showed that these compounds were only 
slightly cytotoxic; however, preliminary in-vivo results showed that both the C10 and 
C22 TDE have anti-tumour activities. Thus the mechanism by which the trehalose 
glycolipids exert anti-tumour activity needs to be further investigated.  
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3.4 Experimental 
Material and methods for Biological Assays: C57BL/6 male mice were bred and 
housed in a conventional animal facility at the Malaghan Institute of Medical 
Research, Wellington, New Zealand. All animals used for the experiments were aged 
between 8-10 weeks. All experimental procedures were approved by the Victoria 
University Animal Ethics Committee in accordance with their guidelines for the care 
of animals. All synthetic compounds were confirmed to be free of endotoxin, at a 
sensitivity of ≤0.125 EU/mL by testing them in Limulus amebocyte lysate (LAL) 
assay using an endotoxin kit (Pyrotell, Limulus Amebocyte Lysate). 
 
Generation of bone marrow derived macrophages (BMMs): Bone marrow cells 
were collected from the tibia and femur of C57BL/6, Mincle
-/-
 or TLR2/4
-/-
 mice and 
were cultured (250 000 cells/mL) in Iscove’s Modified Dulbecco’s Media (IMDM-
Gibco) supplemented with 5% FBS (Gibco), 1% Penicillin streptomycin (Gibco) and 
55 μM 2-mercaptoethanol (Invitrogen) containing 10 ng/mL GM-CSF (clone 
X63/GM-CSF murine cells). Cells were incubated at 37 °C (5% CO2) and the media 
changed on days 2, 5 and 7. On day 10, the media was removed and the BMM were 
primed with 10ng/mL IFN-γ (Peprotech) for 3 h prior to the addition of the 
compounds.
2 
 
BMM Assay: TDEs, TMEs, trehalose, and docasonoic acid stock solutions were 
prepared (2.5 mg/mL in PBS containing 2% DMSO), vortexed and warmed to 50 °C 
for 30 min (x 3) to ensure complete solubilisation of the compounds prior to 
administration to BMM cultures. BMM cultures were then treated with 20 or 40 
μg/mL of TDE, TMEs, trehalose, or behenic acid, with LPS (100 ng/mL) as a 
positive control and media only as a negative control for the times indicated. 
Supernatants were collected and tested immediately for NO levels or stored at -80
 
°C 
for subsequent cytokine analysis.
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NO and cytokine analysis: NO levels in supernatants were determined using the 
Griess assay. Levels of IL-6 and IL-1β cytokine in the supernatants sandwich ELISA 
(R&D Systems and BD Biosciences respectively), as per manufacturer’s instructions.  
 
HepG2 cell culture: HepG2 cells were maintained in RPMI supplemented with 10% 
(v/v) fetal calf serum (FCS), 2 mM glutamate, 100 U/mL penicillin, and 100 µg/mL 
streptomycin and were kept at 37 °C in a humidified incubator maintained at 5% 
CO2. 
 
Cell Metabolism MTT assay: Cell metabolism activity was measured using the 2-
day MTT assay as previously described and reviewed.
53,54
 Doxorubicin was used as a 
positive control in these experiments. HepG2 cells were plated into 96-well plates in 
the presence of different concentration of the TDEs and TMEs (final cell 
concentration = 0.1 x 10
6 
cells/mL in complete RPMI) and incubated for 48 h (37 °C, 
5% CO2). 20 μL of MTT (2.5 mg/mL in HBSS) was then added to each well and the 
cells incubated for 2 h before adding 100 μL of SDS lysing buffer (10%)w/v SDS, 
45% v/v dimethylforamide/H2O, pH 4.7) and further overnight incubation. The 
absorbance at 570 nm was measured in a FLUOstar OPTIMA plate reader (BMG 
Labtechnologies Pty. Germany). All assays were performed in triplicate and the 
mean result recorded.   
 
Murine tumour and compound preparation: EG.7-OVA (thymoma) cells were 
cultured and washed with PBS and resuspended in PBS to a final concentration of 1 
x 10
6
 cell/mL. C10 and C22 TDEs stock solutions were prepared (3.0 mg/mL in PBS 
containing 2% DMSO), vortexed and warmed to 50 °C for 30 min (x3) to ensure 
complete solubilisation of the compounds prior to administration. 
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Treatment of mice with established tumour transplants: On day 1 groups of 5 
mice received 100 μL of viable thymoma cells subcutaneously, followed by 50 μL of 
TDEs, 2% DMSO in PBS (negative control) or 2x10
6 
CFU M. smegmatis (positive 
control). At day 2, 4, 6 and 8 thereafter, the same groups were given intra-tumoural 
injection of TDEs, 2% DMSO in PBS or 2x10
6 
CFU M. smegmatis. 
 
Evaluation of tumour growth: The tumour size for individual mice were measured 
(using calipers) every 2 days until the tumour reached 150 mm
2
 
 
Statistical Analysis: Statistical significance was determined by student’s t-test. 
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4.1 Introduction 
Fráter-Seebach alkylation is a key step commonly used in the synthesis of trehalose 
dimycolates (TDMs, 1, Figure 1) and trehalose dicorynomycolate (TDCM, 2) to 
install the α-chain in the mycolic acid and corynomycolic acid fragments, 
respectively. However, using this methodology for installing long alkyl chains at the 
-position of -hydroxy esters has been met with mixed success. In order to improve 
the efficacy of this reaction for the installation of long alkyl chains, we developed a 
strategy whereby allyl halides are used as electrophiles. 
4 An Improved Fráter-Seebach Alkylation1 
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Figure 1. TDM (1) and TDCM (2) 
 
Allyl halides are known to have excellent reactivity, which arises from 
stereoelectronic interactions between the *C-X orbital and the adjacent  system.
2,3
 
In the transition state for the SN2 reaction of an allylic halide (I, Scheme 1), the 
overlap between the p orbital developed on the carbon at which displacement occurs 
and the p orbitals of the conjugated double bond allows for electron density of the  
system to be delocalised over the three carbon atoms involved in the allylic system 
(II). This, in turn, leads to a lower transition state energy when compared to that of 
the corresponding saturated halide, resulting in higher yield of the product (III).  
 
 
Scheme 1. Transition state for allyl halide substitution via an SN2 reaction 
Accordingly, we proposed that a Fráter-Seebach alkylation using highly reactive long 
chain allylic iodides would lead to more efficient -alkylations when compared to 
the alkyl halide counterpart. The hydroxy-ester of choice was diethyl malate (3) 
which could be derivatised at a later stage to form the corynomycolic or mycolic 
121 
 
acids for the synthesis for TDCMs and TDMs respectively. A range of allylic iodides 
(4) were used to form alkylated esters 5 of varying lipid lengths (Scheme 2). 
 
Scheme 2. Proposed Fráter-Seebach alkylation 
 
4.2 Results and Discussion 
4.2.1 Synthesis of allylic iodides  
To prepare the required allylic iodides, an efficient two-step strategy was proposed,  
that first involved the Grignard addition of vinyl magnesium bromide to an aldehyde
3 
and a subsequent SN2' substitution of the in situ generated 
alkoxytriphenylphosphonium iodide intermediate (Scheme 3).
4
 The starting 
aldehydes, pentanal 6a and dodecanal 6b, were sourced commercially, while 
octadecanal 6c, eicosanal 6d, and docosanal 6e were prepared via a pyridinium 
chlorochromate (PCC) oxidation of the corresponding alcohols.
5
 In case of pentanal 
and dodecanal, the Grignard reaction was carried out smoothly in THF with 1M vinyl 
magnesium bromide solution, to give the corresponding allylic alcohols 7a-b in good 
yields. However, when longer aldehydes 6c-6e were used, the yield for this reaction 
was quite low, with reduction of the aldehyde to the corresponding alcohols also 
observed. In order to reduce this by-product formation, the solvent was replaced with  
toluene, which had been previously reported to minimise aldehyde reduction.
6
 
Indeed, a small improvement in product yield was observed, however, the by-product 
was still present. Other reasons for this by-product formation were attributed to the 
lower reactivity of long chain aldehydes, and the quality of the reagents used. Thus, 
in an attempt to improve the latter, vinyl magnesium bromide was prepared in situ
7
 
and the reaction was performed at 0 °C in toluene, which did indeed lead to 
improved yields (71–89%) of the allylic alcohols 7c-7e.    
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Scheme 3. Synthesis of representative allylic iodides 
 
The intermediate allylic alcohols 7a-e were then subjected to a short silica gel plug 
and used immediately in the iodination reaction, as they are prone to decomposition.
4
 
Treatment of each alcohol with a solution of triphenylphosphine and iodine in THF 
gave the corresponding allylic iodides, 4a (n = 3), 4b (n = 10), 4c (n = 16), 4d (n = 
18) and 4e (n = 20) in 89%, 81%, 70%, 71% and 73% yield, respectively, over two 
steps. As anticipated, each of the allylic iodides 4a-e were found to be an inseparable 
isomeric mixture consisting mainly of the E-isomer (E:Z ca. 4:1), as determined by 
the 18.6 Hz vs 8.5 Hz coupling constant for the alkene protons in the 
1
H NMR of the 
crude reaction mixtures. Spectroscopically, a very minor (<5%) amount of the 
corresponding 1,3-diene elimination product was also observed during the reaction.   
The iodination of allylic alcohol 4a-e could be asserted to occur via a SN2' 
mechanism (Scheme 4).
3
 Here, the in situ generated iodophosphonium iodide (IV), 
undergoes a nucleophilic attack by alcohol V, which results in the generation of an 
alkoxytriphenylphosphonium iodide (VI). SN2' attack of the iodide then leads to the 
generation of the desired internal alkene (VII), with triphenylphosphine oxide (VIII) 
being generated as a by-product.  
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Scheme 4. Mechanism for the SN2' reaction  
 
4.2.2 Fráter-Seebach Alkylation 
With the necessary allylic halides in hand, we set out to investigate their potential in 
a Fráter-Seebach alkylation. Thus, diethyl malate 3, was prepared via esterification 
of the commercially available L-malic acid in a good (95%) yield,
8 
and then alkylated 
with the allylic halides or their saturated counterparts (Table 1). The saturated alkyl 
iodides were prepared via the iodination of the corresponding alcohols or, in the case 
of iodo-tetradecane, via cross halogenation of bromo-tetradecane. Overall yields 
were, in general, similar to those for the preparation of the allylic iodides. The 
alkylations were performed in THF using 2.5 equivalents of lithium 
diisopropylamide (LDA, generated in situ at -78 °C), to which was added 1 
equivalent of diethyl malate 3, followed by 1.5 equivalents of the alkyl or alkenyl 
halide. 
Our first study involved the alkylation of diethyl malate 3, using either allyl bromide 
(entry 1), or allyl iodide (entry 2), in the absence of hexamethylphosphoramide 
(HMPA). As illustrated, both reactions proceeded smoothly to give anti-5a as the 
predominant diastereomer in respectable yield. Use of heptyl iodide, however 
resulted in a decreased yield with 5b being obtained in 37% following purification by 
flash column chromatography (entry 3). There was no other identifiable product 
obtained from the reaction, and although excess alkyl halide could be recovered from 
the reaction mixture, diethyl malate 3 had decomposed. On the other hand,  
124 
 
alkylation with the C7 allylic iodide, 1-iodo-hept-2-ene (4a), resulted in an improved 
(55%) yield of the desired -alkylated -hydroxy ester with a diastereoselectivity of 
9:1; anti:syn (entry 4). This result was encouraging and demonstrated the improved 
reactivity of the allylic system. 
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Table 1. Alkylation Conditions and Yields 
 
 
 
Entry 
 
R-X 
 
n 
 
Conditions
[a] 
 
Major 
Product 
 
Yield
[b]
 
 
Ratio 
anti:syn
[c,d]
 
1 
 
- A 5a 57% 14:1 
2 
 
- A 5a 52%  9:1  
3 
 
3 A 5b 37% 7:1 
4 
 
3 A 5c 55% 9:1 
5 
 
10 A 5d 15% 9:1  
6 
 
10 A 5d 7% 7:1 
7 
 
10 B 5d 35% 7:1 
8 
 
10 A 5e 51% 10:1 
9 
 
10 B 5e 45% 9:1 
10 
 
16 A 5f 5% 6:1 
11 
 
16 A 5g 48% 9:1 
12 
 
18 A 5h 8% 6:1 
13 
 
18 A 5i 42% 9:1 
14 
 
20 A 5j 41% 9:1 
 
[a] A. LDA (2.5 equiv.), 3 (1 equiv.), R-X (1.5 equiv.), THF; B. As in A, but with the 
addition of HMPA (HMPA:THF; 1:1).
 
[b] Isolated yield following purification by flash chromatography 
[c] Determined by 
1
H NMR (in case of the allylic compounds after hydrogenation) of the 
crude reaction mixture 
[d] Used as a mixture of isomers (E:Z ca. 4:1) 
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When either 1-iodotetradecane or 1-bromotetradecane was used as the electrophile, 
very poor yield of the corresponding -alkylated ester 5d was observed (entries 5 
and 6). In an attempt to improve these yields, HMPA was added to the reaction 
vessel as a co-solvent. HMPA has been shown to enhance SN2 reactions via its 
ability to strongly solvate cations,
 
and has been used by Utaka et al.
9
 and Fujisawa et 
al.
10 
to perform -alkylations using 1-iodotetradecane. Indeed, we also observed an 
improvement in reaction yield (35%) when HMPA was added (entry 7). These 
results were then compared to similar reactions using the corresponding C14 allylic 
iodide. In the absence of HMPA, the use of 1-iodotetradec-2-ene (entry 8) gave an 
improved 51% yield of ester 5e (cf. entry 5). Surprisingly, the addition of HMPA to 
the reaction mixture (entry 9) did not further improve the yield (cf. entry 8). In view 
of the toxicity of this reagent and the lack of improvement in reaction yield, HMPA 
was not used in subsequent alkylations. 
The difficulties in obtaining good yields when using long chain alkyl iodides in the 
Fráter-Seebach alkylation was further demonstrated when attempts were made to 
alkylate diethyl malate 3 using 1-iodoeicosane (entry 10). In our hands, this reaction 
resulted in a dismal 5% yield. The general problem we encountered when performing 
this -alkylation was that the reaction was very slow and required the gradual 
warming of the reaction mixture from -78 °C to 0 °C for any product formation to be 
observed via TLC. Unfortunately, the temperature at which the reaction commenced 
(ca. -20 °C) was also the temperature at which diethyl malate 3 began to decompose. 
Many changes to solvent, reaction time, and equivalents of reagents were then made 
in an attempt to improve this yield, but without success. A change to iodo-eicos-2-
ene, however, gave the desired -alkylated ester 5g in a much improved 49% yield 
(entry 11). Although some decomposition of diethyl malate 3 was observed, we were 
satisfied with the final yield of the ester anti-5g, given the difficulty of this -
alkylation. Attempts at performing the Fráter-Seebach alkylation using 1-
iododocosane gave a mere 8% yield of 5h (entry 12), while the use of iodo-docos-2-
ene as an electrophile improved the yield of the alkylation to 42% (entry 13). The 
methodology was then used to synthesise ester anti-5j, which contains the most 
common mycolic acid α-chain length. Gratifyingly, the yield for this reaction was a 
respectable 41% (entry 14). In all examples, the diastereoselectivity of the allylic 
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alkylations was excellent (ca. 9:1, anti:syn), and was higher than those observed for 
the corresponding saturated alkyl halides. 
 
4.2.3 Hydrogenation 
Having demonstrated the benefit of allylic halides in the Fráter-Seebach alkylation, 
we then set about to hydrogenate the ,-unsaturated esters (Scheme 4). The 
mixtures of diastereomers anti:syn (n = 3, 10, 16, 18, 20) were thus hydrogenated in 
the presence of catalytic (5 wt%) Pd/C (Scheme 5). Following hydrogenation, the 
diastereomers were readily separable by flash column chromatography and the 
desired esters anti-5b (n = 3), anti-5d (n = 10), anti-5f (n = 16), anti-5h (n = 18) and 
anti-5k (n = 20) were isolated as pure compounds in excellent yields (90-91%).  
 
Scheme 5. Hydrogenation of ,-unsaturated esters 
 
4.2.4 Diastereoselectivity  
In an attempt to prove that the major diastereomer obtained from the Fráter-Seebach 
reaction was indeed the anti-isomer, we set about hydrolysising ester anti-5b to form 
the di-acid 8. This could potentially be crystallised, enabling the use of X-ray 
crystallography to determine the absolute stereochemistry of the compound. We 
opted to use this method as crystallisation of the hydrolysed product of malic ester 5a 
had been reported in Seebach’s earlier work.11 To this end, ester anti-5b (obtained 
after hydrogenation of 5c) was subjected to hydrolysis with potassium carbonate in 
MeOH:H2O (1:1) in order to form di-acid 8 (Scheme 6). The crude product was 
obtained as a white solid, however, despite several attempts, compound 8 could not 
be crystallised, with  a waxy solid being obtained in most instances. This may be due 
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to the lipid chain at the α-position of the molecule, and thus another method of 
distereoselectivity determination was investigated.   
 
Scheme 6. Hydrolysis of product 5b 
We envisaged using cross metathesis as a means of deducing the stereochemistry of 
the alkylated compounds. Thus, Grubbs cross metathesis reaction
12
 was performed 
between allylic ester anti-5a (of known 2S, 3R stereochemistry),
11 
and 1-tridecene to 
give the unsaturated ester anti-5e in 41% yield and in an E:Z ratio of 4:1 (Scheme 7). 
In addition, the homo-dimerisation product of 1-tridecene was observed along with 
unreacted allylic ester anti-5a, which accounted for the remainder of the material. 
Hydrogenation of ester anti-5e then gave a product that exhibited spectral data 
consistent with those obtained from the direct alkylation of ethyl (S)-malate 5 with 1-
iodotetradecane (Table 1). This unequivocally established that the major isomer from 
the allylic alkylation was the anticipated 2S, 3R-ester. 
 
Scheme 7. Confirming the stereochemistry of the alkylated products 
To explain the preferential formation of the 2S, 3R diastereomer, the rigid cyclic 
intermediate that is formed during the course of reaction needs to be considered 
(Scheme 8).  More than two equivalents of LDA are added to the β-hydroxy ester, 
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whereby, one equivalent is used to deprotonate the hydroxyl, which results in the 
formation of a monoanion where the negatively charged oxygen is countered by the 
lithium cation, while the second equivalent of LDA leads to the formation of an ester 
enolate where the lithium cation bridges the two negative charges via a six-
membered cyclic intermediate IX. Regeneration of the carbonyl then allows the 
enolate X, to attack the alkyl halide, R–X, at the face opposite to the ester which is 
adjacent to the β-hydroxyl substituent due to steric hindrance thus leading to the anti-
diastereomer XI.
13 
It should also be noted that greater reactivity of the allylic system 
leads to higher diastereoselectivities, due to the ability of the reactions to be 
performed at lower temperatures. 
 
Scheme 8. Explanation of stereoselectivity in the Fráter-Seebach alkylation 
 
4.2.5 Product Characterisation 
The Fráter-Seebach reaction products were characterised by NMR and mass spectral 
analyses. As shown for compound 5j (Figure 2 and 3), the distinct resonance for the 
alkylated products included peaks at 5.56 ppm (dt, J = 15.1 Hz, J = 6.8 Hz) and 5.39 
ppm (dt, J = 15.1 Hz, J = 6.5 Hz) for the alkene protons. In addition, the resonance at 
2.91 ppm (ddd, J = 9.1 Hz, J = 9.1 Hz, J = 3.2 Hz)  intergrated for one proton and had 
COSY correlations to α-protons of the lipid chain at 2.58–2.53 ppm (m) and at 2.38 
ppm (ddd, J = 14.3 Hz, J = 8.3 Hz, J = 8.3 Hz), indicating that alkylation has occured 
at the desired position. Furthmore, the different signals for the two α-protons of the 
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lipid chain were indictive of an adjacent chiral centre. A clear HMBC between the 
resonance at 5.39 ppm and C-3 at 48.6 ppm, establised the postion of the respective 
allylic protons. Mass spectral analysis of the product was in agreement the expected 
mass; [HRMS(ESI) m/z calcd. for [C32H60O5+Na]
+
: 547.4338, obsd.: 547.4344.] and 
full assignment was made on the basis of 2D NMR (COSY, HSQC and HMBC) (see 
experimental for full assignment). With the saturated alkylated products as shown for 
5k (Figure 4 and 5), key peaks in the 
1
H NMR included resonance at 2.84 (td, J = 7.3 
Hz, J = 3.7 Hz) intergrating for one proton and the protons from the α-chains at 1.83 
(ddt, J = 13.9 Hz, J = 7.6 Hz, J = 7.6 Hz), and 1.66 ppm (ddt, J = 13.9 Hz, J = 7.1 Hz, 
J = 7.1 Hz). HMBC correlation between the α-protons and carbonyl peak at 172.9 
ppm establised the resonances for one of the carbonyl carbons. Mass spectral 
analysis of the product was in agreement with the expected mass; [HRMS(ESI) m/z 
calcd. for [C32H62O5+Na]
+
: 549.4495, obsd.: 549.4490]
+
 and full assignment was 
made on the basis of 2D NMR (COSY, HSQC and HMBC) (see experimental for full 
assignment).  
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Figure 2. 
1
H NMR spectrum of product 5j 
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Figure 3. 
13
C NMR spectrum for product 5j 
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Figure 4. 
1
H NMR spectrum of product 5k 
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Figure 5. 
13
C NMR spectrum of product 5k 
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4.3 Conclusion 
We have developed an improved methodology for the synthesis of long chain -
alkylated -hydroxy esters via the use of allylic halides in the Fráter-Seebach 
alkylation. This allylic alkylation is highly diastereoselective, and when compared to 
similar reactions using the corresponding saturated alkyl halides, gives superior 
yields. The prerequisite allylic iodides are themselves readily prepared in two steps 
and in good yield from the corresponding aldehydes, while the unsaturated -
alkylated -hydroxy esters can be readily hydrogenated in excellent yield. The final 
-alkylated -hydroxy esters are, in turn, valuable synthetic intermediates for the 
preparation of a number of biologically important lipids.  
 
4.4 Experimental 
Unless stated otherwise all reactions were performed under N2. Prior to use, THF 
was distilled from Na wire and benzophenone, toluene was dried and stored under 
Na wire, CH2Cl2 was distilled from P2O5 and acetone was dried with K2CO3, distilled 
and stored over 4Å MS. HMPA was dried with CaH2, distilled and stored under 
nitrogen, di-isopropylamine was dried with NaOH, distilled and stored under 
nitrogen, allyl bromide, allyl iodide and heptyl iodide were dried with MgSO4, 
distilled and stored under nitrogen. L-(–)-Malic acid (Sigma), bromotetradecane 
(Fluka), 1-docosanol (Aldrich), 1-eicosanol (Alfa Aesar), 1M vinylmagnesium 
bromide (Aldrich) pentanal (Koch-Light Laboratories), n-BuLi (Aldrich, 2M solution 
in hexanes), dodecanal (Aldrich), octadecanol (BDH), PPh3 (Merck), I2 (Unilab), 
Pd/C (Aldrich), H2SO4 (Lab-Scan), ethanol (Pure Science), anhydrous Et2O (Biolab), 
EtOAc (Panreac), petroleum ether (Pure Science), CHCl3 (Panreac), NaHCO3 (Pure 
Science), K2CO3 (Pure Science), Na2S2O3 (Panreac), MgSO4  (Pure Science), NaCl 
(Panreac) were used as received. 1-Iodotetradecane
14
 and L-diethyl malate
8
 were 
prepared using literature procedures. All solvents were removed via evaporation at 
reduced pressure. Reactions were monitored by TLC analysis on Macherey-Nagel 
silica gel coated plastic sheets (0.20 mm, Polygram SIL G/UV254) by coating with a 
solution of 5% KMnO4 and 1% NaIO4 in H2O followed by heating. Column 
chromatography was performed using Pure Science silica gel (40-63 μm). High 
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resolution mass spectra were recorded on a Waters Q-TOF Premier
TM 
Tandem Mass 
Spectrometer using positive electro-spray ionisation and atmospheric-pressure 
chemical ionisation. Optical rotations were recorded on a Perkin-Elmer 241 
polarimeter or Autopol II (Rudolph Research Analytical) at 589 nm (sodium D-line). 
Infrared spectra were recorded as thin films using a Bruker Tensor 27 FTIR 
spectrometer equipped with an Attenuated Total Reflectance (ATR) sampling 
accessory and are reported in wave numbers (cm
-1
). Nuclear magnetic resonance 
spectra were recorded at 20
 
°C in CDCl3 using a Varian INOVA operating at 500 
MHz. Chemical shifts are given in ppm (δ) relative to solvent residual peak. NMR 
peak assignments were made using COSY, HSQC and HMBC 2D experiments. 
 
 1-Iodotetradecane.
15
 Sodium iodide (10.81 g, 90.1 mmol) was 
added to a stirring solution of 1-bromotetradecane (10.0 g, 36.1 
mmol) in acetone (20 mL). The reaction mixture was refluxed 
under nitrogen for 48 h, after which the mixture was filtered and concentrated in 
vacuo. The resulting residue was dissolved in diethyl ether and washed with sat. 
Na2S2O3, brine dried (MgSO4) and concentrated in vacuo. The product was obtained 
after silica gel flash chromatography (eluting in petroleum ether) as colourless oil 
(13.7g, 84.7 mmol, 94%). Rf  = 0.82 (PE/EA, 2/1, v/v); IR (film) 2921, 2852, 1176, 
720 cm
-1
;
 1
H NMR (500 MHz, CDCl3)  3.19 (t, J = 7.1 Hz, 2H, H-1), 1.83 (pentet, 
Jα,β = Jβ,γ = 7.1 Hz, 2H, H-2), 1.40–1.36 (m, 2H, H-3), 1.28–1.20 (m, 20H, H-4–H-
13), 0.89 (t, J = 7.1 Hz, 3H, H-14); 
13
C NMR (125 MHz, CDCl3)  33.5 (C-2), 31.9, 
30.5, 29.70, 29.66, 29.63, 29.57, 29.44, 29.37, 28.56, 22.7 (C-3–C-13), 14.1 (C-14), 
7.3 (C-1).  
  
General Procedure for the synthesis of alkyl iodides from the corresponding 
alcohol. PPh3 (12 mmol, 1.2 equiv.) was added to a solution of the appropriate 
alcohol (10 mmol, 1 equiv.) in dry THF (100 mL), followed by imidazole (18 mmol, 
1.8 equiv.). The flask was then lowered into a water bath and I2 (13 mmol, 1.3 equiv.) 
was added slowly to maintain the temperature at ca. 25 ºC. The resulting mixture was 
refluxed for 5 h, after which water was added to quench the reaction and the mixture 
was extracted with DCM. The organic layer was washed with Na2S2O3, water and 
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brine, dried (MgSO4) and concentrated in vacuo. The product was purified using 
silica gel column chromatography and the eluent given.  
 
1-Iodoeicosane. By subjecting 1-eicosanol (1.0g, 3.35 mmol) to 
the general procedure for the synthesis of alkyl iodides, 1-
iodoeicosane was obtained (eluting in petroleum ether) as a white 
solid (0.95 g, 2.35 mmol, 70%). Rf  = 0.80 (PE/EA, 2/1, v/v); IR (film) 2920, 2851, 
917, 783 cm
-1
;
 1
H NMR (500 MHz, CDCl3)  3.20 (t, J = 7.1 Hz, 2H, H-1), 1.83 
(pentet, Jα,β = Jβ,γ = 7.1 Hz, 2H, H-2), 1.44–1.37 (m, 2H, H-3), 1.31–1.70 (m, 32H, H-
4–H-19), 0.90 (t, J = 6.9 Hz, 3H, H-20); 13C NMR (125 MHz, CDCl3)  33.6 (C-2), 
32.0, 30.5, 29.73, 29.71, 29.69, 29.65, 29.58, 29.45, 29.40, 28.58, 22.7 (C-3–C-19), 
14.2 (C-20), 7.3 (C-1). 
 
1-Iododocosane. By subjecting 1-docosanol (1.0 g, 3.06 mmol) to 
the general procedure for synthesis of alkyl iodides, 1-
iododocosane was obtained (eluting in petroleum ether) as a white solid (0.8 g, 1.84 
mmol, 60%). Rf  = 0.79 (PE/EA, 2/1, v/v); IR (film): 2915, 2848, 1165, 740 cm
-1
;
 1
H 
NMR (500 MHz, CDCl3)  3.19 (t, J = 7.1 Hz, 2H, H-1), 1.83 (pentet, Jαβ = Jβγ = 7.4 
Hz, 2H, H-2), 1.40-1.36 (m, 2H, H-3), 1.33-1.26 (m, 36H, H-4–H-21), 0.89 (t, J = 
6.8 Hz, 3H, H-22); 
13
C NMR (125 MHz, CDCl3)  33.6 (C-2), 31.9, 30.5, 29.70, 
29.67, 29.63, 29.56, 29.43, 29.37, 28.56, 26.06, 22.7 (C-3–C-21), 14.1 (C-22), 7.4 
(C-1). 
 
Diethyl-L-malate (3).
 8
 L-Malic acid (15 g, 112 mmol) was 
dissolved in ethanol and conc. H2SO4 (0.36 ml, 89.9 mmol) 
was added. The reaction mixture was refluxed for 72 h, after 
which the reaction was stopped and the solvent evaporated in vacuo. The light 
yellow residue was purified via silica gel column chromatography (5:1, petroleum 
ether/EtOAc, v/v) to afford diethyl malate 3 as a colourless oil (20.2 g, 106 mmol, 
94.9%). Rf = 0.40 PE/EA, 5/1, v/v); [α]D
23
 = -6.3 (c = 1.0, CHCl3); IR (film): 3481, 
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2984, 2940, 1731, 1447, 1373, 1267, 1177, 1099, 1023, 859, 735 cm
-1
; 
1
H NMR (500 
MHz, CDCl3)  4.49 (ddd, J2,3a = J2,3b = J2,OH = 5.3 Hz, 1H, H-2), 4.32–4.25 (m, 2H, 
CH2O-1), 4.18 (q, J = 7.2 Hz, 2H, CH2O-4), 3.21 (d, J2,OH = 5.3 Hz, 1H, OH), 2.86 
(dd, J3a,3b = 16.3 Hz, J2,3a = 4.5 Hz, 1H, H-3a), 2.79 (dd, J3a,3b = 16.3 Hz, J2,3b = 6.0 
Hz, 1H, H-3b), 1.31 (t, J = 7.2 Hz, 3H, CH3, 1-OEt), 1.28 (t, J = 7.2 Hz, 3H, CH3, 4-
OEt); 
13
C NMR (125 MHz, CDCl3)  173.4 (C-1), 170.5 (C-4), 67.3 (C-2), 62.1 
(CH2O, 1-OEt), 61.0 (CH2O, 4-OEt), 38.7 (C-3), 14.1 (CH3, 1-OEt), 14.1 (CH3, 4-
OEt); HRMS(ESI) m/z calcd. for [C8H14O5+Na]
+
: 213.0739, obsd.: 213.0737. 
 
1-Octadecanal (6c). 1-Octadecanol (5.00 g, 18.5 mmol) was 
added to a solution of PCC (7.97 g, 37 mmol) and molecular sieves 
Å (5.6 g) in DCM (90 mL) under nitrogen and the reaction mixture 
stirred at r.t. for 6 h. The mixture was then reduced in vacuo and the resulting oil 
subjected to silica gel flash chromatography with 1-octadecanal eluting in petroleum 
ether/EtOAc 20:1 (v/v) as white solid (4.86 g, 18.1 mmol, 98%). Rf  = 0.78 (PE/EA, 
2/1, v/v); IR (film) 2953, 2913, 2848, 1711, 1275 cm
-1
;
 1
H NMR (500 MHz, CDCl3) 
 9.75 (t, J = 1.9 Hz, 1H, H-1), 2.40 (dt, J2a,2b = 14.7 Hz, J2,3 = 7.4 Hz, 2H, H-2), 1.61 
(pentet, Jα,β = Jβ,γ = 7.3 Hz, 2H, H-3), 1.32–1.24 (m, 28H, H-4–H-17), 0.86 (t, J = 7.2 
Hz, 3H, H-18); 
13
C NMR (125 MHz, CDCl3)  202.9 (C-1), 43.9 (C-2), 31.9 (C-3), 
29.70, 29.69, 29.68, 29.66, 29.63, 29.60, 29.57, 29.42, 29.36, 29.35, 29.2, 22.7, 22.1 
(C-4–C-17), 14.1 (C-18).   
 
1-Eicosanal (6d). 1-Eicosanol (5.00 g, 16.7 mmol) was added to a 
solution of PCC (7.22 g, 33.5 mmol) and molecular sieves 4Å (5.0 
g) in DCM (80 mL) under nitrogen and the reaction mixture stirred 
at r.t. for 6 h. The reaction mixture was then reduced in vacuo and the resulting oil 
subjected to silica gel flash chromatography with 1-eicosanal eluting in petroleum 
ether/EtOAc, 20:1 (v/v) as white solid (4.45 g, 15.0 mmol, 90%). Rf  = 0.82 (PE/EA, 
2/1, v/v); IR (film): 2913, 2849, 1711, 1264 cm
-1
;
 1
H NMR (500 MHz, CDCl3)  9.78 
(t, J = 1.9 Hz, 1H, H-1), 2.43 (dt, J2a,2b = 14.8 Hz, J2,3 = 7.4 Hz, 2H, H-2), 1.64 
(pentet, Jα,β = Jβ,γ = 7.5 Hz, 2H, H-3), 1.30–1.25 (m, 32H, H-4–H-19), 0.89 (t, J = 7.1 
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Hz, 3H, H-20); 
13
C NMR (125 MHz, CDCl3)  203.0 (C-1), 43.9 (C-2), 31.9 (C-3),  
29.70, 29.68, 29.68, 29.66, 29.63, 29.58, 29.42, 29.36, 29.35, 29.2, 22.7, 22.1 (C-4–
C-19), 14.1 (C-20).   
 
1-Docosanal (6e). 1-Docosanol (2.00 g, 6.12 mmol) was added to 
a solution of PCC (2.64 g, 12.2 mmol) and molecular sieves 4Å 
(1.84 g) in DCM (40 mL) under nitrogen and the reaction mixture 
stirred at r.t. for 6 h. The reaction mixture was then reduced in vacuo and the 
resulting oil subjected to silica gel flash chromatography with 1-docosanal eluting in 
petroleum ether/EtOAc, 20:1 (v/v) as white solid (1.75 g, 5.38 mmol, 88%). Rf  = 
0.66 (PE/EA, 2/1, v/v); IR (film): 2913, 2849, 1711, 1264 cm
-1
;
 1
H NMR (500 MHz, 
CDCl3)  9.77 (t, J = 1.7 Hz, 1H, H-1), 2.43 (dt, J2a,2b = 13.2 Hz, J2,3 = 7.6 Hz, 2H, 
H-2), 1.63 (pentet, Jα,β = Jβ,γ = 7.1 Hz, 2H, H-3), 1.30–1.26 (m, 36H, H-4–H-21), 0.89 
(t, J = 6.8 Hz, 3H, H-22); 
13
C NMR (125 MHz, CDCl3)  203.0 (C-1), 44.0 (C-2), 
31.8 (C-3),  29.70, 29.69, 29.68, 29.66, 29.63, 29.60, 29.42, 29.38, 29.35, 29.2, 22.7, 
22.1 (C-4–C-21), 14.1 (C-22). 
  
General procedure for the synthesis of allylic iodides. To a solution of aldehyde 
(10 mmol, 1.0 equiv.) in dry THF (50 mL), 1M vinyl magnesium bromide in THF (15 
mmol, 1.5 equiv.) was added dropwise at 0 °C. For the longer lipids (4c-4e), freshly 
prepared vinyl magnesium bromide was used and the aldehyde was dissolved in 
toluene instead of THF. The mixture was stirred for 90 min at 0 °C, followed by 1 h 
at room temperature. The reaction was then quenched by the addition of NH4Cl, 
extracted with Et2O (3 x 50 mL) and the combined organic layers were dried over 
MgSO4, filtered and concentrated in vacuo to give the allylic alcohol as a viscous oil 
which was used without further purification. To a solution of PPh3 (15 mmol, 1.5 
equiv.) in CH2Cl2 (15 mL) was added iodine (15 mmol, 1.5 equiv.) and the mixture 
stirred at room temperature for 5 min. A solution of the crude allylic alcohol (10 
mmol, 1 equiv.) in CH2Cl2 (30 mL) was then added and the mixture stirred at r.t. 
overnight. The reaction mixture was diluted with Et2O and successively washed with 
sat. Na2S2O3, (3 x until the organic layer was free of iodine), water, saturated sodium 
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bicarbonate solution and brine. The organic layer was dried over MgSO4, filtered and 
concentrated in vacuo.  Purification of the crude residue by silica gel flash column 
chromatography (petroleum ether) afforded the allylic iodide. 
 
1-Iodo-hept-2-ene (4a). By subjecting pentanal (10.0 g, 116 mmol) 
to the general procedure for the synthesis of allylic iodides, iodo-
heptene 4a was obtained (eluting in petroleum ether) as a pale 
yellow oil (23.0 g, 103 mmol, 89% over 2 steps). Rf = 0.71 (PE/EA, 2/1, v/v); IR 
(film): 2956, 2928, 2859, 1458, 970, 741 cm
-1
;
 1
H NMR (500 MHz, CDCl3)  5.74–
5.71 (m, 2H, H-2 and H-3), 3.91–3.88 (m, 2H, H-1a and H-1b), 2.04 (dd, J3,4 = J4,5 = 
7.0 Hz, 2H, H-4a and H-4b), 1.39–1.24 (m, 4H, H-5 and H-6), 0.82 (t, J6,7 = 7.2 Hz, 
3H, CH3-7); 
13
C NMR (125 MHz, CDCl3)  135.3 (C-2), 127.8 (C-3), 31.7, 30.9, 
22.1 (C-4–C-6), 13.9 (C-7), 7.1 (C-1); HRMS(APCI) m/z calcd. for [C7H13I+H]
+
: 
225.0140, obsd.: 225.0149. 
 
1-Iodo-tetradec-2-ene (4b). By subjecting dodecanal (1.00 g, 5.42 
mmol) to the general procedure for the synthesis of allylic iodides, 
iodo-tetradecene 4b was obtained (eluting in petroleum ether) as a pale yellow oil 
(1.40 g, 4.39 mmol, 81% over 2 steps). Rf = 0.76 (PE/EA, 2/1, v/v); IR (film): 2955, 
2922, 2852, 1464, 961, 721 cm
-1
; 
1
H NMR (500 MHz, CDCl3)  5.73–5.71 (m, 2H, 
H-2 and H-3), 3.90–3.88 (m, 2H, H-1a and H-1b), 2.03 (dd, J3,4 =  J4,5 = 7.2 Hz, 2H, 
H-4a and H-4b), 1.39–1.27 (m, 18H, H-5–H-13), 0.82 (t, J6,7 = 7.2 Hz, 3H, CH3-14); 
13
C NMR (125 MHz, CDCl3)  135.4 (C-2), 127.7 (C-3), 32.0, 31.9, 29.65,29.62, 
29.60, 29.4, 29.3, 29.1, 28.8, 22.7 31.7 (C-4–C-13), 14.1 (C-14), 7.1 (C-1); 
HRMS(APCI) m/z calcd. for [C14H27I+H]
+
: 323.1236, obsd.: 323.1242. 
 
1-Iodo-eicos-2-ene (4c). By subjecting octadecanal (1.69 g, 6.32 
mmol) to the general procedure for the synthesis of allylic iodides, 
iodo-eicosene 4c was obtained (eluting in petroleum ether) as a 
white solid (1.80 g, 4.42 mmol, 70% over 2 steps). Rf  = 0.86 (PE/EA, 2/1, v/v); IR 
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(film): 2924, 2853, 1464, 961, 738 cm
-1
; 
1
H NMR (500 MHz, CDCl3)  5.73–5.71 
(m, 2H, H-2 and H-3), 3.89–3.87 (m, 2H, H-1a and H-1b), 2.03 (dd, J3,4 = J4,5 = 7.2 
Hz, 2H, H-4a and H-4b), 1.44–1.22 (m, 30H, H-5–H-19), 0.89 (t, J6,7 = 6.7 Hz, 3H, 
CH3-20); 
13
C NMR (125 MHz, CDCl3)  135.4 (C-2), 127.8 (C-3), 32.1, 31.9, 29.71, 
29.68, 29.67, 29.65, 29.6, 29.50, 29.45, 29.3, 29.1, 28.8, 28.7, 26.8, 22.7 (C-4–C-19), 
14.1 (C-20), 7.1 (C-1); HRMS(APCI) m/z calcd. for [C20H39I+H]
+
: 407.2175, obsd.: 
407.2168. 
 
1-Iodo-docos-2-ene (4d). By subjecting eicosanal (1.20 g, 4.05 
mmol) to the general procedure for the synthesis of allylic iodides, 
iodo-docosene 4d was obtained (eluting in petroleum ether) as a 
white solid (1.25 g, 2.87 mmol, 71 % over 2 steps). Rf  = 0.95 (PE/EA, 2/1, v/v); IR 
(film): 2922, 2852, 1464, 962, 740 cm
-1
; 
1
H NMR (500 MHz, CDCl3)  5.72–5.71 
(m, 2H, H-2 and H-3), 3.88–3.87 (m, 2H, H-1a and H-1b), 2.01 (dd, J3,4 =  J4,5 = 7.2 
Hz, 2H, H-4a and H-4b), 1.43–1.28 (m, 34H, H-5–H-21), 0.89 (t, J6,7 = 6.7 Hz, 3H, 
CH3-22); 
13
C NMR (125 MHz, CDCl3)  135.4 (C-2), 127.7 (C-3), 32.0, 31.9, 29.70, 
29.67, 29.66, 29.65, 29.58, 29.5, 29.44, 29.36, 29.3, 29.1, 28.8, 28.7, 26.9, 26.8, 22.7 
(C-4–C-21), 14.1 (C-22), 7.1 (C-1); HRMS(APCI) m/z calcd. for [C22H43I+H]
+
: 
435.2488, obsd.: 435.2494. 
 
1-Iodo-tetracos-2-ene (4e). By subjecting docosanal (3.50 g, 10.8 
mmol) to the general procedure for the synthesis of allylic iodides, 
iodo-tetracosene 4e was obtained (eluting in petroleum ether) as a 
white solid (3.63 g, 7.87 mmol, 73.2 % over 2 steps). Rf  = 0.95 (PE/EA, 2/1, v/v); IR 
(film): 2915, 2848, 1713, 1471, 739 cm
-1
; 
1
H NMR (500 MHz, CDCl3)  5.73–5.71 
(m, 2H, H-2 and H-3), 3.89–3.88 (m, 2H, H-1a and H-1b), 2.02 (dd, J3,4 =  J4,5 = 6.8 
Hz, 2H, H-4a and H-4b), 1.37–1.26 (m, 38H, H-5–H-23), 0.89 (t, J6,7 = 7.1 Hz, 3H, 
CH3-24); 
13
C NMR (125 MHz, CDCl3)  135.4 (C-2), 127.8 (C-3), 32.0, 31.9, 29.72, 
29.69, 29.68, 29.67, 29.60, 29.47, 29.39, 29.1, 28.8, 22.7 (C-4–C-23), 14.1 (C-24), 
7.1 (C-1); HRMS(APCI) m/z calcd. for [C24H47I+H]
+
: 463.2801, obsd.: 463.2805. 
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General Procedure for the Synthesis of α-Alkenyl-β-Hydroxy-Diesters. n-BuLi 
(11.5 mL, 2.0m solution in hexanes, 23.0 mmol) was added to a solution of di-
isopropylamine (3.6 mL, 25.0 mmol) in THF (20 mL) at 0 °C. After 30 min the 
solution was cooled down to -78°C and diethyl malate 5 (1.9 g, 10 mmol) in THF (20 
mL) was added. The resulting mixture was stirred at -78 °C for 1 h, warmed up to -
20 °C over 1 h and stirred at -20 °C for 20 min. After cooling down to -78 °C, the 
allylic iodide (15.0 mmol, 1.5 equiv.) in THF (20 mL) was added dropwise and the 
reaction was stirred for 1 h at -50 °C and then a further 1h during which time the 
temperature increased to -20 °C. The reaction was then quenched using NH4Cl (sat.) 
and extracted with EtOAc (3 x 100 mL). The combined organic layers were washed 
with water (30 mL) and brine (30 mL), dried (MgSO4), filtered and the solvent 
removed in vacuo to yield a crude yellow oil. Purification of the residue, using silica 
gel flash column chromatography and the eluent given, gave the alkylated product.  
 
Ethyl 2S-hydroxy-3R-ethoxycarbonyl-hex-4-enoate (anti-
5a). By reacting diethyl malate 3 (3.96 g, 20.9 mmol) with 
allyl bromide (2.64 mL, 31.25 mmol) according to the general 
procedure for the synthesis of α-alkenyl-β-hydroxy-diesters, 
hexenoate 5a was obtained (eluting in 10:1, petroleum 
ether/EtOAc, v/v) as a colourless oil (2.72 g, 11.9 mmol, 57%, anti:syn = 14:1). Rf = 
0.39 (PE/EA, 2/1, v/v); [α]D
23
 = +13.0 (c = 2.23, CHCl3), Lit
[34] [α]D
20
 = +11.3 (c = 
2.23, CHCl3); IR (film): 3079, 2982, 2961, 2924, 1733, 1643, 1132, 1099, 1031, 736, 
703 cm
-1
; 
1
H NMR (500 MHz, CDCl3)  5.75 (ddt, J5,6-trans = 17.1 Hz, J5,6-cis = 10.2 
Hz, J4a,5 = J4b,5 = 7.5 Hz, 1H, H-5), 5.11 (d, J5,6-trans = 17.1Hz, 1H, H-6-cis), 5.05 (d, 
J5,6-trans = 10.2 Hz, 1H, H-6-trans), 4.25–4.14 (m, 3H, CH2O-1 and H-2), 4.12–4.01 
(m, 2H, 3-CO2CH2), 2.90 (m, 1H, H-3), 2.56 (ddd, J4a,4b = 14.4 Hz, J3,4a = J4a,5 = 7.5 
Hz,  1H, H-4a), 2.38 (ddd, J4a,4b = 14.4 Hz, J3,4b = J4b,5 = 7.5 Hz, 1H, H-4b), 1.24 (t, J 
= 7.1 Hz, 3H, CH3, 1-OEt), 1.17 (t, J = 7.0 Hz, 3H, CH3, 3-CO2Et); 
13
C NMR (125 
MHz, CDCl3)  173.6 (C-1), 172.0 (3-CO2), 134.9 (C-5), 118.0 (C-6), 70.2 (C-2), 
61.9 (CH2O, 1-OEt), 61.0 (CH2O, 3-CO2CH2), 48.1 (C-3), 32.2 (C-4), 14.1 (CH3, 1-
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OEt), 14.1 (CH3, 3-CO2Et); HRMS(ESI) m/z calcd. for [C11H18O5+Na]
+
: 253.1052, 
obsd.: 253.1055. 
 
Ethyl 2S-hydroxy-3R-ethoxycarbonyl-decen-5-enoate (anti-
5c). By reacting diethyl malate 3 (3.98 g, 20.9 mmol) with 1-
iodo-hept-2-ene (7.03 g, 31.42 mmol) according to the general 
procedure for the synthesis of α-alkenyl-β-hydroxy-diesters, 
decenoate 5c was obtained (eluting in 15:1, petroleum 
ether/EtOAc, v/v) as a colourless oil (3.28 g, 11.5 mmol, 55%, 
anti:syn = 9:1). Rf  = 0.42 (PE/EA 2/1, v/v); [α]D
23 
= +19.0 (c = 1.0, CHCl3); IR 
(film): 3234, 2983, 2960, 2929, 1734, 1466, 1374, 1198, 861, 736 cm
-1
; 
1
H NMR 
(500 MHz, CDCl3)  5.57 (dt, J5,6 = 15.2 Hz, J6,7a = J6,7b = 6.6 Hz, 1H, H-6), 5.39 (dt, 
J5,6 = 15.2 Hz, J4a,5 = J4b,5 = 6.2 Hz, 1H, H-5), 4.21–4.31 (m, 3H, CH2O-1 and H-2), 
4.16–4.10 (m, 2H, 3-CO2CH2), 2.90 (ddd, J3,4a = J3,4b = 8.3 Hz, J2,3 = 3.2 Hz, 1H, H-
3), 2.58–2.51 (m, 1H, H-4a), 2.38 (ddd, J4a,4b = 14.4 Hz, J3,4b = 8.3 Hz, J4b,5 = 6.2 Hz, 
1H, H-4b), 2.01 (q, J6,7 = J7,8 = 6.6 Hz,  2H, H-7), 1.33–1.27 (m, 4H, H-8 and H-9), 
1.24 (t, J = 7.3 Hz, 6H, 2 x CH3), 0.88 (t, J = 7.2 Hz, 3H, CH3-10); 
13
C NMR (125 
MHz, CDCl3)  173.7 (C-1), 172.3 (3-CO2), 134.4 (C-6), 125.9 (C-5), 70.2 (C-2), 
61.8 (CH2O, 1-OEt), 60.8 (CH2O, 3-CO2CH2), 48.6 (C-3), 32.2 (C-4), 31.5 (C-7), 
31.1 (C-8), 22.2 (C-9), 14.2 (C-10), 14.1 (CH3, 1-OEt), 14.1 (CH3, 3-CO2Et); 
HRMS(ESI) m/z calcd. for [C15H26O5+Na]
+
: 309.1678, obsd.: 309.1682. 
 
Ethyl 2S-hydroxy-3R-ethoxycarbonyl-heptadecen-5-enoate 
(anti-5e). By reacting diethyl malate 3 (3.99 g, 21.0 mmol) 
with 1-iodo-tetradec-2-ene (10.14 g, 31.5 mmol) according to 
the general procedure for the synthesis of α-alkenyl-β-hydroxy-
diesters, heptadecenoate 5e was obtained (eluting in 15:1, 
petroleum ether/EtOAc, v/v) as a colourless oil (4.11 g, 10.7 mmol, 51%, anti:syn = 
10:1). Rf  = 0.5 (PE/EA, 2/1, v/v); [α]D
23 
= +2.0 (c = 0.1, CHCl3); IR (film): 3522, 
2924, 2853, 1737, 1219, 1032, 772 cm
-1
; 
1
H NMR (500 MHz, CDCl3)  5.57 (dt, J5,6 
= 15.1 Hz,  J6,7a = J6,7b = 7.1 Hz, 1H, H-6), 5.39 (dt, J5,6 = 15.1 Hz, J4a,5 = J4b,5 = 7.2 
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Hz, 1H, H-5), 4.31–4.20 (m, 3H, CH2O-1 and H-2), 4.16–4.11 (m, 2H, 3-CO2CH2), 
3.18 (d, J2,OH = 7.4Hz, 1H, OH), 2.90 (ddd, J3,4a = J3,4b = 8.3 Hz, J2,3 = 3.2 Hz, 1H, H-
3), 2.58–2.51 (m, 1H, H-4a), 2.38 (ddd, J4a,4b = 14.2 Hz, J3,4b = 8.3 Hz, J4b,5 = 7.2 Hz, 
1H, H-4b), 1.99 (q, J6,7  = J7,8 = 7.1 Hz,  2H, H-7), 1.32–1.23 (m, 24H, H-8–H-16 and 
2 x CH3), 0.88 (t, J = 7.2 Hz, 3H, CH3-17); 
13
C NMR (125 MHz, CDCl3)  173.7 (C-
1), 172.3 (3-CO2), 134.4 (C-6), 125.8 (C-5), 70.2 (C-2), 61.8 (CH2O, 1-OEt), 60.8 
(CH2O, 3-CO2CH2), 48.6 (C-3), 32.2 (C-4), 31.9 (C-7), 31.1 (C-8), 29.7, 29.6, 29.6, 
29.5, 29.4, 29.3, 29.2, 22.68 (C-9–C-16), 14.1 (C-17), 14.1 (CH3, 1-OEt), 14.1 (CH3, 
3-CO2Et); HRMS(ESI) m/z calcd. for [C22H40O5+Na]
+
: 407.2773, obsd.: 407.2781. 
 
Ethyl 2S-hydroxy-3R-ethoxycarbonyl-tricos-5-enoate (anti-5g). By reacting 
diethyl malate 3 (0.40 g, 2.11 mmol) with 1-iodo-eicos-2-ene 
(1.28 g, 3.16 mmol) according to the general procedure for the 
synthesis of α-alkenyl-β-hydroxy-diesters, tricosenoate 5g was 
obtained (eluting in 15:1, petroleum ether/EtOAc, v/v) as 
white solid (0.48 g, 1.03 mmol, 49%, anti:syn = 9:1). Rf  = 
0.49 (PE/EA, 2/1, v/v); [α]ᴅ22 = +6.0 (c = 1.0, CHCl3); IR 
(film): 3517, 2924, 2853, 1737, 1219, 1032, 970, 772, cm
-1
; 
1
H NMR (500 MHz, 
CDCl3)  5.56 (dt, J5,6 = 15.4 Hz, J6,7a = J6,7b = 6.6 Hz, 1H, H-6), 5.40 (dt, J5,6 = 15.4 
Hz, J4a,5 = J4b,5  = 6.6 Hz, 1H, H-5), 4.31–4.22 (m, 3H, CH2O-1 and H-2), 4.19–4.10 
(m, 2H, 3-CO2CH2), 2.90 (ddd, J3,4a = J3,4b = 8.8 Hz, J2,3 = 3.2 Hz, 1H, H-3), 2.58–
2.52 (m, 1H, H-4a), 2.38 (ddd, J4a,4b = 15.2 Hz, J3,4b = J4b,5 = 8.8 Hz, 1H, H-4b), 1.99 
(q, J6,7  = J7,8  = 7.1 Hz, 2H, H-7a,b), 1.32–1.23 (m, 36H, H-8–H-22 and 2 x CH3), 
0.89 (t, J = 7.1 Hz, 3H, CH3-23); 
13
C NMR (125 MHz, CDCl3)  173.7 (C-1), 172.3 
(3-CO2), 134.4 (C-6), 125.8 (C-5), 70.2 (C-2), 61.8 (CH2O, 1-OEt), 60.8 (CH2O, 3-
CO2CH2), 48.6 (C-3), 32.2 (C-4), 31.9 (C-7), 31.1 (C-8), 29.7, 29.66, 29.65, 29.5, 
29.4, 29.2, 22.7 (C-9–C-22), 14.1 (C-23), 14.1 (CH3, 1-OEt), 14.1 (CH3, 3-CO2Et); 
HRMS(ESI) m/z calcd. for [C28H52O5+Na]
+
: 491.3712, obsd.: 491.3706. 
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Ethyl 2S-hydroxy-3R-ethoxycarbonyl-pentacos-5-enoate 
(anti-5i). By reacting diethyl malate 3 (0.53 g, 2.77 mmol) 
with 1-iodo-docos-2-ene (1.80 g, 4.15 mmol) according to the 
general procedure for the synthesis of α-alkenyl-β-hydroxy-
diesters, pentacosenoate 5i was obtained (eluting in 15:1, 
petroleum ether/EtOAc, v/v) as a white solid (0.57 g, 1.16 
mmol, 42%, anti:syn = 9:1). Rf = 0.6 (PE/EA, 2/1, v/v); [α]ᴅ
23 
= +5.0 (c = 1.0, 
CHCl3); IR (film): 3523, 2916, 2849, 1735, 1373, 1213, 1032, 969, 756cm
-1
; 
1
H 
NMR (500 MHz, CDCl3)  5.56 (dt, J5,6 = 15.1 Hz, J6,7a = J6,7b  = 6.9 Hz, 1H, H-6), 
5.39 (dt, J5,6 = 15.1 Hz, J4a,5 = J4b,5  = 7.3 Hz, 1H, H-5), 4.30–4.22 (m, 3H, CH2O-1 
and H-2), 4.14–4.10 (m, 2H, 3-CO2CH2), 3.18 (d, J2,OH = 6.9 Hz, 1H, OH), 2.90 
(ddd, J3,4a = J3,4b = 8.3 Hz, J2,3 = 3.2 Hz, 1H, H-3), 2.58–2.52 (m, 1H, H-4a), 2.38 
(ddd, J4a,4b = 14.1 Hz, J3,4a = J4a,5 = 7.8 Hz, 1H, H-4b), 1.99 (q, J6,7   = J7,8 = 7.1 Hz, 
2H, H-7a,b), 1.33–1.21 (m, 40H, H-8–H-24 and 2 x CH3), 0.88 (t, J = 7.2 Hz, 3H, 
CH3-25); 
13
C NMR (125 MHz, CDCl3)  173.7 (C-1), 172.3 (3-CO2), 134.5 (C-6), 
125.8 (C-5), 70.2 (C-2), 61.8 (CH2O, 1-OEt), 60.8 (CH2O, 3-CO2CH2), 48.6 (C-3), 
32.5 (C-4), 31.9 (C-7), 31.1 (C-8), 29.7, 29.66, 29.64, 29.5, 29.4, 29.2, 22.7 (C-9–C-
24), 14.1 (C-25), 14.1 (CH3, 1-OEt), 14.1 (CH3, 3-CO2Et); HRMS(ESI) m/z calcd. 
for [C30H56O5+Na]
+
: 519.4025, obsd.: 519.4029. 
 
Ethyl 2S-hydroxy-3R-ethoxycarbonyl-heptacos-5-enoate 
(anti-5j). By reacting diethyl malate 3 (0.55 g, 2.89 mmol) with 
1-iodo-tetracos-2-ene (2.0 g, 4.32 mmol) according to the 
general procedure for the synthesis of α-alkenyl-β-hydroxy-
diesters, heptacosenoate 5j was obtained (eluting in 15:1, 
petroleum ether/EtOAc, v/v) as a white solid (0.62 g, 1.19 mmol, 41%, anti:syn = 
9:1). Rf = 0.58 (PE/EA, 2/1, v/v); [α]ᴅ
22 
= +0.1 (c = 1.0, CHCl3); IR (film): 3351, 
2922, 2852, 1736, 1376, 1215, 1042, 756 cm
-1
; 
1
H NMR (500 MHz, CDCl3)  5.56 
(dt, J5,6 = 15.1 Hz, J6,7a = J6,7b  = 6.8 Hz, 1H, H-6), 5.39 (dt, J5,6 = 15.1 Hz, J4a,5 = J4b,5  
= 6.5 Hz, 1H, H-5), 4.30–4.22 (m, 3H, CH2O-1 and H-2), 4.16–4.12 (m, 2H, 3-
CO2CH2), 3.17 (d, J2,OH = 7.3 Hz, 1H, OH), 2.91 (ddd, J3,4a = J3,4b = 9.1 Hz, J2,3 = 3.2 
Hz, 1H, H-3), 2.58–2.53 (m, 1H, H-4a), 2.38 (ddd, J4a,4b = 14.3 Hz, J3,4a = J4a,5 = 8.3 
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Hz, 1H, H-4b), 2.00 (q, J6,7   = J7,8 = 7.1 Hz, 2H, H-7a,b), 1.37–1.18 (m, 44H, H-8–H-
26 and 2 x CH3), 0.88 (t, J = 6.8 Hz, 3H, CH3-27); 
13
C NMR (125 MHz, CDCl3)  
173.7 (C-1), 172.3 (3-CO2), 134.5 (C-6), 125.8 (C-5), 70.2 (C-2), 61.8 (CH2O, 1-
OEt), 60.8 (CH2O, 3-CO2CH2), 48.6 (C-3), 32.6 (C-4), 31.9 (C-7), 31.1 (C-8), 29.71, 
29.67, 29.65, 29.58, 29.52, 29.37, 29.2, 22.7 (C-9–C-26), 14.2 (C-27), 14.1 (CH3, 1-
OEt), 14.1 (CH3, 3-CO2Et); HRMS(ESI) m/z calcd. for [C32H60O5+Na]
+
: 547.4338, 
obsd.: 547.4344. 
General Procedure for the Synthesis of α-Alkyl-β-Hydroxy-Diesters. n-BuLi 
(11.5 mL, 2.0m solution in hexanes, 23.0 mmol) was added to a solution of di-
isoproplyamine (3.6 mL, 25.0 mmol) in THF (20 mL)  at 0 °C. After 30 min, the 
solution was cooled down to -78°C and diethyl malate 5 (1.9 g, 10 mmol) in THF (20 
mL) was added. The resulting mixture was stirred at -78 °C for 1 h, warmed up to -
20 °C over 1 h and stirred at -20°C for 20 min. After cooling down to -78 °C, the 
alkyl iodide (15.0 mmol, 1 equiv.) in THF (20 mL) was added dropwise and the 
reaction stirred for 2 h, during which time the temperature increased to 0°C  and 
stirred for a further 2 h at room temperature. The reaction was quenched using 
NH4Cl (sat.) and extracted with EtOAc (3 x 100 mL). The combined organic layers 
were washed with water (30 mL) and brine (30 mL), dried (MgSO4), filtered and the 
solvent removed in vacuo to yield a crude yellow oil. Purification of the residue 
using silica gel flash column chromatography and the eluent given, gave the 
alkylated product.  
 
Ethyl 2S-hydroxy-3R-ethoxycarbonyl-decanoate (anti-5b). 
By reacting diethyl malate 3 (3.97 g, 20.9 mmol) with 1-
iodoheptane (5.13 mL, 31.3 mmol) according to the general 
procedure for the synthesis of α-alkylated-β-hydroxy-diesters, 
decanoate 5b was obtained  (eluting in 15:1, petroleum 
ether/EtOAc, v/v) as a colourless oil (2.24 g, 7.4 mmol, 37%, anti:syn = 7:1). Rf = 
0.73 (PE/EA, 2/1, v/v); [α]ᴅ23 = +0.7 (c = 0.1, CHCl3); IR (film): 3522, 3020, 2928, 
2857, 1734, 1376, 1216, 1027, 754, 668 cm
-1
; 
1
H NMR (500 MHz, CDCl3) δ 4.31–
4.21 (m, 3H, CH2O-1 and H-2), 4.14 (q, Ja,b = 7.1 Hz, 2H, CH2O, 3-CO2CH2), 3.19 
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(d, J2,OH = 7.6 Hz, 1H, OH), 2.84 (td, J3,4 = 7.1 Hz, J2,3 = 3.7 Hz, 1H, H-3), 1.85 (ddt, 
J4a,4b = 14.9 Hz, J3,4a=  J4a,5a =  J4a,5b = 7.1 Hz, 1H, H-4a), 1.66 (ddt, J4a,4b = 14.9 Hz,  
J3,4b = J4b,5a = J4b,5b = 6.8 Hz, 1H, H-4b), 1.40–1.24 (m, 16H, H-5–H-9, 2 x CH3), 0.89 
(t, J = 6.9 Hz, 3H, CH3-10); 
13
C NMR (125 MHz, CDCl3) δ 173.5 (C-1), 172.9 (3-
CO2), 71.1 (C-2), 61.8 (CH2O, 1-OEt), 60.8 (CH2O, 3-CO2CH2), 48.6 (C-3), 31.8 (C-
4), 29.4, 29.1, 28.1, 27.4, 22.6 (C-5–C-9), 14.1 (C-10), 14.1 (CH3, 1-OEt), 14.1 
(CH3, 3-CO2Et); HRMS(ESI) m/z calcd. For [C15H28O5+Na]
+
: 311.1833, obsd.: 
311.1834. 
 
Ethyl 2S-hydroxy-3R-ethoxycarbonyl-heptadecanoate (anti-
5d). By reacting diethyl malate 3 (0.44 g, 2.35 mmol) with 1-
iodotetradecane (1.14 g, 3.53 mmol) according to the general 
procedure for the synthesis of α-alkyl-β-hydroxy-diesters, 
heptadecanoate 5d was obtained (eluting in 15:1, petroleum 
ether/EtOAc, v/v) as a colourless oil (0.14 g, 0.34 mmol, 15%, anti:syn = 9:1). Rf = 
0.66 (PE/EA, 2/1, v/v); [α]ᴅ23 = +4.0 (c = 1.0, CHCl3); IR (film): 3514, 3020, 2925, 
2584, 1735, 1466, 1369, 1216, 755 cm
-1
;
 1
H  NMR (500 MHz, CDCl3) δ 4.29–4.22 
(m, 3H, CH2O-1 and H-2), 4.14 (q, J = 7.1 Hz, 2H, 3-CO2CH3), 3.19 (d, J2,OH = 7.6 
Hz, 1H, OH), 2.84 (td, J3,4 = 7.3 Hz, J2,3 = 3.5 Hz, 1H, H-3), 1.83 (ddt, J4a,4b = 14.0 
Hz, J3,4a=  J4a,5a =  J4a,5b = 7.0 Hz, 1H, H-4a), 1.66 (ddt, J4a,4b = 14.0 Hz,  J3,4b = J4b,5a = 
J4b,5b = 7.2 Hz, 1H, H-4b), 1.45–1.21 (m, 30H, H-5–H-16 and 2 x CH3), 0.87 (t, J = 
6.4 Hz, 3H, CH3-17); 
13
C NMR (125 MHz, CDCl3) δ 173.5 (C-1), 172.9 (3-CO2), 
71.1 (C-2), 61.8 (CH2O, 1-OEt), 60.8 (CH2O, 3-CO2CH2), 48.6 (C-3), 31.9 (C-4), 
29.7, 29.7, 29.7, 29.7, 29.6, 29.6, 29.4, 28.1, 27.4, 22.7 (C-5–C-16), 14.2 (C-17), 
14.1 (CH3, 1-OEt), 14.1 (CH3, 3-CO2Et); HRMS(ESI) m/z calcd. For 
[C22H42O5+Na]
+
: 409.2931, obsd.: 409.2928. 
 
Ethyl 2S-hydroxy-3R-ethoxycarbonyl-tricosanoate (anti-
5f). By reacting diethyl malate 3 (0.22 g, 1.15 mmol) with 1-
iodoeicosane (0.70 g, 1.72 mmol) according to the general 
procedure for the synthesis of α-alkyl-β-hydroxy-diesters, 
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tricosanoate 5f was obtained (eluting in 15:1, petroleum ether/EtOAc, v/v) as a white 
solid (0.02 g, 0.05 mmol, 4%, anti:syn = 6:1). Rf  = 0.58 (PE/EA, 2/1, v/v); [α]ᴅ
22 
= 
+2.0 (c = 1.0, CHCl3); IR (film): 2918, 2850, 1737, 1252, 1182, 1099, 1030, 837, 
757, cm
-1
;
 1
H  NMR (500 MHz, CDCl3) δ 4.31–4.21 (m, 3H, CH2O-1 and H-2), 
4.18–4.12 (m, 2H, 3-CO2CH3), 3.20 (d, J2,OH = 7.8 Hz, 1H, OH), 2.84 (td, J3,4 = 7.2 
Hz, J2,3 = 3.7 Hz, 1H, H-3), 1.83 (ddt, J4a,4b = 14.4 Hz, J3,4a=  J4a,5a =  J4a,5b = 7.8 Hz, 
1H, H-4a), 1.66 (ddt, J4a,4b = 14.4 Hz,  J3,4b = J4b,5a = J4b,5b = 7.4 Hz, 1H, H-4b), 1.39–
1.23 (m, 42H, H-5–H-22 and 2 x CH3), 0.89 (t, J = 6.9 Hz, 3H, CH3-23); 
13
C NMR 
(125 MHz, CDCl3) δ 173.5 (C-1), 172.9 (3-CO2), 71.0 (C-2), 61.8 (CH2O, 1-OEt), 
60.8 (CH2O, 3-CO2CH2), 48.6 (C-3), 31.9 (C-4), 29.68, 29.66, 29.64, 29.62, 29.5, 
29.4, 29.3, 28.1, 27.4, 22.7 (C-5–C-22), 14.2 (C-23), 14.1 (CH3, 1-OEt), 14.1 (CH3, 
3-CO2Et); HRMS(ESI) m/z calcd. For [C28H54O5+Na]
+
: 493.3869, obsd.: 493.3871. 
 
Ethyl 2S-hydroxy-3R-ethoxycarbonyl-pentacosanoate 
(anti-5h). By reacting diethyl malate 3 (0.22 g, 1.16 mmol) 
with 1-iododocosane (0.78 g, 1.77 mmol) according to the 
general procedure for the synthesis of α-alkyl-β-hydroxy-
diesters, pentacosanoate 5h was obtained (eluting in 15:1, 
petroleum ether/EtOAc, v/v) as a white solid (0.05 g, 0.096 mmol, 8%, anti:syn = 
6:1). Rf  = 0.58 (PE/EA, 2/1, v/v); [α]ᴅ
22 
= +3.0 (c = 0.1, CHCl3); IR (film) 3473, 
2917, 2850, 1737, 1599, 2032, 837, 758, 721, 668 cm
-1
;
 1
H  NMR (500 MHz, CDCl3) 
δ 4.30–4.21 (m, 3H, CH2O-1 and H-2), 4.14 (m, 2H, 3-CO2CH2), 3.20 (d, J2,OH = 7.6 
Hz, 1H, 2-OH), 2.84 (td, J3,4 = 7.6 Hz, J2,3 = 3.7 Hz, 1H, H-3), 1.83 (ddt, J4a,4b = 14.2 
Hz, J3,4a= J4a,5a = J4a,5b = 7.2 Hz, 1H, H-4a), 1.66 (ddt, J4a,4b = 14.2 Hz,  J3,4b = J4b,5a = 
J4b,5b = 7.2 Hz, 1H, H-4b), 1.40–1.24 (m, 46H, H-5–H-24, 2 x CH3), 0.89 (t, J = 6.6 
Hz, 3H, CH3-25); 
13
C NMR (125 MHz, CDCl3) δ 173.5 (C-1), 172.9 (3-CO2), 71.1 
(C-2), 61.8 (CH2O, 1-OEt), 60.8 (CH2O, 3-CO2CH2), 48.6 (C-3), 31.9 (C-4), 29.7, 
29.7, 29.7, 29.6, 29.4, 29.4, 28.1, 27.4, 22.7 (C-5–C-24), 14.2 (C-25), 14.1 (CH3, 1-
OEt), 14.1 (CH3, 3-CO2Et); HRMS(ESI) m/z calcd. For [C30H58O5+Na]
+
: 521.4182, 
obsd.: 521.4180. 
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General Procedure for Hydrogenation. Pd/C (5 wt%) was added to a solution of 
the allylic alkylated diester (1 mmol) in a mixture of CH2Cl2/MeOH (10 mL, 1/1, 
v/v) and stirred at room temperature under H2 (gas) overnight. The reaction mixture 
was filtered through Celite, the Celite washed thoroughly with CH2Cl2/MeOH (20 
mL, 1/1, v/v) and the filtrate concentrated in vacuo. The product was purified using 
silica gel flash chromatography and the eluent given.  
Ethyl 2S-hydroxy-3R-ethoxycarbonyl-decanoate (anti-5b). By subjecting 
decenoate (anti:syn 9:1) 5c (2.01 g, 6.99 mmol) to the general procedure for 
hydrogenation pure anti- 5b was obtained (eluting in 15:1 petroleum ether/EtOAc, 
v/v) as a colourless oil (1.81 g, 6.29 mmol, 90%). The spectral data matched that 
reported earlier. 
Ethyl 2S-hydroxy-3R-ethoxycarbonyl-heptadecanoate (anti-5d). By subjecting 
heptadecenoate (anti:syn 10:1) 5e (3.60 g, 9.38 mmol) to the general procedure for 
hydrogenation pure  anti-5d was obtained (eluting in 15:1, petroleum ether/EtOAc, 
v/v) as a colourless oil (3.29 g, 8.52 mmol, 91%). The spectral data matched that 
reported earlier. 
Ethyl 2S-hydroxy-3R-ethoxycarbonyl-tricosanoate (anti-5f). By subjecting 
tricosenoate (anti:syn 9:1) 5g  (0.40g, 0.85 mmol)  to the general procedure for 
hydrogenation pure anti-5f was obtained (eluting in 15:1, petroleum ether/EtOAc, 
v/v) as a white solid (0.36 g, 0.77 mmol, 90%). The spectral data matched that 
reported earlier. 
Ethyl 2S-hydroxy-3R-ethoxycarbonyl-pentacosanoate (anti-5h). By subjecting 
pentacosenoate (anti:syn 9:1) 5i (0.80 g, 1.61 mmol) to the general procedure for 
hydrogenation pure anti-5h was obtained (eluting in 15:1, petroleum ether/EtOAc, 
v/v) as a white solid   (0.72 g, 1.45 mmol, 90%). The spectral data matched that 
reported earlier. 
 
Ethyl 2S-hydroxy-3R-ethoxycarbonyl-heptacosanoate (anti-
5k). By subjecting heptacosenoate (anti:syn 9:1) 5j (0.11 g, 
0.21 mmol) to the general procedure for hydrogenation pure 
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anti-5k was obtained (eluting in 15:1, petroleum ether/EtOAc, v/v) as a white solid 
(0.10 g, 0.19 mmol, 90%). Rf  = 0.54 (PE/EA, 2/1, v/v); [α]ᴅ
22 
= +2.0 (c = 0.1, 
CHCl3); IR (film) 3473, 2917, 2850, 1737, 1208, 1029, 771, 668 cm
-1
;
 1
H  NMR (500 
MHz, CDCl3) δ 4.30–4.20 (m, 3H, CH2O-1 and H-2), 4.18–4.12 (m, 2H, 3-CO2CH2), 
3.20 (d, J2,OH = 7.9 Hz, 1H, 2-OH), 2.84 (td, J3,4 = 7.3 Hz, J2,3 = 3.7 Hz, 1H, H-3), 
1.83 (ddt, J4a,4b = 13.9 Hz, J3,4a= J4a,5a = J4a,5b = 7.6 Hz, 1H, H-4a), 1.66 (ddt, J4a,4b = 
13.9 Hz,  J3,4b = J4b,5a = J4b,5b = 7.1 Hz, 1H, H-4b), 1.43–1.24 (m, 50H, H-5–H-26, 2 x 
CH3), 0.89 (t, J = 6.8 Hz, 3H, CH3-27); 
13
C NMR (125 MHz, CDCl3) δ 173.5 (C-1), 
172.9 (3-CO2), 71.0 (C-2), 61.8 (CH2O, 1-OEt), 60.8 (CH2O, 3-CO2CH2), 48.6 (C-3), 
31.9 (C-4), 29.7, 29.68, 29.67, 29.65, 29.58,  29.45, 29.37, 28.1, 27.4, 22.7 (C-5–C-
26), 14.2 (C-27), 14.1 (CH3, 1-OEt and CH3, 3-CO2Et); HRMS(ESI) m/z calcd. For 
[C32H62O5+Na]
+
: 549.4495, obsd.: 549.4490. 
 
Cross metathesis for the preparation of ethyl-2S-hydroxy-3R-ethoxycarbonyl-
heptadecanoate (anti-5d). To a solution of compound anti-5a (0.106 g, 0.46 mmol) 
in CH2Cl2 (2.5 mL), was added Grubbs second generation catalyst (0.02 g, 0.023 
mmol) followed by 1-tridecene (0.11 mL, 0.46 mmol) and the reaction mixture 
refluxed under nitrogen for 14 hours before being cooled down and reduced in 
vacuo. The resulting crude product was columned yielding the heptadecenoate anti-
5e (eluting in 15:1, petroleum ether/EtOAc, v/v) as a colourless oil (0.07 g, 0.19 
mmol, 41%). Subsequent hydrogenation of anti-5e according to the above general 
procedure, then yielded pure anti-5d (0.07 g, 0.18 mmol, 99 %) as a colourless oil. 
The spectral data matched that previously determined as reported herein.  
 
General procedure for alkylation using HMPA as a solvent. n-BuLi (11.5 mL, 
2.0m solution in hexanes, 23.0 mmol) was added to a solution of di-isopropylamine 
(3.6 mL, 25.0 mmol) in THF (20 mL) at 0 ºC. After 30 min the solution was cooled 
down to -78 ºC and diethyl malate 3 (1.9 g, 10 mmol) in THF (20 mL) was added. 
The resulting mixture was stirred at -78 ºC for 1 h, warmed up to -20 ºC over 1 h and 
stirred at -20 ºC for 20 min. After cooling down to -78 ºC , the appropriate iodide 
(15.0 mmol, 1.5 equiv.) in HMPA (20 mL) was added dropwise and the reaction was 
stirred for 1 h at -50 ºC and then a further 1h during which time the temperature 
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increased to 0 ºC . The reaction was then quenched using NH4Cl (sat.) and extracted 
with EtOAc (3 x 100 mL). The combined organic layers were washed with water (30 
mL) and brine (30 mL), dried (MgSO4), filtered and the solvent removed in vacuo to 
yield a crude yellow oil. Purification of the residue, using silica gel flash column 
chromatography and the eluent given, gave the alkylated product.  
Ethyl 2S-hydroxy-3R-ethoxycarbonyl-heptadecanoate (anti-5d). By reacting 
diethyl malate 3 (0.47 g, 2.45 mmol) with 1-iodotetradecane (1.19 g, 3.69 mmol) 
according to the general procedure for alkylation described above, heptadecanoate 5d 
was obtained (eluting in 15:1, petroleum ether/EtOAc, v/v) as a colourless oil (0.32 
g, 0.83 mmol, 35%, anti:syn = 7:1). The spectral data matched that reported earlier. 
Ethyl 2S-hydroxy-3R-ethoxycarbonyl-heptadecen-5-enoate (anti-5e). By reacting 
diethyl malate 3 (0.45 g, 2.35 mmol) with 1-iodo-tetradec-2-ene (1.14 g, 3.53 mmol) 
according to the general procedure described above, heptadecenoate 5e was obtained 
(eluting in 15:1, petroleum ether/EtOAc, v/v) as a colourless oil (0.40 g, 1.05 mmol, 
45%, anti:syn = 9:1). The spectral data matched that reported earlier. 
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5.1 Introduction 
Trehalose dicorynomycolates (TDCMs, 1, Figure 1) are naturally occurring 
glycolipids found in Corynebacteria which exhibit important immunological 
properties such as adjuvant
1,2
 and tumor regression activities.
3
 With recent advances 
in the studies of the biological potential of trehalose glycolipids, interest in TDCMs 
has been renewed. Accordingly, there have been a number of synthetic routes 
reported in literature for accessing TDCMs and their analogues
4,5,6
 (see  Chapter 1, 
Section 1.5.3b). We envisaged, however, that these routes could be improved and 
thus make this important class of compound more readily accessible. With the 
improved Fráter-Seebach methodology already developed (Chapter 4), it was 
proposed that the product from this alkylation could form a key intermediate en route 
to the synthesis of TDCM and analogues. For the purpose of the work presented 
herein, the synthesis of trehalose monocorynomycolate (TMCM, 2) was undertaken 
5 TMCM Synthesis  
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in order to determine other key methodologies that then may be used in the synthesis 
of further TDCMs. Attempts to prepare diester 3 will also be discussed.  
 
Figure 1. TDCM (1), TMCM analogue (2) and TDCM analogue (3)  
 
5.2 TMCM and TDCM Synthesis 
The retrosynthetic strategy for the synthesis of TDCMs 1 and 3 is presented (Scheme 
1). Here, a convergent strategy was proposed whereby the two key intermediates, 
TMS trehalose 4 and tert-butyldimethylsilyl (TBS) protected corynomycolic acid 5a 
or 5b could be coupled to obtain the mono or diester as required. As previously 
illustrated (Chapter 2), it was envisioned that the stoichiometry of acid would 
determine whether the mono- or diester would be formed. TMS trehalose 4, in turn, 
could be synthesised through the previously reported one-pot two-step silylation 
process starting with commercially available α,α-trehalose (6).7 To prepare TBS 
corynomycolic acids 5a and 5b, a copper-mediated Grignard reaction could be 
performed between epoxide 7 and either commercially available n-BuLi (8a) or 
readily synthesised tetradecylmagnesium bromide (8b). Epoxide 7 could be accessed 
in three steps from malic ester 9 according to our previously reported Fráter-Seebach 
alkylation methodology (see Chapter 4). 
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Scheme 1. Retrosynthesis for TDCMs 1 and 3. 
 
To prepare the key TBS corynomycolic acid 5, our synthetic efforts commenced with 
the borane dimethylsulfide (BMS) reduction of malic ester 9 in order to selectively 
reduce the ethyl ester adjacent to the hydroxyl group.
8
 This reaction led to diol 10 in 
a respectable 60% yield and as the only observed product (Scheme 2). The primary 
hydroxyl in 10 was then transformed into a tosylate via reaction of 10 with TsCl, 
Et3N in the presence of catalytic dibutyltin oxide. Subjecting tosylate 11 to basic 
156 
 
conditions then resulted in the formation of epoxide 7 in good (81%) yield over two 
steps.  
 
Scheme 2. Synthesis of epoxide 7 
 
With epoxide 7 in hand, we next attempted to prepare corynomycolic ester 12 using a 
copper-mediated Grignard reaction to open the epoxide.
9,10
 Copper-mediated 
Grignard reactions are versatile tools for carbon-carbon bond formation
11,12,13
 and are 
carried out in the presence of copper salts such as CuCN, CuI, CuCl and CuBr, of 
which CuI is most commonly used.
14
 Accordingly, epoxide 7 was first subjected to 
reaction with CuI (2.5 equiv.) and n-BuLi (5 equiv.) in THF (Table 1, Entry 1). 
Unfortunately, the major product from this reaction was halohydrin 13a with none of 
the desired corynomycolic ester 12a being obtained. This was not entirely 
unexpected as the formation of similar halo-products have been reported in 
literature.
15
 In an attempt to restrict formation of 13a, the amount of CuI was reduced 
(0.15 equiv.), however, the halohydrin was still the only product obtained from the 
reaction mixture (Entry 2). Alexakis et al. had previously reported that use of a 
Lewis acid could reduce the formation of halohydrin products in the nucleophilic 
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ring opening of epoxides.
16
 Thus, BF3.Et2O was used in the reaction (Entry 3). 
Although, a faster reaction was observed, again only halohydrin 13a was isolated. In 
view of this, we then opted to use CuCN as the copper reagent (Entry 4). Fortunately, 
this reaction was successful with complete consumption of starting material seen 
after 4 hours and only the desired alkylated product 12a was observed (71% yield). 
 
Table 1. Copper mediated Grignard reaction  
 
Entry Conditions  Results  Yield(%)[a]  
1 CuI (2.5 equiv.), n-BuLi (5 equiv.), THF,    
-35 °C, 4 h 
13a only  60% 
 
2 CuI (0.1 equiv.), n-BuLi (2 equiv.), THF,            
-35 °C, 4 h 
13a only  10% 
 
3 CuI (2.5 equiv.), n-BuLi (5 equiv.), 
BF3.OEt (5 equiv.), THF, -35 °C, 2 h 
13a only  60% 
 
4 CuCN (2 equiv.), n-BuLi (4 equiv.), THF,   
-50 to -20 °C, 4 h 
12a only  71% 
 
5 CuCN (2 equiv.), C14MgBr (4 equiv. in 
THF), THF, -50 to 0 °C,  5 h 
13b only  60%  
6 CuCN (2 equiv.), C14Li (4 equiv. in 
THF), THF, -50 to 0 °C, 8 h 
Starting material  80%
 [b]
 
7 CuCN (2 equiv.), C14Li (4 equiv. in 
Et2O), -50 to 0 °C, 8 h 
Starting material 
unidentified by-product 
(trace) 
80%
[b]
 
8 CuCN (2 equiv.), C14Li (4 equiv. in 
toluene), THF, -50 to 0 °C, 8 h 
Starting material  80%
[b]
 
9 CuCN (2 equiv.), C14Li (4 equiv. in 
cyclohexane), THF, -50 to 0 °C, 8 h 
Starting material  80%
[b]
 
 [a] Isolated yields 
 [b] Yield of recovered starting material 
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Having successfully synthesised the butylated product 12a, our attention then turned 
to the use of copper-mediated Grignard reaction to install the C14 lipid. Thus, 
tetradecylmagnesium bromide (prepared via reaction of bromo-tetredecane and 
magnesium)
17
 was subjected to Grignard reaction with epoxide 7 and CuCN (Entry 
5). Unfortunately, the only product obtained from the reaction was halohydrin 13b. 
We then opted to use tetradecyllithium (C14Li) in the alkylation so as to avoid 
formation of any halogenated by-products. To this end, C14Li was prepared as a 
solution in THF (via reaction of tetradecylbromide and Li),
18
 and then added to a 
solution of expoxide 7 in THF (Entry 6). Unfortunately, no formation of 12b occured 
and only starting material was isolated. A change of reaction solvent (entries 7–9) 
faired no better, with only starting material recovered.  
In the interest of time, we proceeded using the butylated adduct 12a in the synthesis 
of a short-chain TDCM. It is proposed, however, that the longer alkyl chains could 
be installed via the use of the more reactive alkyne lithium in this reaction.
19
 Though 
adding an additional step (reduction of the triple bond) following alkylation, this 
strategy could still allow for a highly competitive synthesis of the TDCMs.  
Continuing on with the butylated adduct 12a, a TBS protection of the hydroxyl group 
in 12a (using TBSCl and imidiazole in DMF) was attempted. This reaction, however, 
was not successful with starting material and only minor amounts (<10%) of the 
desired product formed. A change of solvent (CH2Cl2), prolonged reaction times, 
heating the reaction mixture, or the addition of DMAP as a catalyst did not improve 
the product yield. As the hydroxyl is in a secondary position with adjacent lipid 
groups, steric hinderance could be a potential cause for the poor yield in the 
protection step. In order to improve the yield, 12a was subjected to the more reactive 
TBSOTf (prepared via reaction of TfOH and TBSCl)
20
 and 2,6-lutidine in CH2Cl2. 
Gratifyingly, the reaction was complete in 30 min and the silylated product obtained 
in high (90%) yield (Scheme 3). Hydrolysis of the ethyl ester using LiOH was then 
attempted so as to generate protected corynomycolic acid 5. Unfortunately, this 
reaction was not chemo-selective and loss of the TBS group also occurred to give 
corynomycolic acid 14.  
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Given this, we resorted to a different strategy whereby corynomycolic ester 12a 
would be first hydrolysed, then bis-silylated.
21
 The bis-silylated product could then 
be subjected to milder basic conditions in order to selectively remove the more labile 
TBS-ester leading to protected corynomyolic acid 5. To this end, corynomycolic 
ester 12a was treated with LiOH and acid 14 was obtained in quantitative yields 
(Scheme 3). Acid 14 was then treated with TBSOTf and 2,6-lutidine to give the bis-
silylated product which, upon treatment with K2CO3, resulted in the desired TBS 
corynomycolic acid 5 in good (89%) yield over two steps.   
 
Scheme 3. Synthesis of TBS protected corynomycolic acid 5. 
 
With the TBS corynomycolic acid 5 in hand, our attention turned to the coupling of 
this acid to the trehalose core. TMS trehalose 4 was synthesised using Johnson’s 
protocol
7
 (see Chapter 2), and subjected to esterification with acid 5 (4.4 equiv.) in 
the presence of EDCI (6.6 equiv.) and DMAP (1.6 equiv.) (Scheme 4). It was 
proposed that these conditions would lead to the diester (as observed with the linear 
trehalose diesters (TDEs) series, Chapter 2). Indeed after stirring at 70 °C overnight, 
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complete consumption of acid 5 was noted and two higher running spots (compared 
to TMS trehalose 4) were observed during TLC analysis of the reaction mixture, 
which were thought to be the mono and diesterified products. One of the products 
obtained was the protected TMCM 15 (30% yield), unfortunately, the other product 
was not the expected diester but tentatively assigned corynomycolic anhydride 16. 
The structure of anhydride 16 was assigned based on 
1
H NMR spectral data. In 
addition, treatment of product 16 with K2CO3, yielded acid 5, which is in agreement 
with the product expected from the reaction of an anhydride with a base. Time did 
not permit further optimisation of the reaction to increase yield of 15, or indeed, to 
investigate ways in which to synthesise the desired diester. It is envisioned that a 
change of solvent and prolonged reaction times could help to improve this reaction. 
Anhydrides are known to react with alcohols in the presence of EDCI and DMAP
22
 
and thus addition of further equivalents of these reagents could potentially drive the 
esterification further. In order to form the final TMCM compound 2, TMCM 15 
would be deprotected using  Dowex-H
+
. 
 
 
Scheme 4. Synthesis of protected TMCM analogue 15. 
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5.3 Conclusion and Future work 
The synthesis of a fully protected truncated TMCM has been achieved. One of the 
key steps in the synthesis was a copper mediated Grignard reaction for the formation 
of the corynomycolic acid moiety. Difficulties were observed when attempts were 
made to install a longer alkyl lipid chain (C14) using this alkylation and one way to 
solve this would be via the use of the more reactive lithiated C14 alkyne in this 
reaction. Functional group manipulations were then performed and the desired silyl 
ether was obtained in good overall yields, however, esterification proved more 
difficult and only the protected TMCM along with the corynomycolic anhydride 
were isolated. To overcome this, it is proposed that prolonged reaction times and 
addition of further equivalents of EDCI and DMAP to the reaction mixture is 
required to drive the reaction further. Once these issues are resolved, it is then 
proposed that this general synthetic strategy can be used for the synthesis of a variety 
of TDCMs.  
 
 
5.4 Experimental 
Unless stated otherwise all reactions were performed under N2. Prior to use, THF 
was distilled from Na wire and benzophenone, toluene was dried and stored under 
Na wire and TfOH (flurochem) was distilled. BH3.Me2S (1M in THF, Acros), NaBH4 
(Aldrich), dibutyltin oxide (Aldrich), tosyl chloride (Aldrich), n-BuLi (Aldrich, 2M 
solution in hexanes), imidiazole (Apollo), TBSCl (Apollo), 2,6-lutidine (Fluka), 
CuCN (Ajax chemicals), LiOH.H2O (Riedel-de-Haën), EDCI (Aldrich), DMAP 
(Merck), anhydrous DMF (Acros), 33% HCl (Panreac), ethanol (Pure Science), 
methanol (Panreac), EtOAc (Panreac), petroleum ether (Pure Science), NaHCO3 
(Pure Science), K2CO3 (Pure Science), MgSO4 (Pure Science), NaCl (Panreac) were 
used as received. All solvents were removed via evaporation at reduced pressure. 
Reactions were monitored by TLC analysis on Macherey-Nagel silica gel coated 
plastic sheets (0.20 mm, Polygram SIL G/UV254) by coating with a solution of 5% 
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KMnO4 and 1% NaIO4 in H2O followed by heating or by dipping in 10% H2SO4 in 
EtOH followed by charring at ~150 °C. Column chromatography was performed 
using Pure Science silica gel (40-63 μm). High resolution mass spectra were 
recorded on a Waters Q-TOF Premier
TM 
Tandem Mass Spectrometer using positive 
electro-spray ionisation. Optical rotations were recorded on a Perkin-Elmer 241 
polarimeter or Autopol II (Rudolph Research Analytical) at 589 nm (sodium D-line). 
Infrared spectra were recorded as thin films using a Bruker Tensor 27 FTIR 
spectrometer equipped with an Attenuated Total Reflectance (ATR) sampling 
accessory and are reported in wave numbers (cm
-1
). Nuclear magnetic resonance 
spectra were recorded at 20
 
°C in CDCl3 using a Varian INOVA operating at 500 
MHz. Chemical shifts are given in ppm (δ) relative to solvent residual peak. NMR 
peak assignments were made using COSY, HSQC and HMBC 2D experiments. 
 
3R-Ethoxycarbonyl-2S-hydroxy-heptadecanol (10). Borane 
dimethylsulfide complex (0.68 mL, 1M in THF, 0.68 mmol) 
was slowly added to a solution of malic ester 9 (0.24 g, 0.62 
mmol) in THF (2 mL). The reaction was stirred at r.t. overnight 
after which time it was cooled to 0 °C  and NaBH4 (0.002 g, 
0.04 mmol) was added. The reaction was allowed to warm to room temperature 
overnight, before being quenched with Dowex-H
+ 
(10% by weight) and then ethanol 
(3 mL) was added. The reaction mixture was filtered, washed (EtOH) and 
concentrated in vacuo. The residue was dissolved in toluene:ethanol (1:1, 5 mL) and 
concentrated (repeated 3 x) in order to remove ethanol and boron as B(OEt)3. The 
resulting crude oil was purified using silica gel flash column chromatography 
(eluting in 1:1, petroleum ether/EtOAc, v/v) to give the title compound 10 as a 
colourless oil (0.13 g, 0.37 mmol, 60%). Rf  = 0.30 (PE/EA, 1/1, v/v); [α]ᴅ
20 
=  4.0  (c 
= 0.1, CHCl3); IR (film) 2922, 2852, 1734, 1176, 756 cm
-1
; 
1
H NMR (500 MHz, 
CDCl3)  4.23–4.10 (m, 2H, 3-CO2CH2), 3.83–3.80 (m, 1H, H-2), 3.69 (dd, J1a,1b = 
11.0 Hz, J1a,2 = 6.8 Hz, 1H, H-1a), 3.55 (dd, J1a,1b = 11.0 Hz, J1b,2 = 6.8 Hz, 1H, H-
1b), 3.11 (d, J2,OH = 3.4 Hz, C2-OH), 2.53 (dt, J2,3 = J3,4a = J3,4b = 8.0 Hz, 1H, H-3), 
2.13 (bs, 1H, C1-OH), 1.69–1.60 (m, 1H, H-4a), 1.59–1.55 (m, 1H, H-4b), 1.31–1.28 
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(m, 27H, H-5–H-16 and OCH2CH3), 0.88 (t, J16,17 = 7.1 Hz, 3H, CH3-17); 
13
C NMR 
(125 MHz, CDCl3)  175.5 (3-CO2), 72.7 (C-2), 65.0 (C-1), 60.8 (CH2O, 3-
CO2CH2), 47.5 (C-3), 31.9, 29.68, 29.67, 29.65, 29.61, 29.5, 29.44, 29.39, 29.36, 
29.34, 27.14, 22.69 (C-4-C-16), 14.2 (C-17), 14.1 (CH3, 3-CO2Et); HRMS(ESI) m/z 
calcd. for [C20H40O4+Na]
+
: 367.2824, obsd.: 367.2820. 
 
                                  3R-Ethoxycarbonyl-2S-hydroxy- 
heptadecanoyl p-toluenesulfonate (11). To a solution of diol 
10 (0.29 g, 0.84 mmol) in CH2Cl2 (5 mL), Bu2SnO (0.004, 
0.016 mmol), TsCl (0.18 g, 1.01 mmol), and Et3N (0.14 mL, 
1.01 mmol) were added. The resulting reaction mixture was 
stirred at r.t. for 2.5 h, after which time brine was added and the resulting solution 
extracted with CH2Cl2 (3 x 30 mL). The combined organic layers were dried with 
MgSO4 and concentrated in vacuo. The resulting crude solid was purified using silica 
gel flash column chromatography (eluting in 5:1, petroleum ether/EtOAc, v/v) to 
give the title compound as a white solid (0.35 g, 0.70 mmol, 84%). Rf  = 0.56 
(PE/EA, 1/1, v/v); [α]ᴅ20 =  2.0  (c = 1.0, CHCl3); IR (film) 2925, 1539, 1265, 1176, 
753 cm
-1
; 
1
H NMR (500 MHz, CDCl3)  7.80  (d, J = 8.3 Hz, 2H, Harom), 7.35 ( d, J = 
8.1 Hz, 2H, Harom), 4.20–4.12 (m, 2H, 3-CO2CH2), 4.05 (d, J1,2 = 4.9 Hz, 2H, H-1), 
3.9 (dt, J1,2 = J2,3 = 4.9 Hz, 1H, H-2), 2.55 (m, 1H, H-3), 2.46 (s, 3H, Car-CH3), 1.70–
1.64 (m, 1H, H-4a), 1.53–1.43 (m, 1H, H-4b), 1.30–1.25 (m, 27H, H-5–H-16, 
OCH2CH3), 0.88 (t, J16,17 = 6.4 Hz, 3H, CH3-17); 
13
C NMR (125 MHz, CDCl3)  
174.8 (3-CO2), 145.1 (Car-CH3), 132.5 (Car-SO2), 129.9 (Car), 128.0 (Car), 71.6 (C-1), 
70.0 (C-2), 60.8 (CH2O, 3-CO2CH2), 47.0 (C-3), 31.9, 29.69, 29.68, 29.66, 29.61, 
29.53, 29.36, 29.27, 27.11, 22.69, 21.67 (C-4–C16, Car-CH3), 14.14 (C-17), 14.10 
(CH3, 3-CO2Et); HRMS(ESI) m/z calcd. for [C27H46O6S+Na]
+
: 521.2913, obsd.: 
521.2908. 
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Ethyl (2R)-2-[(R)-oxiranyl]-hexadecanoate (7). To a solution of 
tosylate 11 (0.32 g, 0.64 mmol) in MeOH (7 mL) was added K2CO3 
(0.11 g, 0.76 mmol) and the reaction stirred at r.t. for 2 h after 
which time NH4Cl (20 mL) was added. The resulting solution was 
extracted with EtOAc (3 x 30 mL), the combined organic layers 
were dried with MgSO4, concentrated in vacuo and crude solid was 
purified using silica gel flash column chromatography (eluting in 20:1, petroleum 
ether/EtOAc, v/v) to give the title compound as a white solid (0.20 g, 0.61 mmol, 
97%). Rf  = 0.73 (PE/EA, 1/1, v/v); [α]ᴅ
20 
= 1.0 (c = 0.1, CHCl3); IR (film) 2825, 
1733, 1464, 1203, 668 cm
-1
; 
1
H NMR (500 MHz, CDCl3)  4.20 (q, J = 7.1 Hz, 2H, 
1-OCH2), 3.17–3.10 (m, 1H, 2-CH), 2.83 (dd, JCHa,CHb = 8.8 Hz, J2-CH,2-CHCHa = 4.1 
Hz, 1H, 2-CHCHaHb), 2.56 (dd, JCHa,CHb = 8.8 Hz, J2-CH,2-CHCHb = 4.1 Hz, 1H, 2-
CHCHaHb), 2.13 (dt, J2,3 = J2,2-CH = 8.0 Hz, 1H, H-2), 1.75–1.69 (m, 1H, H-3a), 
1.62–1.55 (m, 1H, H-3b), 1.30–1.25 (m, 27H, H-4–H-15, 1-OCH2CH3), 0.88 (t, J15,16 
= 6.6 Hz, 3H, CH3-16); 
13
C NMR (125 MHz, CDCl3)  173.6 (C-1), 60.8 (CH2O, 1-
CO2CH2), 52.7 (2-CHCH2), 49.0 (C-2), 46.4 (2-CHCH2), 31.9, 29.69, 29.67, 29.65, 
29.61, 29.53, 29.47, 29.37, 29.36, 29.08, 27.23, 22.69 (C-3–C-15), 14.3 (C-16), 14.1 
(CH3, 1-OEt); HRMS(ESI) m/z calcd. for [C20H38O3+Na]
+
: 349.2719, obsd.: 
349.2713. 
 
Ethyl-(2R,3R)-3-hydroxy-2-tetradecyl-octanoate (12a). A 
solution of CuCN (13 mg, 0.14 mmol) in THF (0.3 mL) was 
cooled to -50 °C and BuLi (2M in cyclohexane, 0.14 mL, 0.28 
mmol) was added dropwise to the solution. The resulting 
reaction mixture was stirred for 30 min after which time the 
temperature increased to -20 °C. The reaction was then cooled to 
-50 °C and epoxide 7 (23 mg, 0.070 mmol) in THF (0.5 mL) was added. The reaction 
mixture was stirred for a further 2 h during which time the temperature increased to  
-20 °C, then quenched with NH4Cl, extracted with EtOAc (3 x 20 mL), and the 
combined organic layers were washed with water, brine, dried with MgSO4 and 
concentrated in vacuo. The resulting crude solid was purified using silica gel flash 
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column chromatography (eluting in 20:1, petroleum ether/EtOAc, v/v) to give the 
title compound as a white solid (19 mg, 0.050 mmol, 71%). Rf  = 0.41 (PE/EA, 5/1, 
v/v); [α]ᴅ20 =  8.0  (c = 1.0, CHCl3); IR (film) 2924, 2854, 1714, 754, 689 cm
-1 
; 
1
H 
NMR (500 MHz, CDCl3)  4.18 (q, J = 7.3 Hz, 2H, 3-CO2CH2), 3.72–3.61 (m, 1H, 
H-3), 2.51 (d, J3,OH = 8.5Hz, 1H, 3-OH), 2.41 (ddd, J2,3 = 9.1Hz, J1a',2 = J1b',2 = 5.1 
Hz, 1H, H-2), 1.72 (ddt, J1a',1b' = 13.2 Hz, J1a',2 =  J1a',2a' = J1a',2a' = 8.6 Hz, 1H, H-1a'), 
1.58 (ddt, J1a',1b' = 13.2 Hz, J1b',2 =  J1b',2a' = J1b',2a' = 8.2 Hz, 1H, H-1b'), 1.46 (m, 2H, 
H-4), 1.39–1.16 (m, 33H, H-5–H-7, H-2'–H-13', OCH2CH3), 0.88 (t, J7,8 = J13',14' = 
7.1 Hz, 6H, CH3-8 and 14'); 
13
C NMR (125 MHz, CDCl3)  175.9 (C-1), 72.3 (C-3), 
60.4 (CH2O, 1-OEt), 50.8 (C-2), 35.7 (C-4), 31.9, 31.7, 29.70, 29.69, 29.67, 29.63, 
29.57, 29.50, 29.44, 29.37, 27.36, 25.43, 22.7, 22.60 (C-5–C-7 and C-1'–C-13'), 14.3, 
14.1, 14.0 (C-8, C-14' and 1-OEt); HRMS(ESI) m/z calcd. for [C24H48O3+Na]
+
: 
407.3501, obsd.: 407.3508. 
 
 
(2R,3R)-3-Tert-butyldimethylsilyloxy-2-tetradecyl-octanoic 
acid (5). A solution of corynomycolic ester 12a (15 mg, 0.039 
mmol) in THF:MeOH:H2O (12:2:1, 2 mL) was treated with 
LiOH.H2O (54 mg, 1.28 mmol) and the resulting reaction 
mixture was heated at 45 °C overnight (18 h) after which time it 
was acidified with 1M HCl (pH = 3) and diluted with EtOAc (10 
mL). The organic layer was washed with water, brine, dried with MgSO4 and 
concentrated in vacuo. This gave corynomycolic acid 14 in quantitative yield, which 
was used without further purification.   
TBSOTf (0.09 mL, 0.39 mmol) and 2,6-lutidine (0.07 mL, 0.59 mmol) was added to 
a solution of corynomycolic acid 14 (14 mg, 0.039 mmol) in CH2Cl2 (1 mL) and the 
reaction was stirred at r.t. for 90 min after which time complete conversion of the 
starting material to the bis-silyl product was observed. The solvent was then removed 
in vacuo and the residue diluted with EtOAc (10 mL), washed with 0.1 M HCl (3 x 
10 mL), water (10 mL), brine (10 mL), dried with MgSO4 and filtered. Following 
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removal of the solvent in vacuo, the crude product was then dissolved in CH2Cl2 and 
treated with 10% K2CO3 in water (0.05 mL). The reaction mixture was stirred at r.t. 
for 1 h after which time it was neutralised with 1 M HCl (pH = 3) and extracted with 
EtOAc (3 x 20 mL). The combined organic layer was washed with water, brine, dried 
with MgSO4 and concentrated in vacuo. The title compound was obtained after silica 
gel flash column chromatography (eluting in 50:1, petroleum ether/EtOAc, v/v) to 
give the title compound as a pale yellow oil (16.4 mg, 0.035 mmol, 89% over 2 
steps). Rf  = 0.38 (PE/EA, 10/1, v/v); [α]ᴅ
17 
=  20.0  (c =0.1, CHCl3); IR (film) 2924, 
2854, 1708, 1254, 774 cm
-1
; 
1
H NMR (500 MHz, CDCl3)  3.82 (dt, J2,3 = J3,4a = J3,4b 
= 7.3 Hz, 1H, H-3), 2.56–2.46 (m, 1H, H-2), 1.72 (ddt, J1a',1b' = 14.0 Hz, J1a',2 = J1a',2a' 
= J1a',2b' = 6.7 Hz, 1H, H-1a'), 1.59 (ddt, J4a,4b = 13.5 Hz, J3,4a = J4a,5 =  6.6 Hz, 1H, H-
4a), 1.57 (ddt, J4a,4b = 13.5 Hz, J3,4b = J4b,5 = 6.6 Hz, 1H, H-4b), 1.51 (ddt, J1a',1b' = 
14.0 Hz, J1b',2 = J1b',2a' = J1b',2b' = 6.7 Hz, 1H, H-1b'), 1.34–1.26 (m, 33H, H-5–H-7, H-
2'–H-13', OCH2CH3), 0.92 (s, 9H, Si(CH3)3), 0.87 (t, J7,8 = J13',14' = 7.1 Hz, 6H, CH3-
8 and 14'), 0.14 (s, 3H, Si(CH3)), 0.13 (s, 3H, Si(CH3); 
13
C NMR (125 MHz, CDCl3) 
 175.8 (C-1), 73.6 (C-3), 50.2 (C-2), 35.5 (C-4), 31.9, 31.8, 29.8, 29.70, 29.69, 
29.66, 29.63, 29.55, 29.45, 29.40, 29.41, 29.37, 27.44, 25.85, 24.64, 22.70, 22.51 (C-
5–C-7 and C-1'–C-13'), 25.72 (SiC(CH3)3), 17.9 (SiC(CH3)3), 14.1, 14.0 (C-8 and C-
14'), -4.3, -4.9 (SiCH3); HRMS(ESI) m/z calcd. for [C28H58O3Si+Na]
+
: 493.4047, 
obsd.: 493.4059. 
 
                                                                2,2',3,3',4,4'-Hexa-
O-trimethylsilyl-6-O-[(2R,3R)-3-tert-
butyldimethylsilyloxy-2-tetradecyl-octanoyl]-
α,α'-D-trehalose (15). To a solution of TMS 
trehalose 4 (4.0 mg, 0.005 mmol) and protected 
corynomycolic acid 5 (10.3 mg, 0.022 mmol) in toluene (1.5 mL), EDCI (6.0 mg, 
0.033 mmol) and DMAP (1.0 mg, 0.008 mmol) were added and the reaction was 
stirred at 70 °C overnight after which time the resulting precipitate was filtered off 
and washed with EtOAc (3 x 10 mL). The combined organic layers were washed 
with water (10 mL), brine (10 mL) and concentrated in vacuo. Silica gel flash 
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chromatography of the crude product resulted in protected TMCM 15, (eluting in 
30:1 (v/v) Pet. Ether/EtOAc), as a colourless oil (1.84 mg, 0.015 mmol, 30%). Rf = 
0.53 (PE/EA, 5/1, v/v); [α]18D = +60 (c = 0.05, CHCl3); IR (film): 3627, 3019, 2959, 
1721, 1463, 1278, 1070 cm
-1
;
 1
H NMR (500 MHz, CDCl3)  4.90 (d, J1,2/1',2' = 3.0 Hz, 
1H, H-1/1'), 4.83 (d, J1,2/1',2' = 3.0 Hz, 1H, H-1/1'), 4.59 (dd, J6a,6b = 11.6 Hz, J5,6a = 
2.3 Hz, 2H, H-6a), 4.33 (dd, J6a,6b = 11.6 Hz, J5,6b = 4.1 Hz, 2H, H-6b), 3.97 (ddd, J4,5 
= 9.0 Hz, J5,6a = 2.3 Hz, J5,6b = 4.1 Hz, 1H, H-5), 3.93 (dt, J2'',3'' = J3'',4'' = 6.0 Hz, 1H, 
H-3''), 3.88 (dd, J2,3/2',3' = J3,4/3',4' = 9.0 Hz, 1H, H-3), 3.84–3.82 (m, 1H, H-5'), 3.72–
3.65 (m, 2H, H-6a' and 6b'), 3.47 (dd, J3,4/3',4' = J4,5/4',5' = 9.0 Hz, 2H, H-4 and 4'), 3.42 
(dd, J1,2/1',2' = 3.0 Hz, J2,3/2',3' = 9.0 Hz, 1H, H-2/2'), 3.38 (dd, J1,2/1',2' = 3.0 Hz, J2,3/2',3' = 
9.0 Hz, 1H, H-2/2'), 2.55 (ddd, J2'',3'' = 9.4 Hz, J1a''',2'' = J1b''',2'' = 4.8 Hz, 1H, H-2''), 
1.72 (dt, J3'',4'' = J4'',5'' = 5.3 Hz, 2H, H-4''), 1.60–1.52 (m, 2H, H-1'''), 1.33–1.26 (m, 
30H, H-5''–H-7'', H-2'''–H-13'''), 0.93 (s, 9H, Si(CH3)3), 0.167, 0.154, 0.149, 0.120, 
0.059 (6 s, 60H, CH3, TMS and TBS); 
13
C NMR (125 MHz, CDCl3) 174.1 (C-1''), 
94.5 (C-1/1'), 94.4 (C-1/1'), 73.40 (C-3/3'), 73.39 (C-3/3'), 72.72 (C-3''), 72.83 (C-5'), 
72.76 (C-2/2'), 72.72 (C-2/2'), 71.9 (C-4/4'), 71.4 (C-4/4'), 70.7 (C-5), 62.42 (C-6), 
61.65 (C-6'), 51.8 (C-2''), 33.30, 31.92, 31.43, 31.00, 30.17, 29.79, 29.70, 29.67, 
29.53, 29.38, 28.12, 26.94, 26.30, 25.81, 24.50, 22.70, 22.63, 22.06 (C-4''–C-7'' and 
C-1'''–C-13''') 25.81 (SiC(CH3)3), 18.0 (SiC(CH3)3), 14.14, 14.04 (C-8'' and C-14'''), 
1.05, 1.01, 0.92, 0.86, 0.17, 0.04 (SiCH3, TMS), -4.3, -4.9 (SiCH3, TBS); HRMS 
(ESI) m/z calcd. for [C58H126O13Si7+Na]
+
: 1249.7476, obsd.: 1249.7482. 
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6.1 Introduction 
To understand more about the manner in which trehalose dimycolates (TDMs) 
interact with cells of the immune system, we developed the Affinity Based Proteome 
(AfBP) probe 1, which is structurally similar to the parent TDMs whilst also 
containing a benzophenone trap and an alkyne tag group. This particular trap and tag 
system has been chosen due to its small size and hydrophobic character and thus its 
ability to best mimic the TDM lipid. Our probe has been developed so as to leave the 
bioactive carbohydrate portion of the TDM unfunctionalised. 
Previous studies have shown that TDM, as well as its simpler synthetic analogue 
trehalose dibehenate (TDB), binds to macrophage inducible C-type lectin (Mincle) in 
order to induce an immune response,
1,2
 however, to date no other receptors for TDMs 
have been determined. Accordingly, by synthesising probe 1 and using it for Affinity 
Based Proteome Profiling (AfBPP), other proteins that TDMs bind to may be 
identified. The focus of this chapter is the synthesis of AfBP probe 1. The probe 
AfBP Probe Synthesis 
and Biological Testing 6 
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binding and protein identification studies will be performed by our collaborator Dr. 
Faustin Kamena at a later date.   
 
Figure 1. Proposed AfBP Probe 1  
 
6.2 TDM Probe Synthesis 
For the synthesis of probe 1, a convergent strategy was planned whereby the two 
intermediates, TMS mono-trehalose ester 2 and carboxylic acid 3 would be coupled 
followed by deprotection to obtain the final compound (Scheme 1). The TMS mono-
trehalose ester 2 could be obtained through esterification of diol 4 with behenic acid 
(5). Compound 4, in turn, could be synthesised via a one-pot two-step silylation 
process starting with commercially available α,α-D-trehalose.3 To prepare the trap 
and tag, carboxylic acid 3 could be accessed via the alkylation of benzophenone 6 
with iodide 7, with compound 6 prepared in five steps from commercially available 
terephthalic acid (8) and iodide 7 synthesised in five steps from 1,4-butanediol (9).     
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Scheme 1. Retrosynthesis of target AfBP probe 1 
 
To prepare benzophenone 6, terephthalic acid 8 was first converted to dimethyl ester 
10 via reaction with thionyl chloride and MeOH (Scheme 2). Hydrolysis of one of 
the methyl ester groups using potassium hydroxide (1.1 equiv.) gave monoacid 11 in 
good (87%) yield over two steps.
4
 Acid 11 was then converted to acid chloride 12 by 
reacting it with SOCl2. Due to the instability of acid chloride 12, it was immediately 
subjected to Friedel-Crafts acylation with anisole in the presence of aluminium 
chloride in an attempt to form the para-substituted benzophenone compound 13. The 
literature procedure involved addition of AlCl3 in one portion and in our hand, this 
led to a yield of only 40% which was comparable to the reported yield of 42%.
5
 The 
yield of the product could be significantly increased to 70% by portion-wise addition 
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of AlCl3 during the course of the reaction. About 5% of the expected ortho-
substituted product was also formed which was inseparable from the para-substituted 
product. However, the para- and ortho-substituted products could be separated after 
demethylation of benzophenone 13 (vide infra). The major product was identified as 
para- substituted benzophenone 13 based on the proton, COSY, and HMBC spectral 
analysis. The four protons of the anisole moiety in the para-product are in two 
different chemical environments, and as expected only two distinguished resonances 
were observed for them, as opposed to four resonances which would be expected for 
the ortho-substituted product.  
 
 
Scheme 2. Synthesis of benzophenone 6  
 
Having successfully prepared benzophenone ester 13, the next step in our strategy 
was demethylation to generate the target benzophenone 6, ready for coupling to the 
alkynyl iodide 7. To this end, benzophenone 13 was treated with trimethylsilyl iodide 
(1.1 equiv.),
6
 however, despite several attempts this strategy did not eventuate in 
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product formation and only starting material was recovered from the reaction. Use of 
boron trichloride (4 equiv.) was also not successful with starting material retrieved 
from the reaction.  Next, AlCl3 (4 equiv.) was used, according to the more recent 
procedure of Hartmann and co-workers.
7
 This resulted in c.a. 30% of the desired 
product along with unreacted starting material. Fortunately, by increasing the amount 
of AlCl3 (6 equiv.), and adding it in two portions during the reaction, greatly 
enhanced the yield, with benzophenone ester 6 obtained in good (85%) yield. The 
1
H 
NMR spectra of compound 6 (Figure 2), showed one singlet at  3.98 ppm as 
compared to the two singlets at  3.98 and  3.91 ppm for the methyl ester precursor 
13. 
13
C NMR spectral analysis showed a downfield shift of 3.6 ppm for the aromatic 
carbon attached to the hydroxyl group in compound 6 when compared to the same 
carbon in 13. A shift of 1.5 ppm for the adjacent aromatic carbons also provided 
evidence that demethylation occurred. The chemical shifts of the other carbons in 
compounds 6 and 13 were within 0.5 ppm of each other. Mass spectral analysis of 
the product was in agreement of the expected mass, [HRMS calcd. for 
[C15H12O4+Na]
+
: 279.0626, obsd.: 279.0633] and full assignment was made on the 
basis of 2D NMR (COSY, HSQC and HMBC) (see experimental for full 
assignment).  
 
Figure 2. 
1
H NMR spectrum of benzophenone 6  
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To prepare the iodide 7, a convergent synthetic strategy was proposed (Scheme 3). 
First, bromo-hexadecane (14) was reacted with sodium acetylide in order to form 1-
octadecyne (15). The concentration of the reaction mixture proved critical in 
obtaining optimal yields for this reaction, with the use of either THF or DMF at 5 
mL/mmol resulting in no product formation and starting material being recovered 
from the reaction mixture. However, when the reaction was carried out in DMF at  
1.1 mL/mmol,
8
 98% yield of alkyne 15 was achieved. The other key intermediate 
required for the synthesis of iodide 7 was the THP-protected bromide 16. To this 
end, 1,4-butanediol (9) was reacted with hydrogen bromide under Dean-Stark 
conditions to form corresponding mono-substituted bromide.
9
 Though this reaction 
was low yielding (c.a. 40%) the amount of product obtained was comparable to 
literature when either toluene or benzene was used as a solvent. As TLC of the 
reaction mixture showed complete consumption of the starting material, one possible 
reason for this low yield could be due to further reaction of the mono-substituted 
bromide with HBr resulting in formation of THF, which could have been lost during 
work-up and subsequent removal of the solvent in vacuo. Treatment of the desired 
mono-brominated intermediate with 3,4-dihydropyran and pyridinium para-
toluenesulfonate (PPTS), resulted in formation of tetrahydropyran (THP) ether 16 in 
excellent (97%) yield.
10
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Scheme 3. Synthesis of iodide 7 
 
With the required THP ether 16 in hand, a BuLi-mediated alkylation with octadecyne 
15 was then attempted. This proceeded smoothly with alkyne 17 being formed in a 
high (83%) yield. Subsequent removal of the THP protecting group in 17 using para-
toluenesulfonic acid (PTSA) resulted in alcohol 18, which was then isomerised by 
way of a zipper reaction to form alcohol 19.   
The mechanism of the zipper reaction can be explained by a series of allene/alkyne 
interconversions (Scheme 4).
11
 The first step in the process involves reacting a strong 
base (e.g. NaH) with diaminopropane to form sodium 3-propylamide (I), which 
subsequently deprotonates the hydroxyl moiety in alcohol II. This deprotonation is 
followed by a concerted mechanism whereby the distal carbon adjacent to the alkyne 
is deprotonated, and allene III is formed. The reaction then goes through a series of 
allene/alkyne interconversions all of which are in equilibrium. The final product is 
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trapped as a very stable alkyne anion (IV) which is protonated in the work-up to 
form the terminal alkyne product (V). The stability of alkyne anion IV is attributed to 
the presence of the two negative charges on opposite end of the molecule, 
minimising charge repulsion and thus enhancing the stability of the anion. 
 
Scheme 4. Zipper reaction for isomerisation of triple bonds  
 
Comparison of the 
1
H NMR spectral data for alcohol 18 and 19 clearly illustrates the 
migration of the triple bond (Figure 3). In the 
1
H NMR spectrum for alcohol 18, 
characteristic peaks include triplets at 3.68 ppm (J = 6.4 Hz) for H-1 and at 0.89 ppm 
(J = 7.0 Hz) for H-22 and the two resonances at 2.20 ppm (tt, J = 7.1 Hz, 
5
J = 2.2 Hz) 
and 2.14 ppm (tt, J = 6.9 Hz, 
5
J = 2.2 Hz) for H-4 and H-7 corresponding to the two 
methyl protons flanking the triple bond. In the spectrum for alcohol 19, however, 
isomerisation of the triple bond is clearly evident by the presence of a triplet at 1.94 
ppm (
4
J = 2.6 Hz) accounting for the terminal alkyne proton and the absence of the 
peak at approximately 0.89 ppm, (correlating to H-22 in 18). To complete the 
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synthesis of target iodide 7, alcohol 19 was then treated with iodine, 
triphenylphosphine, and imidazole to give 7 in 70% yield. 
 
A 
 
B 
Figure 3. 
1
H NMR spectra of compounds 18 and 19 
 
H-20 H-22 
H-2 H-3 H-8 
 
 
H-1 
H-4 H-7 
H-22 
H-1 
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Having prepared iodide 7, coupling with benzophenone 6 was then attempted (Table 
1). First, sodium hydride (1.1 equiv.) was used as a base and the reaction was carried 
out in toluene (entry 1). Unfortunately, this only gave 10% of the alkylated product 
20, with mainly starting material being obtained from the reaction mixture. 
Increasing the amount of NaH (2.2 equiv.) did not lead to any significant 
improvement in the yield (entry 2) and in addition, degradation of the alkyl iodide 7 
was observed. Use of K2CO3 along with 18-crown-6 ether also did not lead to any 
significant increase in yield (entry 3), however with caesium carbonate a small 
increase in product yield was achieved (entry 4). It was thought that one of the 
reasons for this low yield could be the low solubility of compound 6 in toluene, 
therefore the solvent system was changed to toluene:DMF (1:1) (entry 5). Indeed this 
led to an increased yield (24%), though as the result was still modest we turned our 
attention to the use of a lipid containing a different leaving group.  
 
Table 1. Alkylation conditions for coupling benzophenone 6 and iodide 7 
 
 
 
Entry Conditions Product yield (%) 
1 NaH (1.1 equiv.), toluene, r.t. 10 
2 NaH (2.2 equiv.), toluene, r.t to 70 °C 12 
3 K2CO3 (1.1 equiv.), 18-crown-6, toluene, 70 °C 12 
4 CsCO3 (1.1 equiv.), 18-crown-6, toluene, 70 °C 16 
5 CsCO3 (1.1 equiv.), 18-crown-6, DMF:toluene 1:1, 50 °C 24 
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It was proposed that a triflate group, a good leaving group, would make the adjacent 
carbon electrophile ‘hard’ which is desired in this instance since in O-alkylation the 
nucleophile is an oxygen atom which is a ‘hard’ nucleophile. Accordingly, alcohol 
19 was reacted with triflic anhydride and pyridine, with TLC analysis of the reaction 
mixture after 45 minutes indicating complete consumption of starting material. 
Unfortunately, the triflate product could not be purified with hydrolysis of the 
product to alcohol 19 observed after silica gel column chromatography. At this point 
the tosylate leaving group was chosen, as in addition to being a good leaving group, 
it is more stable than the triflate group. Thus alcohol 19 was reacted with tosyl 
chloride and pyridine
12
 providing tosylate 21 in 97% yield (Scheme 5). Tosylate 21 
was then subjected to alkylation with benzophenone 6 in the presence of NaH (1.1 
equiv.). This resulted in slightly improved but still modest 30% yield of the alkylated 
product 20. However, a change of base to CsCO3 (1.1 equiv.), along with the addition 
of 18-crown-6 ether, resulted in good (64%) product yield, which was deemed 
sufficient to continue on with the synthesis. Subsequent hydrolysis of the methyl 
ester in product 20 with LiOH, led to carboxylic acid 3 in good (80%) yield. Here, it 
should be noted that the hydrolysis was performed under reflux to ensure complete 
solubilisation of the starting material. In addition, the reaction needed to be stopped 
following complete consumption of the starting material to prevent product 
degradation.  
 
Scheme 5. Synthesis of benzophenone building block 3  
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With the synthesis of the benzophenone building block 3 established, our focus then 
turned to the synthesis of the trehalose building block 2. Using a protocol previously 
discussed (see Chapter 2), commercially available α,α-D-trehalose was per-silylated 
using N,O-bis-trimethylsilylacetamide (BSA) and catalytic tetra-butyl ammonium 
fluoride (TBAF), and the more labile primary trimethylsilyl (TMS) ethers were then 
selectively removed via the addition of K2CO3 to give the trehalose diol 4 (Scheme 
6). Esterification of diol 4 with behenic acid 5 (obtained from Jones oxidation of 1-
docosanol), via the mediation of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
(EDCI) and 4-dimethylamino-pyridine (DMAP) led to the mono-trehalose ester 2 in 
75% yield. Compound 2 was then subjected to a second esterification, this time using 
benzophenone 3. Here, it was interesting to note that this coupling was quite slow 
with the reaction only occurring when the mixture was refluxed in toluene over seven 
days. Even then, only a modest (30%) yield of the protected probe 22 was obtained, 
which was then subjected to Dowex-H
+ 
in order to liberate target AfBP 1 in 
quantitative yield. 
181 
 
 
Scheme 6. Total synthesis of AfBP probe 1   
 
 
α,α-D-trehalose 
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The 
1
H NMR spectrum of AfBP probe 1 clearly displayed all the required resonances 
(Figure 4). The key peaks in this instance are the two anomeric signals which were 
present as doublets at 5.84 (d, J = 3.6 Hz) and 5.83 ppm (d, J = 3.6 Hz) indicative of 
the asymmetrical nature of the trehalose moiety. The presence of the aromatic 
resonances for the benzophenone protons are clearly evident as doublets at 8.20 (J = 
8.2 Hz), 7.86 (J = 8.8 Hz), 7.68 (J = 8.2 Hz) and 7.06 ppm (J = 8.8 Hz). The terminal 
alkyne proton had a triplet resonance at 2.68 ppm (
4
J = 2.7 Hz) with the ether protons 
present as a triplet at 3.96 ppm (J = 6.3 Hz). Mass spectral analysis of the product 
was in agreement with the expected mass, [HRMS(ESI) m/z calcd. for 
[C70H112O15+Na]
+
:1215.7893, obsd.:1215.7897] and full assignment was made on 
the basis of 2D NMR (COSY, HSQC and HMBC) (see experimental for full 
assignment). The NMR analysis was carried out using deuterated pyridine as the 
solvent due to the amphiphilic nature of the molecule which made solubilisation of 
the compound difficult in any other solvent system.  
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Figure 4. 
1
H NMR spectrum of AfBP probe 1 
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Figure 5. 
13
C NMR spectrum of AfBP probe 1 
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6.3 Biological Testing 
With AfBP probe 1 in hand, the ability of the probe to activate bone marrow 
macrophages (BMM) was investigated. To this end, bone marrow cells were isolated 
from mice and plated out in 24 well plate at 2.5 x 10
5
 cell/mL to a total of 1 mL in 
each well and differentiated into macrophages over 10 days (see experimental section 
for more details). The macrophages were primed with 10 ng/mL IFN-γ for 3 hours 
after which time they were stimulated with probe 1 or C22 trehalose diester (C22 
TDE) at 20 μg/mL and 40 μg/mL. LPS was used as a positive control in the 
experiments. The supernatants were analysed after 96 hours for nitric oxide (NO) 
production (Figure 6). As seen, the probe did activate macrophages in a 
concentration dependent manner. Although the activation by probe 1 was lower than 
that by the C22 TDE, it was still significant (p = 0.005 at 40 μg/mL). 
The reduced activity of probe 1 when compared to C22 TDE could be due to the 
presence of the benzophenone group next to the trehalose sugar unit in the probe. 
Since it is already known that Mincle is a carbohydrate recognising receptor, the 
presence of the benzophenone group next to trehalose could hinder the binding of the 
probe to this receptor on macrophages. However, probe 1 needs to be tested in 
proteome profiling experiments to deduce its potential as an AfBP probe. 
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Figure 6. NO production by BMM treated with AfBP probe 1. BMM were 
stimulated with 20 or 40 μg/mL of probe 1 or C22 TDE or with LPS (100 ng/mL). At 
96 h the supernatants were analysed for NO using Griess assay.   
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6.4 Future Work  
With the initial macrophage assay completed, the next step is to test the probe in 
proteome profiling experiments in order to deduce its usefulness for identifying 
proteins that trehalose glycolipids bind to. These experiments will be done in vitro, 
whereby BMM will be stimulated using probe 1, followed by light mediated 
attachment of probe 1 to the protein/s it interacts with on macrophages (Figure 7). 
The alkyne functionality would be subjected to a click reaction with an azide linked 
biotin molecule. Following this, the probe-protein-azide-biotin complex would 
undergo streptavidin enrichment, trypsin digestion, and analysis with liquid 
chromatography/mass spectrometry (LC/MS) and sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) analysis in order to elucidate the 
identity of the linked proteins. 
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Figure 7. AfBP probe 1 in Affinity Based Profiling 
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6.5 Conclusion 
The synthesis of an affinity based probe has been achieved using a convergent 
synthetic strategy in an overall 1.4% yield. The key steps in the synthesis included a 
Friedel-Crafts acylation for the formation of the benzophenone building group, and a 
zipper reaction for formation of the terminal alkyne functionality. Final coupling was 
achieved by way of an EDCI, DMAP-mediated esterification of the C22 trehalose 
mono-ester with the benzophenone based carboxylic acid. The probe was able to 
activate BMM albeit at lower levels than the C22 trehalose diester.   
 
 
6.6 Experimental  
6.6.1 Material and methods for Biological Assays 
C57BL/6 male mice were bred and housed in a conventional animal facility at the 
Malaghan Institute of Medical Research, Wellington, New Zealand. All animals used 
for the experiments were aged between 8-10 weeks. All experimental procedures 
were approved by the Victoria University Animal Ethics Committee in accordance 
with their guidelines for the care of animals. Synthesised TDEs were tested to be 
endotoxin-free (≤0.125 EU/mL) with an endotoxin kit (Pyrotell, Limulus Amebocyte 
Lysate). 
 
Generation of bone marrow derived macrophages (BMMs): Bone marrow cells 
were collected from the tibia and femur of C57BL/6 mice and were cultured (250 
000 cells/mL) in Iscove’s Modified Dulbecco’s Media (IMDM-Gibco) supplemented 
with 5% FBS (Gibco), 1% Penicillin streptomycin (Gibco) and 55 μM 2-
mercaptoethanol (Invitrogen) containing 10 ng/mL GM-CSF (clone X63/GM-CSF 
murine cells). Cells were incubated at 37 °C (5% CO2) and the media changed on 
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days 2, 5 and 7. On day 10, the media was removed and the BMM were primed with 
10ng/mL IFN-γ (Peprotech) for 3 h prior to the addition of the compounds. 
 
BMM Assay: C22 TDE and AfBP probe 1 stock solutions were prepared (2.5 
mg/mL in PBS containing 2% DMSO), vortexed and warmed to 50 °C for 30 min (x 
3) to ensure complete solubilisation of the compounds prior to administration to 
BMM cultures. BMM cultures were then treated with 20 or 40 μg/mL of C22 TDE, 
or TDM probe 1 with LPS (100 ng/mL) as a positive control and media only as a 
negative control for the times indicated. Supernatants were collected and tested 
immediately for NO levels. 
NO analysis: NO levels in supernatants were determined using the Griess assay.  
 
6.6.2 Chemistry Experimental 
Unless stated otherwise, all reactions were performed under N2. Prior to use, THF 
was distilled from Na wire and benzophenone, pyridine was dried and stored over 4 
Å molecular sieves (4 Å MS), toluene was dried and stored over Na wire and  
CH2Cl2 was distilled from P2O5. Terephthalic acid (BDH), thionyl chloride (Acros), 
KOH (Science), 33% HCl (Panreac), H2SO4 (Panreac) AlCl3 (Sigma-Aldrich), 
sodium acetylide (Aldrich, 18% in xylene), bromohexadecane (BDH), 1,4-butanediol 
(BDH), HBr (Acros), PPTS (Aldrich), dihydropyran (Pfaltz and Bauer), n-BuLi 
(Aldrich, 2M solution in hexanes), PTSA (Sigma-Aldrich), diaminopropane 
(Aldrich), tosyl chloride (Aldrich), 18-crown-6 ether (Sigma-Aldrich), CrO3 (M&B), 
NaH (Avocado Research Chemicals, 60% dispersion in mineral oil), D-(+)-trehalose 
dihydrate (Sigma), TBAF (Aldrich), BSA (Fluka), Dowex-H
+
 (Supelco), 1-
docosanol (Aldrich), EDCI (Aldrich), DMAP (Merck), anhydrous DMF (Acros), 
anhydrous Et2O (Biolab), EtOAc (Panreac), petroleum ether (Pure Science), CHCl3 
(Panreac), anhydrous MeOH (Panreac), isopropanol (Pure Science), NaHCO3 (Pure 
Science), K2CO3 (Pure Science), MgSO4  (Pure Science) and NaCl (Panreac) were 
used as received.   
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All solvents were removed via evaporation at reduced pressure. Reactions were 
monitored by TLC analysis on Macherey-Nagel silica gel coated plastic sheets (0.20 
mm, Polygram SIL G/UV254) with detection by UV-absorption (short wave UV–
254 nm; long wave UV–366 nm); coating with a solution of 5% KMnO4 and 1% 
NaIO4 in H2O followed by heating or by dipping in 10% H2SO4 in EtOH followed by 
charring at ~150 °C. Column chromatography was performed using Pure Science 
silica gel (40-63 μm). High resolution mass spectra were recorded on a Waters Q-
TOF Premier
TM 
Tandem Mass Spectrometer using positive electro-spray ionisation. 
Optical rotations were recorded on a Perkin-Elmer 241 polarimeter or Autopol II 
(Rudolph Research Analytical) at 589 nm (sodium D-line). Infrared spectra were 
recorded as thin films using a Brüker Tensor 27 FTIR spectrometer equipped with an 
Attenuated Total Reflectance (ATR) sampling accessory and are reported in wave 
numbers (cm
-1
). Nuclear magnetic resonance spectra were recorded at 20
 
°C in 
CDCl3  or  C5D5N using a Varian INOVA operating at 500 MHz. Chemical shifts are 
given in ppm (δ) relative to residual solvent peak. NMR peak assignments were 
made using COSY, HSQC and HMBC 2D experiments. 
 
 Monomethyl terephthalate (11). A solution of terephthalic 
acid (8) (10 g, 60.2 mmol) in MeOH (250 mL) was refluxed for 
30 min after which time SOCl2 (87.2 mL, 1.20 mol) was added 
and the reaction mixture was refluxed for a further 10 h. The reaction mixture was 
then cooled and the solvent removed in vacuo. The product was extracted with Et2O 
(3 x 200 mL) and washed with saturated NaHCO3 (3 x 60 mL) solution. The 
combined organic layers were dried with MgSO4 and concentrated in vacuo to yield 
dimethyl terephthalate (10) as white solid (quant.) and it was used in subsequent 
reaction without further purification.  
Dimethyl terephthalate (10) (9.77 g, 50.2 mmol) was dissolved in MeOH (165 mL) 
and the reaction mixture was refluxed for 30 min after which time it was cooled to 
r.t. followed by KOH addition (3.11 g, 55.4 mmol). The reaction was then heated at 
reflux overnight after which time the mixture was cooled and the solvent removed in 
vacuo. The resulting crude product was dissolved in water and washed with CH2Cl2 
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(3 x 100 mL). The aqueous layer was then neutralised with concentrated 1M HCl and 
the precipitate was extracted with Et2O, dried with MgSO4, and concentrated to yield 
the title compound as a white solid (7.86 g, 43.7 mmol, 87% over two steps). The 
spectral data obtained matched that reported in literature.
4
 
 
Methyl 4–(4-methoxybenzoyl)-benzoate (13). SOCl2 
(3.92 mL, 53.9 mmol) was added to acid 11 (2.44 g, 13.9 
mmol) and the reaction mixture was refluxed until a 
clear solution had formed (c.a. 4 h). The solvent was reduced in vacuo (under 
nitrogen), and the resulting acid chloride 12 (2.76 g, 13.9 mmol) was dissolved in 
CHCl3 (71 mL) and anisole (1.51 mL, 13.9 mmol) and AlCl3 (1.85 g, 13.9 mmol) 
were added. The reaction mixture was then refluxed for 10 h, after which time 
another portion of AlCl3 (1.85 g, 13.9 mmol) was added and the mixture refluxed for 
a further 10 h. Following this, the solution was cooled, quenched with H2O (100 
mL), and extracted with EtOAc (3 x 80 mL). The combined organic layers were 
washed with brine (50 mL), dried over MgSO4, and the solvent removed in vacuo to 
yield the crude product. The title compound was obtained after silica gel flash 
chromatography (eluting in 20:1, Pet. Ether/EtOAc, v/v) as a white solid (2.60 g, 
9.62 mmol, 70%).; Rf = 0.76 (EtOAc); IR (film): 2944, 2832, 1448, 1022, 737 cm
-1
; 
1
H NMR (500 MHz, CDCl3)  8.15 (d, J2,3 = 8.5 Hz, 2H, H-2), 7.83 (d, J7,8 = 8.7 Hz, 
2H, H-7), 7.79 (d, J2,3 = 8.5 Hz, 2H, H-3), 6.98 (d, J7,8 = 8.7 Hz, 2H, H-8), 3.98 (s, 
3H, CO2Me), 3.91 (s, 3H, OMe); 
13
C NMR (125 MHz, CDCl3)  194.8 (C-5), 166.4 
(CO2Me), 163.6 (C-9), 142.2 (C-4), 132.8 (C-1), 132.6 (C-7), 129.6 (C-6), 129.4 (C-
2 and C-3), 113.8 (C-8), 55.6 (-OCH3), 52.4 (CO2Me); HRMS(ESI) m/z calcd. for 
[C16H14O4+Na]
+
: 293.0790, obsd.: 293.0790. 
  
 
Methyl 4–(4-hydroxybenzoyl)-benzoate (6). AlCl3 
(1.46 g, 11.0 mmol) was added to a solution of 
benzophenone 13 (0.99 g, 3.66 mmol) in toluene (15 mL) 
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and the reaction mixture was stirred at r.t. for 30 min followed by 30 min at reflux. 
The reaction was then cooled to r.t., followed by further addition of AlCl3 ((1.46 g, 
11.0 mmol) and 30 min at reflux. The reaction mixture was then poured into 1:1 
ice/H2O mixture, stirred for a further 30 min and extracted with EtOAc (3 x 50 mL). 
The combined organic layers were washed with brine, dried (MgSO4), and 
concentrated in vacuo. The title compound was obtained after silica gel flash 
chromatography (eluting in 10:1, Pet. Ether/EtOAc, v/v) as a white solid (0.80 g, 
3.13 mmol, 85%). Rf = 0.24 (2/1, PE/EA, v/v); IR (film): 3317, 2944, 2832, 1448, 
1022, 741 cm
-1
; 
1
H NMR (500 MHz, CDCl3)  8.15 (d, J2,3 = 8.3 Hz, 2H, H-2), 7.79 
(d, J2,3 = 8.3 Hz, 2H, H-3), 7.79 (d, J7,8 = 8.5 Hz, 2H, H-7), 6.93 (d, J7,8 = 8.5 Hz, 2H, 
H-8), 3.98 (s, 3H, CO2Me); 
13
C NMR (125 MHz, CDCl3)  194.8 (C-5), 166.4 
(CO2Me), 160.0 (C-9), 142.0 (C-4), 133.0 (C-7), 132.8 (C-1), 129.8 (C-6), 129.47 
(C-2), 129.46 (C-3), 115.3 (C-8), 52.4 (CO2Me); HRMS(ESI) m/z calcd. for 
[C15H12O4+Na]
+
: 279.0626, obsd.: 279.0633. 
 
2-(4-Bromobutyloxyl)-tetrahydropyran (16). To a solution 
of 1,4-butanediol (4.46 mL, 50.3 mmol) in toluene (70 mL) 
was added a 48% HBr solution (6.25 mL, 55.2 mmol) and 
the reaction mixture was refluxed using a Dean-Stark apparatus, until all the starting 
material had been consumed (as determined from TLC analysis). The solution was 
then cooled, extracted with CH2Cl2 (3 x 60 mL), washed with water, dried with 
MgSO4, and the solvent removed in vacuo to yield 4-bromo-1-butanol (3.06 g, 20.1 
mmol, 40%), which was used in the consecutive reaction without further purification. 
To a solution of 4-bromo-1-butanol (2.0 g, 13.0 mmol) in CH2Cl2 (30 mL) was added 
pyridinium para-toluenesulfonate (PPTS) (0.65 g, 2.61 mmol) and 3,4-dihydropyran 
(2.77 mL, 30.4 mmol) and the reaction was stirred at r.t. overnight. The reaction 
mixture was then quenched with H2O (20 mL) and extracted with EtOAc (3 x 40 
mL). The combined organic layers were washed with brine (30 mL), dried with 
MgSO4, and the solvent reduced in vacuo. The title compound was obtained after 
silica gel flash chromatography (eluting in 50:1, Pet. Ether/EtOAc, v/v) as a white 
solid (3.03 g, 12.7 mmol, 97%). Rf = 0.83 (1/1, PE/EA, v/v); IR (film): 2940, 2860, 
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1133, 1075, 904, 668 cm
-1
; 
1
H NMR (500 MHz, CDCl3)  4.57 (t, J5,6a = J5,6b = 2.5 
Hz, 1H, H-5), 3.84 (ddd, J9a,9b = 11.0 Hz,  J8a,9a = J8b,9a = 2.4 Hz, 1H, H-9a), 3.76 (dt, 
J1a,1b = 9.8 Hz, J1a,2a  = J1a, 2b  = 6.6 Hz, H-1a), 3.52–3.48 (m, 1H, H-9b), 3.45 (t, J3,4 = 
7.1 Hz, 2H, H-4), 3.41 (dt, J1a,1b = 9.8 Hz, J1b,2a  = J1b,2b = 6.1 Hz, 1H, H-1b), 1.97 
(pentet, Jα,β = Jβ,γ = 7.1 Hz, 2H, H-3), 1.83–1.78 (m, 1H, H-7a), 1.76–1.71 (m, 1H, H-
2), 1.71–1.68 (m, 1H, H-6a), 1.60–1.50 (m, 4H, H-6b, H-7b, H-8); 13C NMR (125 
MHz, CDCl3)  98.8 (C-5), 66.5 (C-1), 62.3 (C-9), 33.8 (C-4), 30.7 (C-6), 29.8 (C-
3), 28.4 (C-2), 25.4 (C-8), 19.6 (C-7); HRMS(ESI) m/z calcd. for [C9H17O2Br+Na]
+
: 
259.0304, obsd.: 259.0318. 
 
Octadecyne (15). A solution of bromo-hexadecane (14) 
(4.54 g, 14.9 mmol) in DMF (20 mL) was cooled to 0 °C 
and sodium acetylide (18% in xylene, 5.95 mL, 22.3 
mmol) was added to it. The reaction mixture was stirred at r.t. overnight after which 
time it was diluted with Et2O (100 mL), washed with water (50 mL), 1M HCl (50 
mL), brine (25 mL) dried with MgSO4, and the solvent reduced in vacuo. 
Octadecyne (15) was obtained after silica gel flash chromatography (eluting in Pet. 
Ether), as a white solid (3.62 g, 14.5 mmol, 98%). Rf = 0.50 (Pet. Ether); IR (film): 
3314, 2922, 2853, 2341, 1236, 668 cm
-1
; 
1
H NMR (500 MHz, CDCl3)  2.19 (dt, 
J3a,3b = 9.8 Hz, J3a,4 = 7.1 Hz, 1H, H-3a), 2.18 (dt, J3a,3b = 9.8 Hz, J3b,4 = 7.1 Hz, 1H, 
H-3b), 1.94 (t, 
4
J1,3 = 2.6 Hz, 1H, H-1), 1.55 (pentet, Jα,β =  Jβγ = 7.1 Hz, 2H, H-4), 
1.44–1.36 (m, 2H, H-5) 1.32–1.26 (m, 24H, H-6–H-17), 0.89 (t, J17,18 = 6.8 Hz, H-
18); 
13
C NMR (125 MHz, CDCl3)  84.8 (C-2), 68.0 (C-1), 31.9, 29.70, 29.68, 29.66, 
29.62, 29.52, 29.37, 29.12, 28.77, 28.50, 22.70 (C-4–C-17), 18.4 (C-3), 14.1 (C-18); 
HRMS(ESI) m/z calcd. for [C18H34+Na]
+
: 273.2558, obsd.: 273.2550. 
 
2-(5-Docosynyloxy)-tetrahydropyran (17). n-
BuLi (8.28 mL, 2.0 M solution in hexanes, 16.6 
mmol) was added to a solution of octadecyne (15) 
(2.07 g, 8.28 mmol) in THF (30 mL) at 0 °C and the reaction mixture was refluxed 
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for 10 h, after which time it was cooled to r.t. and THP ether 16 (4.97 g, 20.7 mmol) 
in THF (30 mL) was added. The reaction was refluxed for a further 24 h then 
quenched with H2O (50 mL), extracted with Pet. Ether (3 x 60 mL), washed with 
brine (40 mL), dried with MgSO4 and reduced in vacuo. The title compound was 
obtained after silica gel flash chromatography (eluting in 75:1, Pet. Ether/EtOAc, 
v/v) as colourless oil (2.8 g, 6.84 mmol, 83%). Rf = 0.69 (2/1, PE/EA, v/v); IR (film): 
2922, 2852, 1363, 1186, 738, 704 cm
-1
; 
1
H NMR (500 MHz, CDCl3)  4.58 (t, J23,24a 
= J23,24b = 2.9Hz, 1H, H-23), 3.86 (ddd, J27a,27b = 11.1 Hz, J26a,27a = J26b,27a = 3.0 Hz, 
1H, H-27a),  3.75 (dt, J1a,1b = 9.7 Hz,  J1a,2a = J1a,2b = 3.9 Hz, 1H, H-1a), 3.51–3.48 
(m, 1H, H-27b), 3.40 (dt, J1a,1b = 9.7 Hz,  J1b,2a = J1b,2b = 3.1 Hz, 1H, H-1b), 2.19 (tt, 
J3,4 = 7.1 Hz, 
5
J4,7 = 2.2 Hz, 2H, H-4), 2.13 (tt, J7,8 = 7.0 Hz, 
5
J4,7 = 2.2 Hz, 2H, H-7), 
1.86–1.77 (m, 1H, H-25a), 1.75–1.62 (m, 3H, H-24a and H-26), 1.61–1.50 (m, 6H, 
H-2, H-3, H-24b and H-25b), 1.47 (pentet, J7,8 = J8,9 = 7.3 Hz, 2H, H-8), 1.37–1.31 
(m, 2H, H-9), 1.30–1.25 (m, 24H, H-10–H-21), 0.88 (t, J1,2 = 6.8 Hz, 2H, H-22); 
13
C 
NMR (125 MHz, CDCl3)  98.8 (C-23), 80.5 (C-6), 79.8 (C-5), 67.1 (C-1), 62.3 (C-
27), 31.9, 30.7, 29.70, 29.68, 29.66, 29.65, 29.57, 29.4, 29.19, 29.16, 28.9, 28.9, 
25.9, 25.5, 22.7 (C-2, C-3, C-8–C-21, C-24, C-26), 19.6 (C-25), 18.8 (C-7), 18.6 (C-
4), 14.1 (C-22); HRMS(ESI) m/z calcd. for [C27H50O2+Na]
+
: 429.3709, obsd.: 
429.3713. 
 
 5-Docosyn-1-ol (18). To a solution of alkyne 17 (2.01 
g, 4.91 mmol) in MeOH (20 mL) was added PTSA 
(0.28 g, 1.47 mmol) and the reaction mixture was 
stirred at r.t. overnight before being quenched with H2O and extracted with EtOAc (3 
x 50 mL). The combined organic layers were washed with H2O (30 mL), brine (30 
mL), dried with MgSO4 and reduced in vacuo. The title compound was obtained after 
silica gel flash chromatography (eluting in 20:1, Pet. Ether/EtOAc, v/v) as a white 
solid (1.40 g, 4.34 mmol, 89%) Rf = 0.33 (5/1, PE/EA, v/v); IR (film): 2984, 1738, 
1447, 1234, 1044 cm
-1
; 
1
H NMR (500 MHz, CDCl3)  3.68 (t, J1,2 = 6.4 Hz, 2H, H-
1), 2.20 (tt, J3,4 = 7.1 Hz, 
5
J4,7 = 2.2 Hz, 2H, H-4), 2.14 (tt, J7,8 = 6.9 Hz, 
5
J4,7 = 2.2 
Hz, 2H, H-7), 1.69 (pentet, Jα,β = Jβ,γ = 6.8 Hz, 2H, H-2), 1.57 (pentet, Jα,β =  Jβ,γ= 6.9 
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Hz, 2H, H-3),1.47 (pentet, Jα,β = Jβ,γ = 7.2 Hz, 2H, H-8), 1.40–1.32 (m, 2H, H-9), 
1.29–1.22 (m, 24H, H-10–H-21), 0.89 (t, J21,22 = 7.0 Hz, 2H, H-22); 
13
C NMR (125 
MHz, CDCl3)  80.8 (C-6), 79.7 (C-5), 62.6 (C-1), 31.93 (C-2), 31.88, 29.71, 29.68, 
29.66, 29.65, 29.57, 29.37, 29.18, 29.15, 28.90, 25.35, 22.70 (C-3, C-8–C-21), 18.7 
(C-7), 18.5 (C-4), 14.1 (C-22); HRMS(ESI) m/z calcd. for [C22H42O+Na]
+
: 345.3133, 
obsd.: 345.3134. 
 
21-Docosyn-1-ol (19). Diaminopropane (10 mL) was 
added to NaH (0.88 g, 22.0 mmol, 60% dispersion in 
mineral oil) and the resulting mixture was stirred at 70 °C until gas evolution ceased 
(c.a. 1 h), after which time the mixture was cooled, and alcohol 18 (0.36 g, 1.10 
mmol) dissolved in diaminopropane (5 mL), was added dropwise. The reaction was 
stirred at 70 °C overnight after which time it was quenched with H2O and extracted 
with EtOAc (3 x 35 mL). The combined organic layer was then washed with water 
(25 mL), brine (25 mL), dried (MgSO4) and the solvent reduced in vacuo. The title 
compound was obtained after silica gel flash chromatography (eluting in 20:1, Pet. 
Ether/EtOAc, v/v) as a white solid (3.1 g, 0.74 mmol, 66%) Rf = 0.32 (5/1, PE/EA, 
v/v); IR (film): 3287, 2917, 2849, 1122 cm
-1
; 
1
H NMR (500 MHz, CDCl3)  3.65 (t, 
J1,2 = 6.6 Hz, 2H, H-1), 2.19 (dt, J20a,20b = 11.5 Hz, J19,20a = 7.1 Hz, 1H, H-20a), 2.18 
(dt, J20a,20b = 11.5 Hz, J19,20b = 7.1 Hz, 1H, H-20b), 1.94 (t, 
4
J20,22 = 2.6 Hz, 1H, H-
22), 1.54 (pentet, Jα,β =  Jβ,γ = 6.8 Hz, 2H, H-2), 1.51 (pentet, Jα,β =  Jβ,γ = 7.3 Hz, 2H, 
H-19), 1.41–1.14 (m, 32H, H-3–H-18); 13C NMR (125 MHz, CDCl3)  84.8 (C-21), 
68.0 (C-22), 63.1 (C-1), 32.8 (C-2) 29.70, 29.69, 29.66, 29.62, 29.51, 29.44, 29.12, 
28.77, 28.50 (C-3–C-19), 22.74 (C-20); HRMS(ESI) m/z calcd. for [C22H42O+H]
+
: 
323.3314, obsd.: 323.3309. 
 
21-Docosynyl p-toluenesulfonate (21). To a solution of 
alcohol 19 (0.20 g, 0.63 mmol) in CH2Cl2 (3 mL) at 0 °C 
was added pyridine (0.10 mL, 1.25 mmol) then TsCl (0.18 
g, 0.94 mmol) and the reaction stirred at r.t. overnight. Et2O (30 mL) and water (20 
197 
 
mL) were added to the reaction mixture and the organic layer was washed with 2M 
HCl (30 mL), followed by 5% NaHCO3 (20 mL), water (30 mL), brine (30 mL) and 
then dried with MgSO4. The solvent was removed in vacuo and the title compound 
obtained after silica gel flash chromatography (eluting in 50:1, Pet. Ether/EtOAc, 
v/v) as a white solid (0.28 g, 0.61 mmol, 97%). Rf = 0.46 (5/1, PE/EA, v/v); IR 
(film):  2917, 2850, 1472, 1173, 668 cm
-1
; 
1
H NMR (500 MHz, CDCl3)  7.80  (d, J 
= 8.3 Hz, 2H, Harom), 7.35 ( d, J = 8.1 Hz, 2H, Harom), 4.03 (t, J1,2 = 6.6 Hz, 2H, H-1), 
2.46 (s, 3H, CH3), 2.19 (dt, J20a,20b = 13.1 Hz, J19,20a = 7.1 Hz, 1H, H-20a), 2.18 (dt, 
J20a,20b = 13.1 Hz, J19,20b = 7.1 Hz, 1H, H-20b), 1.95 (t, 
4
J20,22 = 2.6 Hz, 1H, H-22), 
1.64 (pentet, Jα,β = Jβ,γ = 6.8 Hz, 2H, H-2), 1.52 (pentet, Jα,β = Jβ,γ = 6.6 Hz, 2H, H-
19), 1.40–1.38 (m, 2H, H-3), 1.34–1.22 (m, 30H, H-4–H-18); 13C NMR (125 MHz, 
CDCl3)  144.6 (Car-CH3), 129.8 (Car), 127.9 (Car), 84.8 (C-21), 70.7 (C-1), 68.0 (C-
22), 29.70, 29.68, 29.65, 29.61, 29.50, 29.39, 29.11, 28.92, 28.81, 28.77, 28.50, 
25.32 (C-2–C-19), 21.63 (CH3), 18.4 (C-20); HRMS(ESI) m/z calcd. for 
[C29H48O3S+Na]
+
: 499.3222, obsd.: 499.3222. 
 
                                   Methyl 4-[4-(21-
docosynyloxy)benzoyl]-benzoate 
(20). To a solution of benzophenone 6 
(30.5 mg, 0.12 mmol) in 2 mL DMF was added Cs2CO3 (42.9 mg, 0.13 mmol), 18-
crown-6-ether (37.8 mg, 0.14 mmol) and tosylate 21 (83.0 mg, 0.18 mmol) in toluene 
(2 mL) and the reaction was stirred at r.t. for 30 min and then heated to 50 °C over 2 
nights. The reaction mixture was then cooled down, diluted with CH2Cl2 and water 
(20 mL). The aqueous layer was extracted with CH2Cl2 (2 x 30 mL) and the 
combined organic layers were dried with MgSO4, and the solvent removed in vacuo. 
The title compound was obtained after silica gel flash chromatography (eluting in 
30:1, Pet. Ether/EtOAc, v/v) as a white solid (43.0 mg, 0.08 mmol, 64 %); Rf = 0.63 
(2/1, PE/EA, v/v); IR (film): 2916, 2848, 1638, 1604, 1256, 1107 cm
-1
; 
1
H NMR 
(500 MHz, CDCl3)  8.14 (d, J2,3 = 8.0 Hz, 2H, H-2), 7.81 (d, J7,8 = 8.8 Hz, 2H, H-7), 
7.79 (d, J2,3 = 8.0 Hz, 2H, H-3), 6.96 (d, J7,8 = 8.8 Hz, 2H, H-8), 4.04 (t, J10,11 = 6.6 
Hz, 2H, H-10), 3.97 (s, 3H, CO2Me), 2.19 (tt, J28,29a = 7.3 Hz, 
4
J29,31  = 2.4 Hz, 1H,  
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H-29a), 2.18 (tt, J28,29b = 7.1 Hz, 
4
J29,31 = 2.4 Hz, 1H, H-29b), 1.94 (t, 
4
J29,31 = 2.4 Hz, 
1H, H-31), 1.82 (pentet, J9,10 = J10,11 = 7.1 Hz, 2H, H-11), 1.58–1.50 (m, 2H, H-28), 
1.50–1.42 (m, 2H, H-12), 1.40–1.22 (m, 30H, H-13–H-27); 13C NMR (125 MHz, 
CDCl3)  194.8 (C-5), 166.4 (CO2Me), 163.6 (C-9), 142.2 (C-4), 132.7 (C-1), 132.6 
(C-7), 129.4 (C-3), 129.4 (C-2), 129.3 (C-6), 114.2 (C-8), 84.8 (C-30), 68.4 (C-31), 
68.0 (C-10), 52.4 (CO2Me), 29.70, 29.68, 29.66, 29.62, 29.60, 29.57, 29.51, 29.36, 
29.12, 29.09, 28.77, 28.50, 25.98 (C-11–C-28), 18.40 (C-29); HRMS(ESI) m/z calcd. 
for [C37H52O4+Na]
+
: 583.3763, obsd.: 583.3763. 
 
 
2,2',3,3',4,4'-Hexa-O-trimethylsilyl-6-docosanoyl-6'-
hydroxyl, α,α'-D-trehalose (2). To a solution of diol 4 
(48.9 mg, 0.063  mmol) and behenic acid (5, 28.0 mg, 
0.082 mmol) in dry toluene (2 mL) was added EDCI 
(30.2 mg, 0.16 mmol,) and DMAP (1.1 mg, 0.01 mmol).The reaction was stirred at 
70 °C until analysis by TLC showed no further formation of product. The resulting 
precipitate was removed by filtration and the precipitate washed thoroughly with 
EtOAc (2 x 20 mL). The combined organic layers were washed with water (20 mL) 
and brine (20 mL), dried (MgSO4), filtered and concentrated in vacuo. The title 
compound was obtained after silica gel flash chromatography eluting in 20:1 (v/v) 
Pet. Ether/EtOAc, as colourless oil (52.0 mg, 0.047 mmol, 75%). Rf =  0.55 (PE/EA, 
5/1, v/v); [α]D
18
 = +20.2 (c =1.0, CHCl3); IR (film): 3017, 2923, 2852, 2360, 2341, 
1737, 1372, 1250, 1229, 1166, 1110, 1076, 1007, 965, 896, 872 cm
-1
; 
1
H NMR (500 
MHz, CDCl3)  4.94 (d, J1,2 = 3.5 Hz, 1H, H-1), 4.92 (d, J1',2' = 3.6 Hz, 1H, H-1'), 
4.30 (dd,  J6a,6b = 12.0 Hz, J5,6a = 2.2 Hz, 1H, H-6a), 4.07 (dd, J6a,6b = 12.0 Hz, J5,6b = 
4.6 Hz, 1H, H-6b), 4.03-4.00 (m, 1H, H-5), 3.92 (t, J2/2',3/3' = J3/3',4/4' = 8.8 Hz, 1H, H-
3/3'), 3.91 (t, J2/2',3/3' = J3/3',4/4' = 9.0 Hz, 1H, H-3/3'), 3.85 (dt, J4',5' = 9.5 Hz, J5',6a' = 
J5',6b' = 3.5 Hz, 1H, H-5'), 3.86–3.83 (m, 2H, H-6a' and H-6b'), 3.49 (t, J3,4 = J4,5 = 9.0 
Hz, 1H, H-4), 3.47 (t, J3',4' = J4',5' = 9.0 Hz, 1H, H-4'), 3.44 (dd, J1,2/1',2' = 3.6 Hz, 
J2,3/2',3' = 9.0 Hz, 1H, H-2/2'), 3.43 (dd, J1,2/1',2' = 3.5 Hz, J2,3/2',3' = 9.0 Hz, 1H, H-2/2'), 
2.35 (dt, J8a,8b = 13.2, J8a,9 = 7.3 Hz, 1H, H-8a), 2.34 (dd, J8a,8b = 13.2, J8b,9 = 7.4 Hz, 
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1H, H-8b), 1.66–1.57 (m, 2H, H-9), 1.34–1.26 (m, 36H, H-10–H-27), 0.89 (t, J = 7.1 
Hz, 3H, H-28), 0.17, 0.16, 0.15, 0.14, 0.13 (6 s, 54H, CH3, TMS); 
13
C NMR (125 
MHz, CDCl3) 173.8 (C-7), 94.5 (C-1/1'), 94.4 (C-1/1'), 73.5 (C-3/3'), 73.3 (C-3/3'), 
72.9 (C-2/2'), 72.8 (C-5'), 72.6 (C-2/2'), 71.9 (C-4), 71.4 (C-4'), 70.8 (C-5), 63.3 (C-
6), 61.7 (C-6'), 34.2 (C-8), 31.9, 29.70, 29.66, 29.60, 29.5, 29.4, 29.3, 29.2, 24.8, 
22.7 (C-9–C-27), 14.1 (C-28), 1.04, 1.00, 0.89, 0.85, 0.14, 0.10 (TMS) HRMS (ESI) 
m/z calcd. for [C52H112O12Si6+Na]
+
: 1119.6769, obsd.: 1119.6667.  
 
6'-O-docosanoyl-6-O-4-[4-(21-
docosynyloxy)benzoyl]benzoyl-
2,2',3,3',4,4'-hexa-O-trimethylsilyl-α,α'-
D-trehalose (22). LiOH.H2O (15 mg, 0.36 
mmol) was added to a solution of 20 (20 
mg, 0.04 mmol) in 0.5 mL 
THF:H2O:MeOH (3:1:1) and the reaction mixture was refluxed for 10 min after 
which it was neutralised with 0.1 M HCl (pH =3) and extracted with EtOAc (3x 10 
mL). The combined organic layers were washed with water, brine, dried (MgSO4), 
filtered and concentrated in vacuo to yield  carboxylic acid 3 as a white solid (15 mg, 
0.03 mmol, 80%) which was used without further purification. 
To a solution of mono-trehalose ester 2 (8.5 mg, 0.008 mmol) and carboxylic acid 3 
(14 mg, 0.03 mmol) in dry toluene (1 mL) was added EDCI (6.5 mg, 0.034 mmol) 
and DMAP (0.2 mg, 0.001 mmol) and the reaction was refluxed for 7 days after 
which time the resulting precipitate was removed by filtration and the precipitate 
washed thoroughly with EtOAc (3 x 10 mL). The combined organic layers were 
washed with water (10 mL), brine (10 mL) dried with MgSO4, filtered and 
concentrated in vacuo. The title compound was obtained after silica gel flash 
chromatography (eluting in 25:1, Pet. Ether/EtOAc, v/v) as colourless oil (3.5 mg, 
0.002 mmol, 30%). Rf = 0.54 (PE/EA, 5/1, v/v); [α]
22
D = +0.06 (c = 0.1 CHCl3); IR 
(film): 3628, 2920, 1457, 720, 677 cm
-1
; 
1
H NMR (500 MHz, CDCl3)  8.14 (d, J3'',4'' 
= 8.5 Hz, 2H, H-3''), 7.81 (d, J8'',9'' = 8.8 Hz, 2H, H-8''), 7.79 (d, J3'',4'' = 8.5 Hz, 2H, H-
4''), 6.96 (d, J8'',9'' = 8.8 Hz, 2H, H-9''), 4.95 (d, J1,2/1',2' = 3.2 Hz, 1H, H-1/1'),  4.94 (d, 
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J1,2/1',2' = 3.2 Hz, 1H, H-1/1'), 4.59 (dd, J6a,6b = 12.0 Hz, J5,6a = 2.3 Hz, 1H, H-6a), 4.33 
(dd, J6a,6b = 12.0 Hz, J5,6b = 3.5 Hz, 1H, H-6b), 4.27 (dd, J6a',6b' = 12.0 Hz, J5',6a' = 2.3 
Hz, 1H, H-6a'), 4.13 (ddd, J4,5 = 9.0 Hz, J5,6a = 2.3 Hz, J5,6b = 3.5 Hz, 1H, H-5), 4.09 
(dd, J6a',6b' = 12.0 Hz, J5',6b' = 3.5 Hz, 1H, H-6b'), 4.04 (t, J11'',12'' = 6.4 Hz, 2H, H-11''), 
4.02–3.97 (m, 1H, H-5'), 3.96 (dd, J2,3 = J3,4 = 9.0 Hz, 1H, H-3), 3.92 (dd, J2',3' =J3',4' = 
9.0 Hz, 1H, H-3'), 3.64 (dd, J3,4  = J4,5 = 9.0 Hz, 1H, H-4), 3.49 (dd, J2,3/2',3' = 9.0 Hz, 
J1,2/1',2' = 3.2 Hz, 1H, H-2/2') 3.48 (dd, J3',4' = J4',5' = 9.0 Hz, 1H, H-4'), 3.47 (dd, J2,3/2',3' 
= 9.0 Hz, J1,2/1',2' = 3.2 Hz, 1H, H-2/2'), 2.34 (dt, J2a''',2b''' = 11.4 Hz, J2a''',3''' = 7.3 Hz, 
1H, H-2a'''), 2.33 (dt, J2a''',2b''' = 11.4 Hz, J2b''',3''' = 7.3 Hz, 1H, H-2b''') 2.19 (dtt, 
J30a'',30b'' = 9.9 Hz, J29'',30a'' = 7.3 Hz, 
4
J30a'',32'' = 2.6 Hz, 1H, H-30a''), 2.17 (ddt, J30a'',30b'' 
= 9.9 Hz, J29'',30b'' = 7.3 Hz, 
4
J30b'',32'' = 2.6 Hz, 1H, H-30b''), 1.94 (t, 
4
J30'',32'' = 2.6 Hz, 
1H, H-32), 1.82 (pentet, J11'',12'' = J12''13'' = 6.7 Hz, 2H, H-12''), 1.64–1.52 (m, 4H, H-
3''' and H-13''), 1.50–1.22 (m, 68H, H-14''–H-29'' and H-4'''–H-21'''), 0.88 (t, J21''',22''' = 
7.0 Hz, H-22'''), 0.17, 0.16, 0.15, 0.14, 0.13 (6 s, 54H, CH3, TMS); 
13
C NMR (125 
MHz, CDCl3) 194.5 (C-6''), 173.8 (C-1'''), 165.5 (C-1''), 163.1 (C-10''), 142.2 (C-
5''), 132.4 (C-4''), 132.3 (C-2''), 129.3 (C-3''), 129.2 (C-8''), 128.7 (C-7''), 114.0 (C-
9''), 94.29 (C-1/1'), 94.25 (C-1/1'), 84.6 (C-31''), 73.4 (C-3), 73.2 (C-3'), 72.44 (C-
2/2'), 72.40 (C-2/2'), 71.66 (C-4), 71.60 (C-4'), 70.53 (C-5'), 70.50 (C-5), 68.2 (C-
11''), 67.8 (C-32''), 63.8 (C-6), 63.0 (C-6'), 33.9 (C-2'''), 31.7, 31.2, 29.9, 29.8, 29.5, 
29.43, 29.38, 29.34, 29.35, 29.27, 29.24, 29.20, 29.14, 29.1, 28.9, 28.88, 28.54, 
28.26, 25.76, 24.78, 24.54, 22.47, 21.85, (C-3'''–C21''' and C-12''–C-29''), 18.17 (C-
30''), 13.9 (C-22'''), 0.86, 0.83, 0.70, 0.65, 0.01, 0.00 (TMS); HRMS (ESI) m/z calcd. 
for [C88H160O15Si6+Na]
+
: 1648.0265, obsd.: 1648.0280. 
 
   
6'-O-Docosanoyl-6-O-4-[4-(21-
docosynyloxy)benzoyl]benzoyl-α,α'-D-
trehalose (1). To a solution of the 
protected probe 22 (1.7 mg, 0.001 mmol) 
in 0.4 mL CH2Cl2:MeOH mixture (3/1, 
v/v) was added Dowex-H
+
 (10% by 
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weight) and the reaction stirred at room temperature. After 30 min, the reaction 
mixture was filtered and concentrated in vacuo. AfBP probe 1 was obtained after 
silica gel flash column chromatography (eluting in 97:3, EtOAc/MeOH, v/v) as a 
white solid (1.25 mg, 0.001 mmol, quant.). Rf = 0.31 (EtOAc); [α]
18
D = +0.6 (c = 0.1, 
C5H5N); IR (film); 3567,  2970,  1739, 1365, 1217, 651 cm
-1
; 
1
H NMR (500 MHz, 
C5D5N)  8.20 (d, J3'',4'' = 8.2 Hz, 2H, H-3''), 7.86 (d, J8'',9'' = 8.8 Hz, 2H, H-8''), 7.68 
(d, J3'',4'' = 8.2 Hz, 2H, H-4''), 7.06 (d, J8'',9'' = 8.8 Hz, 2H, H-9''), 5.84 (d, J1,2/1',2' = 3.6 
Hz, 1H, H-1/1'), 5.83 (d, J1,2/1',2' = 3.6 Hz, 1H, H-1/1'), 5.20–5.17 (m, 1H, H-5), 5.15–
4.94 (m, 5H, H-5, H-6a,b and H-6'a,b), 4.70 (dd, J2,3 = J3,4 = 9.6 Hz, 1H, H-3), 4.68 
(dd, J2',3' =J3',4' = 9.6 Hz, 1H, H-3'), 4.28 (dd, J2,3/2',3' = 9.6 Hz, J1,2/1',2' = 3.6 Hz, 1H, H-
2/2'), 4.24 (dd, J2,3/2',3' = 9.6 Hz, J1,2/1',2' = 3.6 Hz, 1H, H-2/2'), 4.09 (dd, J3,4  = J4,5 = 
9.6 Hz, 1H, H-4), 4.09 (dd, J3',4' = J4',5' = 9.6 Hz, 1H, H-4'), 3.96 (t, J11'',12'' = 6.3 Hz, 
2H, H-11''), 2.68 (t, 
4
J30'',32'' = 2.7 Hz, 1H, H-32''), 2.20 (dt, J2a''',2b''' = 12.2 Hz, J2a''',3''' = 
7.9 Hz, 2H, H-2a'''), 2.19 (dt, J2a''',2b''' = 12.2 Hz, J2b''',3''' = 7.9 Hz, 1H, H-2b'''), 2.12 
(dtt, J30a'',30b'' = 9.9 Hz, J29'',30a'' = 7.0 Hz, 
4
J30a'',32'' = 2.7 Hz, 1H, H-30a''), 2.10 (dtt, 
J30a'',30b'' = 9.9 Hz, J29'',30b''  = 7.0 Hz, 
4
J30b'',32'' = 2.7 Hz 1H, H-30b''), 1.69 (pentet, 
J11'',12'' = J12''13'' = 6.3 Hz, 2H, H-12''), 1.50 (pentet, J2''',3''' = J3''',4''' = 6.1 Hz, 2H, H-3'''), 
1.39–1.35 (m, 2H, H-13''), 1.20–1.06 (m, 68H, H-14''–H-29'' and H-4'''–H-21'''), 0.77 
(t, J21''',22''' = 6.6 Hz, H-22'''); 
13
C NMR (125 MHz, C5D5N) 193.0 (C-6''), 172.3 (C-
1'''), 164.6 (C-1''), 162.2 (C-10''), 133.8 (C-5''), 131.7 (C-4''), 128.4 (C-2''), 128.3 (C-
3''), 128.0 (C-8''), 127.3 (C-7''), 113.3 (C-9''), 94.6 (C-1 and C-1'), 83.7 (C-31''), 73.6 
(C-3), 73.5 (C-3'), 72.0 (C-2/2'), 72.40 (C-2/2'), 70.70 (C-4), 70.60 (C-4'), 70.23 (C-
5'), 70.16 (C-5), 68.7 (C-32'') 67.2 (C-11''), 64.3 (C-6), 62.9 (C-6'), 33.0 (C-2'''), 30.7, 
28.62, 28.60, 28.54, 28.52, 28.51, 28.48, 28.38, 28.34, 28.25, 28.21, 28.16, 28.0, 
27.96, 27.94, 27.58, 27.41, 24.87, 23.85, 21.54 (C-3'''–C21''' and C-12''–C-29''), 
17.18 (C-30''), 12.9 (C-22'''); HRMS(ESI) m/z calcd. for 
[C70H112O15+Na]
+
:1215.7893, obsd.:1215.7897. 
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7.1 Summary 
The use of bacteria in the treatment of disease was first illustrated by Coley who 
treated a number of cancer patients in the late 1800s using a concoction known as 
‘Coley’s Toxin’ (Streptococcal pyogenes and Serratia marcescens). Following this 
seminal work, there has been much interest in the potential of bacterial cell wall 
components in the treatment of disease, as highlighted in the introduction to this 
thesis (Chapter 1). In particular, Chapter 1 focuses on the trehalose glycolipids and 
outlines their synthesis, biological activities, and how such glycolipids can be used to 
understand cellular processes [e.g. via Affinity Based Proteome Profiling (AfBPP)].  
In Chapter 2, the synthesis of linear fatty acid trehalose diesters (TDEs) is reported. 
The different synthetic strategies used to obtain a range of TDEs and the isolation of 
linear fatty acid trehalose monoesters (TMEs) is described. Initial methodology 
involved using benzyl protecting groups in the synthesis of these glycolipids, 
however, with long lipid chains, the removal of the benzyl protecting groups proved 
 7 Summary and Future Prospects 
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difficult. A switch to using trimethylsilyl (TMS) protecting groups yielded better 
results. In summary, nine TDEs and two TMEs were synthesised in good overall 
yields.  
Chapter 3 focuses on the biological activities of the synthesised TDEs and TMEs. 
The importance of lipid length in inducing macrophage activation was studied along 
with investigations into the importance of having two lipid chains on the trehalose 
moiety for recognition by macrophages. It was observed that a lipid length of C18 or 
more is required to induce macrophage activation and one long lipid chain (≥C22) on 
trehalose is sufficient for activation. This is the first time that it has been shown that 
TMEs are also able to activate macrophages. The synthesised TMEs and TDEs were 
also tested for their cytotoxicity and, interestingly, no appreciable cytotoxicity was 
noted. Using knock-out models, it was shown that both TDEs and TMEs are ligands 
for Macrophage Inducible C-type Lectin (Mincle).   
In Chapter 4, Fráter-Seebach alkylation methodology for the synthesis of α-alkyl-β-
hydroxy esters is presented. Here it was shown that allylic iodides were more 
effective alkylating reagents and gave better product yields as compared to their 
saturated alkyl halide counterparts. This was attributed to the delocalisation of the 
electron density over the allylic carbons in the transition state which leads to a lower 
transition state energy relative to the transition state of the corresponding saturated 
halides.  
Use of the improved Fráter-Seebach alkylation for the synthesis of a fully protected 
trehalose monocorynomycolate (TMCM) is described in Chapter 5. Key steps in the 
synthetic route were a copper-mediated Grignard reaction for the synthesis of the 
corynomycolic acid moiety, selective formation of the silyl-ether and esterification to 
give the trehalose monoester. Problems were noted when a longer lipid chain (C14) 
was used for the Grignard reaction and also during the esterification reaction, 
whereby formation of corynomycolic anhydride was noted with no diester observed. 
It is envisioned that these problems, however, can be solved and that the general 
synthetic strategy can be used for the subsequent syntheses of a variety of TDCMs.  
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In Chapter 6, the design of an affinity based proteome (AfBP) probe for 
understanding the protein interactions of trehalose glycolipids is described. 
Incorporation of a benzophenone trap group and an alkyne tag to prepare a C22 
trehalose probe was undertaken. Key synthetic steps included Friedel-Craft acylation 
for the formation of the benzophenone moiety and a Zipper reaction to prepare the 
terminal alkyne functionality.  Initial biological testing of the AfBP probe was 
performed and it was observed that the probe led to macrophage activation (as 
determined by NO production) albeit at lower levels than the corresponding 
dibehenate derivative. 
 
7.2 Future Prospects 
7.2.1 TDEs and TMEs and associated biological activities 
With our finding that long chain TMEs and TDEs are required to activate 
macrophages, our next step would be to understand more about the mechanism of 
this activation. For example, all macrophage experiments should be repeated using 
knock-out mice (e.g. Mincle
-/-
, TLR
-/-
 and Myd88
-/- 
BMMs) so that potential 
receptors can be identified. The ability of the trehalose esters to form aggregates (e.g. 
micelles) and the effect that this has on macrophage activation also needs to be 
determined, as does the ability of the compounds to switch the macrophage 
phenotype from M2 (e.g. TAMs) to M1. The ability of these compounds to be used 
as priming agents should also be further explored. Such experiments, along with the 
appropriate references, were described in more detail in Chapter 3.  
 
7.2.2 TMCM and TDCM Synthesis  
Having developed an improved Fráter-Seebach alkylation methodology, the next step 
is to apply this to the synthesis of more complex TDCMs. Problems encountered 
during the synthesis of the TDCMs included the copper-mediated Grignard 
alkylation when longer alkyl lipids were used and difficulties in the esterification 
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reaction to form diesters. The use of lithiated alkyne lipids in the Grignard reaction 
could solve this problem and allow for the synthesis of longer chain TDCM 
analogues. For the esterification reaction a change of solvent, prolonged reaction 
times and further addition of EDCI and DMAP in order to form the diesters would be 
investigated as highlighted in Chapter 5. The TDCMs should also be tested for their 
biological activities – first in a macrophage activation assay, and then, for their 
potential as adjuvants and anti-tumour agents. By doing so, greater insight into the 
effects of trehalose glycolipid structure on biological function can be determined. 
 
7.2.3 AfBP 
The C22-trehalose AfBP probe (Chapter 6) is to be used in subsequent proteomic 
experiments to elucidate other receptors that the TDMs may bind to upon interaction 
with macrophages in the host cell. This work is to be undertaken by Dr. Faustin 
Kamena (Max-Plank Institute, Berlin). Depending on the results from these studies, 
other probes with varying trap and tag groups could then be designed and tested. 
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     1H and 13C NMR spectra of      
synthesised compounds 
 
 
Chapter 2 
 
2,2',3,3',4,4'-Hexa-O-benzyl-6,6'-di-O-trityl-α,α'-D-trehalose (3)  
1H NMR (500 MHz, CDCl3) 
 
2,2',3,3',4,4'-Hexa-O-benzyl-6,6'-di-O-trityl-α,α'-D-trehalose 
(3)  
13C NMR (125 MHz, CDCl3) 
208 
2,2',3,3',4,4'-Hexa-O-benzyl-α,α'-D-trehalose (4) 
1H NMR (500 MHz, CDCl3) 
 
209 
2,2',3,3',4,4'-Hexa-O-benzyl-α,α'-D-trehalose (4) 
13C NMR (125 MHz, CDCl3) 
 
2,2',3,3',4,4'-Hexa-O-benzyl-6,6'-di-O-butanoyl-α,α'-D-
trehalose (5a) 
1H NMR (500 MHz, CDCl3) 
 
2,2',3,3',4,4'-Hexa-O-benzyl-6,6'-di-O-butanoyl-α,α'-D- 
trehalose (5a)  
13C NMR (125 MHz, CDCl3) 
210 
2,2',3,3',4,4'-Hexa-O-benzyl-6,6'-di-O-heptanoyl-α,α'-D-
trehalose (5b) 
1H NMR (500 MHz, CDCl3) 
 
2,2',3,3',4,4'-Hexa-O-benzyl-6,6'-di-O-heptanoyl-α,α'-D-
trehalose (5b)  
13C NMR (125 MHz, CDCl3) 
211 
O
O
BnO
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OBn
OBn
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O
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O
2,2',3,3',4,4'-hexa-O-benzyl-6,6'-di-O-decanoyl-α,α'-D-
trehalose (5c) 
1H NMR (500 MHz, CDCl3) 
 
2,2',3,3',4,4'-hexa-O-benzyl-6,6'-di-O-decanoyl-α,α'-D-
trehalose (5c) 
13C NMR (125 MHz, CDCl3) 
212 
2,2',3,3',4,4'-Hexa-O-benzyl-6,6'-di-O-stearoyl-α,α'-D-
trehalose (5d) 
1H NMR (500 MHz, CDCl3) 
 
2,2',3,3',4,4'-Hexa-O-benzyl-6,6'-di-O-stearoyl-α,α'-D-
trehalose (5d) 
13C NMR (125 MHz, CDCl3) 
213 
O
O
BnO
BnO
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OBn
OBn
O
O
O
O
O
2,2',3,3',4,4'-hexa-O-trimethylsilyl-α,α'-D-trehalose (6) 
1H NMR (500 MHz, CDCl3) 
 
2,2',3,3',4,4'-hexa-O-trimethylsilyl-α,α'-D-trehalose (6) 
13C NMR (125 MHz, CDCl3) 
214 
2,2',3,3',4,4'-Hexa-O-trimethylsilyl-6,6'-di-eicosanoyl-
α,α'-D-trehalose (7e) 
1H NMR (500 MHz, CDCl3) 
2,2',3,3',4,4'-Hexa-O-trimethylsilyl-6,6'-di-eicosanoyl-
α,α'-D-trehalose (7e) 
13C NMR (125 MHz, CDCl3) 
215 
2,2',3,3',4,4'-Hexa-O-trimethylsilyl-6,6'-di-docosanoyl-
α,α'-D-trehalose (7f) 
1H NMR (500 MHz, CDCl3) 
2,2',3,3',4,4'-Hexa-O-trimethylsilyl-6,6'-di-docosanoyl-
α,α'-D-trehalose (7f) 
13C NMR (125 MHz, CDCl3) 
216 
2,2',3,3',4,4'-Hexa-O-trimethylsilyl-6,6'-di-hexacosanoyl-
α,α'-D-trehalose (7g) 
1H NMR (500 MHz, CDCl3) 
2,2',3,3',4,4'-Hexa-O-trimethylsilyl-6,6'-di-
hexacosanoyl-α,α'-D-trehalose (7g) 
13C NMR (125 MHz, CDCl3) 
217 
6,6'-Di-O-butanoyl-α,α'-D-trehalose (1a)  
1H NMR (500 MHz, CD3OD) 
6,6'-Di-O-butanoyl-α,α'-D-trehalose (1a) 
13C NMR (125 MHz, CD3OD) 
218 
6,6'-Di-O-heptanoyl-α,α'-D-trehalose (1b) 
1H NMR (500 MHz, CD3OD) 
6,6'-Di-O-heptanoyl-α,α'-D-trehalose (1b) 
13C NMR (125 MHz, CD3OD) 
219 
6,6'-Di-O-decanoyl-α,α'-D-trehalose (1c) 
1H NMR (500 MHz, CD3OD) 
2,2,3,3,4,4,hexa(trimethylsialyl)-trehalose-6,6di-hexacosanoate; 
13C NMR (125 MHz, CDCl3) 
220 
6,6'-Di-O-decanoyl-α,α'-D-trehalose (1c) 
13C NMR (125 MHz, CD3OD) 
6,6'-Di-O-stearoyl-α,α'-D-trehalose (1d) 
1H NMR (500 MHz, CD3OD) 
6,6'-Di-O-stearoyl-α,α'-D-trehalose (1d) 
13C NMR (125 MHz, CD3OD) 
221 
6,6'-Di-O-eicosanoyl-α,α'-D-trehalose (1e) 
1H NMR (500 MHz, C5D5N) 
6,6'-Di-O-eicosanoyl-α,α'-D-trehalose (1e) 
13C NMR (125 MHz, C5D5N) 
222 
6,6'-Di-O-docosanoyl-α,α'-D-trehalose (1f) 
1H NMR (500 MHz, C5D5N) 
6,6'-Di-O-docosanoyl-α,α'-D-trehalose (1f) 
13C NMR (125 MHz, C5D5N) 
223 
6,6'-Di-O-hexacosanoyl-α,α'-D-trehalose (1g) 
1H NMR (500 MHz, C5D5N) 
6,6'-Di-O-hexacosanoyl-α,α'-D-trehalose (1g) 
13C NMR (125 MHz, C5D5N)) 
224 
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1-Octadecanal (6c) 
1H NMR (500 MHz, CDCl3) 
1-Octadecanal (6c) 
13C NMR (125 MHz, CDCl3) 
225 
1-Eicosanal (6d) 
1H NMR (500 MHz, CDCl3) 
1-Eicosanal (6d) 
13C NMR (125 MHz, CDCl3) 
226 
1-Iodotetradecane 
1H NMR (500 MHz, CDCl3) 
1-Iodotetradecane 
13C NMR (125 MHz, CDCl3) 
227 
1-Iodoeicosane 
1H NMR (500 MHz, CDCl3) 
1-Iodoeicosane 
13C NMR (125 MHz, CDCl3) 
228 
1-Iododocosane 
1H NMR (500 MHz, CDCl3) 
1-Iododocosane 
13C NMR (125 MHz, CDCl3) 
229 
1-Iodo-hept-2-ene (4a) 
1H NMR (500 MHz, CDCl3) 
1-Iodo-hept-2-ene (4a) 
13C NMR (125 MHz, CDCl3) 
230 
E 
Z 
1-Iodo-tetradec-2-ene (4b)  
1H NMR (500 MHz, CDCl3) 
1-Iodo-tetradec-2-ene (4b) 
13C NMR (125 MHz, CDCl3) 
231 
1-Iodo-eicos-2-ene (4c) 
1H NMR (500 MHz, CDCl3) 
1-Iodo-eicos-2-ene (4c) 
13C NMR (125 MHz, CDCl3) 
232 
1-Iodo-docos-2-ene (4d) 
1H NMR (500 MHz, CDCl3) 
1-Iodo-docos-2-ene (4d) 
13C NMR (125 MHz, CDCl3) 
233 
Diethyl L-malate (3) 
1H NMR (500 MHz, CDCl3) 
 
Diethyl L-malate (3) 
13C NMR (125 MHz, CDCl3) 
 
(8); 
13C NMR (125 MHz, CDCl3) 
234 
Ethyl  2S-hydroxy-3R-ethoxycarbonyl-hex-4-enoate (5a)  
1H NMR (500 MHz, CDCl3) 
Ethyl 2S-hydroxy-3R-ethoxycarbonyl-hex-4-enoate (5a) 
13C NMR (125 MHz, CDCl3) 
235 
Ethyl 2S-hydroxy-3R-ethoxycarbonyl-decanoate (5b) 
1H NMR (500 MHz, CDCl3) 
Ethyl 2S-hydroxy-3R-ethoxycarbonyl-decanoate (5b) 
13C NMR (125 MHz, CDCl3) 
236 
From the reduction of 5c 
Ethyl 2S-hydroxy-3R-ethoxycarbonyl-decen-5-enoate (5c)  
1H NMR (500 MHz, CDCl3) 
Ethyl 2S-hydroxy-3R-ethoxycarbonyl-decen-5-enoate (5c)  
13C NMR (125 MHz, CDCl3) 
237 
Ethyl 2S-hydroxy-3R-ethoxycarbonyl-heptadecanoate (5d) 
1H NMR (500 MHz, CDCl3) 
Ethyl 2S-hydroxy-3R-ethoxycarbonyl-heptadecanoate (5d) 
13C NMR (125 MHz, CDCl3) 
238 
From the reduction of 5e 
Ethyl 2S-hydroxy-3R-ethoxycarbonyl-heptadecen-5-enoate (5e) 
 1H NMR (500 MHz, CDCl3) 
Ethyl 2S-hydroxy-3R-ethoxycarbonyl-heptadecen-5-enoate (5e)  
13C NMR (125 MHz, CDCl3) 
239 
Ethyl 2S-hydroxy-3R-ethoxycarbonyl-tricosanoate (5f)  
1H NMR (500 MHz, CDCl3) 
Ethyl 2S-hydroxy-3R-ethoxycarbonyl-tricosanoate (5f ) 
13C NMR (125 MHz, CDCl3) 
240 
From the reduction of 5g 
Ethyl 2S-hydroxy-3R-ethoxycarbonyl-tricos-5-enoate (5g) 
 1H NMR (500 MHz, CDCl3) 
Ethyl 2S-hydroxy-3R-ethoxycarbonyl-tricos-5-enoate (5g) 
13C NMR (125 MHz, CDCl3) 
241 
Ethyl 2S-hydroxy-3R-ethoxycarbonyl-pentacosanoate (5h)  
1H NMR (500 MHz, CDCl3) 
Ethyl 2S-hydroxy-3R-ethoxycarbonyl-pentacosanoate (5h) 
13C NMR (125 MHz, CDCl3) 
242 
From the reduction of 5i 
Ethyl 2S-hydroxy-3R-ethoxycarbonyl-pentacos-5-enoate 
(5i) 
1H NMR (500 MHz, CDCl3) 
Ethyl 2S-hydroxy-3R-ethoxycarbonyl-pentacos-5-enoate 
(5i) 
13C NMR (125 MHz, CDCl3) 
243 
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3R-Ethoxycarbonyl-2S-hydroxy-heptadecanol (10) 
1H NMR (500 MHz, CDCl3) 
3R-Ethoxycarbonyl-2S-hydroxy-heptadecanol (10) 
13C NMR (125 MHz, CDCl3) 
244 
Ethyl (2R)-2-[(R)-oxiranyl]-hexadecanoate (7) 
1H NMR (500 MHz, CDCl3) 
Ethyl (2R)-2-[(R)-oxiranyl]-hexadecanoate (7) 
13C NMR (125 MHz, CDCl3) 
245 
Ethyl -(2R,3R)-3-hydroxy-2-tetradecyl-octanoate (12a) 
1H NMR (500 MHz, CDCl3) 
Ethyl -(2R,3R)-3-hydroxy-2-tetradecyl-octanoate (12a) 
13C NMR (125 MHz, CDCl3) 
246 
(2R,3R)-3-Tert-butyldimethylsilyloxy-2-tetradecyl-
octanoic acid (5) 
1H NMR (500 MHz, CDCl3) 
(2R,3R)-3-Tert-butyldimethylsilyloxy-2-tetradecyl-
octanoic acid (5) 
13C NMR (125 MHz, CDCl3) 
247 
2,2',3,3',4,4'-Hexa-O-trimethylsilyl-6-O-[(2R,3R)-3-tert-
butyldimethylsilyloxy-2-tetradecyl-octanoyl]-α,α'-D-trehalose (15) 
1H NMR (500 MHz, CDCl3) 
248 
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2-(4-Bromobutyloxy)-tetrahydropyran (16)  
1H NMR (500 MHz, CDCl3) 
 
2-(4-Bromobutyloxy)-tetrahydropyran (16)  
13C NMR (125 MHz, CDCl3) 
249 
Octadecyne (15) 
1H NMR (500 MHz, CDCl3) 
 
Octadecyne (15) 
13C NMR (125 MHz, CDCl3) 
250 
2-(5-Docosynyloxy)-tetrahydropyran (17)  
1H NMR (500 MHz, CDCl3) 
 
2-(5-Docosynyloxy)-tetrahydropyran (17)  
13C NMR (125 MHz, CDCl3) 
251 
5-Docosyn-1-ol (18) 
1H NMR (500 MHz, CDCl3) 
 
5-Docosyn-1-ol (18) 
13C NMR (125 MHz, CDCl3) 
252 
21-Docosyn-1-ol (19) 
1H NMR (500 MHz, CDCl3) 
21-Docosyn-1-ol (19) 
13C NMR (125 MHz, CDCl3) 
253 
21-Docosynyl p-toluenesulfonate (21)  
1H NMR (500 MHz, CDCl3) 
21-Docosynyl p-toluenesulfonate (21)  
13C NMR (125 MHz, CDCl3) 
254 
 Methyl 4-[4-(21-
docosynyloxy)benzoyl]-benzoate (20) 
1H NMR (500 MHz, CDCl3) 
Methyl 4-[4-(21-
docosynyloxy)benzoyl]-benzoate (20)  
13C NMR (125 MHz, CDCl3) 
255 
2,2',3,3',4,4'-Hexa-O-trimethylsilyl-6-
docosanoyl-6'-hydroxyl, α,α'-D-trehalose (2) 
1H NMR (500 MHz, CDCl3) 
2,2',3,3',4,4'-Hexa-O-trimethylsilyl-6-
docosanoyl-6'-hydroxyl, α,α'-D-trehalose (2).  
13C NMR (125 MHz, CD3OD) 
256 
2,2',3,3',4,4'-Hexa-O-trimethylsilyl-6'-O-
docosanoyl-6-O-4-[4-(21-
docosynyloxy)benzoyl]benzoyl-α,α'-D-
trehalose (22) 1H NMR (500 MHz, 
CDCl3) 
257 
2,2',3,3',4,4'-Hexa-O-trimethylsilyl-6'-O-
docosanoyl-6-O-4-[4-(21-
docosynyloxy)benzoyl]benzoyl-α,α'-D-
trehalose (22).  
13C NMR (125 MHz, CDCl3) 
6'-O-Docosanoyl-6-O-4-[4-(21-
docosynyloxy)benzoyl]benzoyl-α,α'-
D-trehalose (1)  
1H NMR (500 MHz, C5D5N) 
258 
6'-O-Docosanoyl-6-O-4-[4-(21-
docosynyloxy)benzoyl]benzoyl-α,α'-
D-trehalose (1)  
13C NMR (125 MHz, C5D5 N) 
